Document:

4th Amended & Restated Investor Rights Agreement

 Exhibit 4.2 
 [EXECUTION COPY] 
 BIOLEX, INC. 
  

 FOURTH AMENDED AND RESTATED 

 INVESTOR RIGHTS AGREEMENT 
  

 This Fourth Amended and Restated Investor Rights Agreement (the “Agreement”) is entered into as of
May 18, 2007 by and among Biolex, Inc., a Delaware corporation (the “Company”), the holders of the Company’s Series AA1 Preferred Stock (the “Series AA1 Stock”) listed on Exhibit A attached hereto
(the “Series AA1 Investors”), the holders of the Company’s Series AA2 Preferred Stock (the “Series AA2 Stock”) listed on Exhibit B attached hereto (the “Series AA2 Investors”), the
holders of the Company’s Series BB Preferred Stock (the “Series BB Stock”), listed on Exhibit C attached hereto (the “Series BB Investors”), the holders of the Company’s Series CC Preferred Stock
(the “Series CC Stock” and together with the Series AA2 Stock and the Series BB Stock, the “Senior Stock”) listed on Exhibit D attached hereto (the “Series CC Investors”, and together with
the Series BB Investors and the Series AA2 Investors, the “Senior Investors”), and the holders of the Company’s Common Stock (the “Common Stock”) listed on Exhibit E attached hereto. The Series AA1
Stock, Series AA2 Stock, Series BB Stock and Series CC Stock shall also be referred to herein as “Investor Stock,” and the Series AA1 Investors, Series AA2 Investors, Series BB Investors and the Series CC Investors shall also be
referred to herein as the “Investors.” 
 WHEREAS, the Company, the Common Holders (as defined below), the Series AA1
Investors, the Series AA2 Investors and the Series BB Investors are party to that certain Third Amended and Restated Investor Rights Agreement, dated as of August 22, 2005, and as amended on June 1, 2006 (the “Existing Rights
Agreement”); and 
 WHEREAS, in connection with the issuance and sale of shares of the Series CC Stock to the Series CC Investors
pursuant to that certain Series CC Preferred Stock Purchase Agreement, dated as of May 18, 2007, by and among the Company and the Investors (the “Purchase Agreement”), the Company desires to provide the Investors certain rights
with respect to registration of the shares of stock held by them and certain other rights with respect to such shares as an inducement to the Series CC Investors to purchase shares of the Series CC Stock; and 
 WHEREAS, pursuant to Section 8.5 of the Existing Rights Agreement, the Company and the Investors (as defined in the Existing Rights Agreement)
desire to amend and restate the Existing Rights Agreement in the manner and to the extent set forth herein. 
 NOW, THEREFORE, in
consideration of the mutual agreements, covenants and conditions contained herein, the Company, the Investors and the Common Holders hereby agree as follows. 
  

 1 

 Section 1. 
 RESTRICTIONS ON TRANSFER 
 1.1 Restrictive Legend . Each certificate representing (i) the
Common Stock held by the Common Holders, (ii) the Investor Stock, (iii) the Common Stock issued upon conversion of the Investor Stock, and (iv) any other securities issued in respect of the Investor Stock or Common Stock issued upon
conversion of the Investor Stock upon any stock split, stock dividend, recapitalization, merger, consolidation or similar event, shall (unless otherwise permitted by the provisions of Section 1.2 below) be stamped or otherwise imprinted with a
legend in substantially the following form (in addition to any legend required under applicable state securities laws). 
 “THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE,
AND MAY NOT BE SOLD, MORTGAGED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND ANY APPLICABLE STATE SECURITIES LAWS, OR THE
AVAILABILITY OF AN EXEMPTION FROM THE REGISTRATION PROVISIONS OF THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS. COPIES OF THE STOCK PURCHASE AGREEMENT AND INVESTOR RIGHTS AGREEMENT PROVIDING FOR RESTRICTIONS ON
TRANSFER OF THESE SECURITIES MAY BE OBTAINED UPON WRITTEN REQUEST BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE CORPORATION AT THE PRINCIPAL EXECUTIVE OFFICES OF THE CORPORATION.” 
 Each Holder (as defined in Section 2.1 below), and Common Holder consents to the Company’s making a notation on its records and giving
instructions to any transfer agent of the Investor Stock or the Common Stock in order to implement the restrictions on transfer established in this Section 1. Such legend shall be removed by the Company from any certificate at such time as the
holder of the shares represented by the certificate satisfies the requirements of Rule 144(k) under the Securities Act of 1933, as amended (the “1933 Act”), provided that Rule 144(k) as then in effect does not differ substantially
from Rule 144(k) as in effect as of the date of this Agreement, and provided further that the Company has received from the Holder or Common Holder a written representation that (i) such Holder or Common Holder is not an affiliate of the
Company and has not been an affiliate during the preceding three months, (ii) such Holder or Common Holder has beneficially owned the shares represented by the certificate for a period of at least two years, (iii) such Holder or Common
Holder otherwise satisfies the requirements of Rule 144(k) as then in effect with respect to such shares, and (iv) such Holder or Common Holder will submit the certificate for any such shares to the Company for reapplication of the legend at
such time as the holder becomes an affiliate of the Company or otherwise ceases to satisfy the requirements of Rule 144(k) as then in effect. 
  

 2 

 1.2 Notice of Proposed Transfers . The holder of each certificate representing Registrable
Securities (as defined in Section 2.1 below) by acceptance thereof agrees to comply in all respects with the provisions of this Section 1.2. Prior to any proposed sale, assignment, transfer or pledge of any Registrable Securities, unless
there is in effect a registration statement under the 1933 Act covering the proposed transfer, the holder thereof shall give written notice to the Company of such holder’s intention to effect such transfer, sale, assignment or pledge. Each such
notice shall describe the manner and circumstances of the proposed transfer, sale, assignment or pledge in sufficient detail, and shall be accompanied at such holder’s expense by a written opinion of legal counsel who shall, and whose legal
opinion shall, be reasonably satisfactory to the Company addressed to the Company, to the effect that the proposed transfer of the Registrable Securities may be effected without registration under the 1933 Act; provided, however, that no such
written opinion of legal counsel shall be required in connection with transfers of Registrable Securities by any Investor to any current or former manager, member, limited partner, general partner, stockholder or officer of such Investor. Each
certificate evidencing the Registrable Securities transferred as above provided shall bear, except if such transfer is made pursuant to Rule 144, the appropriate restrictive legend set forth in Section 1.1 above, except that such certificate
shall not bear such restrictive legend if in the opinion of counsel for such holder and the Company such legend is not required in order to establish compliance with any provisions of the 1933 Act. 
 Section 2. 
 REGISTRATION RIGHTS 

 The Company hereby grants to each of the Holders (as defined below) the registration rights set forth in this Section 2, with respect
to the Registrable Securities (as defined below) owned by such Holders. The Company and the Holders agree that the registration rights provided herein set forth the sole and entire agreement, and supersede any prior agreement, between the Company
and the Holders with respect to registration rights for the Company’s securities. 
 2.1 Certain Definitions. As used in this
Agreement: 
 (a) The terms “register,” “registered” and “registration” refer to a
registration effected by filing with the Securities and Exchange Commission (the “SEC”) a registration statement (the “Registration Statement”) in compliance with the 1933 Act, and the declaration or ordering by the
SEC of the effectiveness of such Registration Statement. 
 (b) The term “Registrable Securities” means, without duplication
(i) Common Stock issued or issuable upon conversion of the shares of Investor Stock held by Investors or any transferee as permitted by Section 2.8 hereof; and (ii) any Common Stock issued as (or issuable upon the conversion or
exercise of any warrant, right or other security that is issued as) a dividend or other 

  

 3 

 
distribution with respect to, or in exchange or in replacement of, such Registrable Securities; provided, however, that shares of Common Stock or other
securities shall only be treated as Registrable Securities if and so long as (A) they have not been sold to or through a broker or dealer or underwriter in a public distribution or a public securities transaction, (B) they have not been
sold in a transaction exempt from the registration and prospectus delivery requirements of the 1933 Act under Section 4(1) thereof so that all transfer restrictions and restrictive legends with respect thereto are removed upon the consummation
of such sale, and (C) the registration rights associated with such securities have not been terminated pursuant to Section 2.15 hereof. 
 (c) The term “Holder” (collectively, “Holders”) means each Investor and any transferee, as permitted by Section 2.8 hereof, holding Registrable Securities, securities exercisable or convertible into
Registrable Securities or securities exercisable for securities convertible into Registrable Securities. 
 (d) The term “Initiating
Holders” means any Holder or Holders of at least a majority of the Registrable Securities then outstanding and not registered at the time of any request for registration made pursuant to Section 2.2 of this Agreement. 
 (e) The term “Major Investor” means each Investor and each transferee, as permitted by Section 2.8 hereof, holding a number of
shares of Registrable Securities equal to at least five percent (5%) of all Registrable Securities outstanding as of the date hereof (or, if there are subsequent closings under the Purchase Agreement after the date hereof, as of each such
subsequent closing under the Purchase Agreement). 
 (f) The term “Common Holder” means those holders of Common Stock listed
on Exhibit D attached hereto; provided, however, that when used in Section 2.3, Section 2.14 and clause (ii) of the first sentence of Section 8.5, the term “Common Holder” shall mean only those holders of
Common Stock listed on Exhibit D attached hereto with an asterisk (*) next to their name. 
 2.2 Demand Registration.

 (a) Demand for Registration. If the Company shall receive from Initiating Holders a written demand that the Company effect any
registration (a “Demand Registration”) of the Registrable Securities (other than a registration on Form S-3 or any related form of registration statement, such a request being provided for under Section 2.9 hereof), then
outstanding, having an anticipated aggregate offering price of at least $5,000,000, the Company will: 
 (i) promptly (but in any event
within ten (10) days) give written notice of the proposed registration to all other Holders; and 
 (ii) use its best efforts to effect
such registration as soon as practicable and as will permit or facilitate the sale and distribution of all or such portion of such Initiating Holders’ Registrable Securities as are specified in such demand, together with all or such portion of
the Registrable Securities of any Holder or Holders joining in such demand as are specified in a written demand received by the Company within fifteen (15) days after such written notice is given, provided that the Company shall
not be obligated to take any action to effect any such registration pursuant to this Section 2.2: 
  

 4 

 (A) in any particular jurisdiction in which the Company would be required to execute a general consent
to service of process in effecting such registration, qualification or compliance unless the Company is already subject to service in such jurisdiction and except as may be required by the 1933 Act; 
 (B) after the Company has effected two (2) such registrations pursuant to this Section 2.2 and the sales of the shares of Common Stock under
such registrations have closed; 
 (C) if the Company shall furnish to such Holders a certificate signed by the President of the Company,
stating that in the good faith judgment of the Board of Directors of the Company it would be seriously detrimental to the Company and its stockholders for such Registration Statement to be filed at the date filing would be required, in which case
the Company shall have an additional period or periods of not more than ninety (90) days within which to file such Registration Statement; provided, however, that the Company shall not use this right to delay the filing more than once in any
12-month period; or 
 (D) prior to the earlier of (1) the fourth (4th) anniversary of the date of this Agreement or (2) the date six (6) months after the effective date of the initial public offering of the
Company’s securities pursuant to a Registration Statement under the 1933 Act. 
 (b) Underwriting. If the Initiating
Holders intend to distribute the Registrable Securities covered by their demand by means of an underwriting, they shall so advise the Company as part of their demand made pursuant to this Section 2.2, including the identity of the managing
underwriter; and the Company shall include such information in the written notice referred to in Section 2.2(a)(i). In such event, the right of any Holder to registration pursuant to this Section 2.2 shall be conditioned upon such
Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. 
 The Company shall, together with all holders of capital stock of the Company proposing to distribute their securities through such underwriting, enter into an underwriting agreement in customary form with the
underwriter or underwriters selected by a majority-in-interest of the Initiating Holders and reasonably satisfactory to the Company. Notwithstanding any other provision of this Section 2.2, if the underwriter shall advise the Company that
marketing factors (including, without limitation, an adverse effect on the per share offering price) require a limitation of the number of shares to be underwritten, then the Company shall so advise all Holders of Registrable Securities that have
requested to participate in such offering, and the number of shares of Registrable Securities that may be included in the registration and underwriting shall be allocated pro rata among such Holders thereof in proportion, as nearly as practicable,
to the amounts of Registrable Securities held by such Holders at the time of filing the Registration Statement. No Registrable Securities excluded from the underwriting by reason of the underwriter’s marketing limitation shall be included in
such registration. 
  

 5 

 If any Holder disapproves of the terms of the underwriting, such Holder may elect to withdraw therefrom
by written notice to the Company, the underwriter and the Initiating Holders. The Registrable Securities so withdrawn shall also be withdrawn from registration. 
 If the underwriter has not limited the number of Registrable Securities to be underwritten, the Company may include securities for its own account (or for the account of other stockholders) in such registration if the
underwriter so agrees and if the number of Registrable Securities would not thereby be limited and the per share offering price would not be adversely affected. 
 2.3 Piggyback Registration. 
 (a) Company Registration. If at any time or from time to time the
Company shall determine to register any of its securities, either for its own account or for the account of security holders, other than a registration relating solely to employee benefit plans, a registration on Form S-4 relating solely to an SEC
Rule 145 transaction or a registration pursuant to Section 2.2 or 2.9 hereof, the Company will: 
 (i) promptly (but in any event within
ten (10) days) give to each Holder written notice thereof; and 
 (ii) include in such registration (and any related qualification
under state securities laws or other compliance), and in any underwriting involved therein, all the Registrable Securities specified in a written request or requests, made within fifteen (15) days after receipt of such written notice from the
Company, by any Holder or Holders, except as set forth in Section 2.3(b) below. 
 (b) Underwriting. If the registration of which
the Company gives notice is for a registered public offering involving an underwriting, the Company shall so advise the Holders as a part of the written notice given pursuant to Section 2.3(a)(i). In such event the right of any Holder to
registration pursuant to this Section 2.3 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein.

 All Holders proposing to distribute their Registrable Securities through such underwriting shall, together with the Company and the other
parties distributing their securities through such underwriting, enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by the Company. Notwithstanding any other provision of this
Section 2.3, if the underwriter determines that marketing factors require a limitation of the number of shares to be underwritten, the underwriter may limit the number of Registrable Securities to be included in the registration and
underwriting, or may exclude Registrable Securities entirely from such registration and underwriting subject to the terms of this Section 2.3. The Company shall so advise all holders of the Company’s securities that would otherwise be
registered and underwritten pursuant hereto, and the number of shares of such securities, including Registrable Securities, that may be included in the registration and underwriting shall be allocated 

  

 6 

 
in the following manner: (i) first, shares, other than Registrable Securities and other securities that have contractual rights with respect to
registration similar to those provided for in this Section 2.3, requested to be included in such registration by stockholders shall be excluded; (ii) second, if a limitation on the number of shares still is required, shares requested to be
included by the Common Holders shall be excluded; (iii) third, if a limitation of the number of shares still is required, the number of securities, other than Registrable Securities, that have contractual rights with respect to registration
that may be included shall be excluded; and (iv) fourth, if a limitation on the number of shares is still required, the number of Registrable Securities that may be included shall be allocated among the holders thereof in proportion, as nearly
as practicable, to the amounts of Registrable Securities and such other securities held by each such holder at the time of filing the Registration Statement; provided that in no event shall the number of Registrable Securities permitted to be
registered pursuant to this Section 2.3 be reduced to below 25% of the total number of securities included in such registration (unless such registration is in connection with the Company’s initial Qualified Public Offering (as defined in
the Company’s Amended and Restated Certificate of Incorporation)). For purposes of any such underwriter cutback, all Registrable Securities and other securities held by any holder that is a partnership, limited liability company or corporation
shall also include any Registrable Securities held by the partners, retired partners, members, stockholders or affiliated entities of such holder, or the estates and family members of any such partners, retired partners, members and any trusts for
the benefit of any of the foregoing persons, and such holder and other persons shall be deemed to be a single “selling holder,” and any pro rata reduction with respect to such “selling holder” shall be based upon the aggregate
amount of shares carrying registration rights owned by all entities and individuals included in such “selling holder,” as defined in this sentence. No securities excluded from the underwriting by reason of the underwriter’s marketing
limitation shall be included in such registration. Notwithstanding the foregoing, nothing in this Section 2.3(b) shall diminish or restrict in any way a Holder’s ability to exercise its registration rights under Section 2.2 or 2.9.

 If any Holder disapproves of the terms of the underwriting, it may elect to withdraw therefrom by written notice to the Company and the
underwriter. The Registrable Securities so withdrawn shall also be withdrawn from registration. 
 (c) Right to Terminate
Registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.3 prior to the effectiveness of such registration whether or not any Holder has elected to include securities in
such registration. 
 2.4 Expenses of Registration. All expenses incurred in connection with all registrations effected pursuant to
Sections 2.2, 2.3 and 2.9, including without limitation all registration, filing and qualification fees (including state securities law fees and expenses), printing expenses, escrow fees, fees and disbursements of counsel for the Company, fees and
disbursements of one counsel for the participating Holders, and expenses of any special audits incidental to or required by such registration shall be borne by the Company; provided, however, that the Company shall not be required to
pay stock transfer taxes or underwriters’ discounts or selling commissions relating to Registrable Securities. Notwithstanding anything to the contrary above, the Company shall not be required to 

  

 7 

 
pay for any expenses of any registration proceeding under Section 2.2 if the registration request is subsequently withdrawn at the request of the
Holders of a majority of the Registrable Securities to have been registered (after exclusion of any Registrable Securities excluded due to underwriter requirements); provided, however, that in the event that Holders holding at least a majority of
the Registrable Securities agree to forfeit their right to a demand registration pursuant to Section 2.2 (in which event such right shall be forfeited by all Holders), then the Company shall be required to pay the expenses of the withdrawn
registration. In the absence of such an agreement to forfeit a demand registration, the Holders of Registrable Securities to have been registered shall bear all such expenses pro rata on the basis of the number of Registrable Securities to have been
registered. Notwithstanding the preceding sentence, however, if at the time of the withdrawal, the Holders have learned of a materially adverse change in the condition, business or prospects of the Company from that known to the Holders at the time
of their request, then the Holders shall not be required to pay any of said expenses (which shall instead be paid by the Company) and shall retain their rights pursuant to Section 2.2. 
 2.5 Obligations of the Company. Whenever required under this Section 2 to effect the registration of any Registrable Securities, the Company
shall, as expeditiously as reasonably possible: 
 (a) prepare and file with the SEC a Registration Statement with respect to such Registrable
Securities and use its best efforts to cause such Registration Statement to become effective, and keep such Registration Statement effective for the lesser of one hundred eighty (180) days or until the Holder or Holders have completed the
distribution of all Registrable Securities relating thereto; 
 provided, however, the Company shall have the right for up to thirty (30) days (the
“Suspension Period”), to delay the filing or effectiveness of any such Registration Statement or suspend the use or effectiveness of any such Registration Statement (and the Initiating Holders hereby agree not to offer or sell any
Registrable Securities pursuant to such Registration Statement during the Suspension Period) upon notice to the participating Holders, to the extent necessary in the sole discretion of the Company upon the advice of counsel, if the Company
reasonably believes that the Company may, in the absence of such delay or suspension hereunder, be required under state or federal securities laws to disclose any corporate development, the disclosure of which could reasonably be expected to have a
material adverse effect upon the Company, its stockholders, a potentially significant transaction or event involving the Company, or any negotiations, discussions, or proposals directly relating thereto, provided, however, that the Company may
invoke no more than two Suspension Periods in any twelve (12) month period. If so directed by the Company, all Holders registering shares under such Registration Statement shall use their commercially reasonable efforts to deliver to the
Company (at the Company’s expense) all copies, other than permanent file copies then in such Holders’ possession, of the prospectus relating to such Registrable Securities current at the time of receipt of such notice. 
 (b) prepare and file with the SEC such amendments and supplements to such Registration Statement and the prospectus used in connection with such
Registration Statement as may be necessary to keep such Registration Statement effective during the time period referred to in Section 2.5(a) and to comply with the provisions of the 1933 Act with respect to the disposition of all securities
covered by such Registration Statement; 
  

 8 

 (c) furnish to the selling Holders such numbers of copies of such registration statement and each
amendment thereto, the prospectus included in such Registration Statement, (including each preliminary prospectus), in conformity with the requirements of the 1933 Act, and such other documents as they may reasonably request in order to facilitate
the disposition of Registrable Securities owned by them; 
 (d) use its best efforts to register or otherwise qualify the securities covered
by such Registration Statement under such other securities laws of such states and other jurisdictions as shall be reasonably requested by the Holders or the managing underwriter, provided that the Company shall not be required in connection
therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions; 
 (e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering. Each Holder
participating in such underwriting shall also enter into and perform its obligations under such an agreement; 
 (f) promptly notify each
Holder of Registrable Securities covered by such Registration Statement, at any time when a prospectus relating thereto is required to be delivered under the 1933 Act, of the happening of any event as a result of which the prospectus included in
such Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the
circumstances then existing; 
 (g) provide a transfer agent and registrar for all such Registrable Securities not later than the effective
date of such Registration Statement; 
 (h) use its best efforts to list the Registrable Securities covered by such Registration Statement
with any securities exchange on which the Common Stock is then listed; 
 (i) make available for inspection by each Holder including
Registrable Securities in such registration, any underwriter participating in any distribution pursuant to such registration, and any attorney, accountant or other agent retained by such Holder or underwriter, all financial and other records,
pertinent corporate documents and properties of the Company, as such parties may reasonably request, and cause the Company’s officers, directors and employees to supply all information reasonably requested by any such Holder, underwriter,
attorney, accountant or agent in connection with such Registration Statement; 
 (j) promptly notify the Holders of Registrable Securities
and the underwriters, if any, of the following events and (if requested by any such person) confirm such notification in writing: (1) the filing of the prospectus or any prospectus supplement and the Registration Statement and any amendment or
post-effective amendment thereto and, with respect to the Registration Statement or any post-effective amendment thereto, the declaration of the effectiveness of such document, (2) any requests by the SEC for 

  

 9 

 
amendments or supplements to the Registration Statement or the prospectus or for additional information, (3) the issuance or threat of issuance by the
SEC of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose and (4) the receipt by the Company of any notification with respect to the suspension of the qualification of
the Registrable Securities for sale in any jurisdiction or the initiation or threat of initiation of any proceeding for such purpose; 
 (k)
make every reasonable effort to prevent the entry of any order suspending the effectiveness of the Registration Statement and obtain at the earliest possible moment the withdrawal of any such order, if entered; 
 (l) If reasonably requested by any underwriter or a selling Holder of Registrable Securities in connection with any underwritten offering, promptly
incorporate in a prospectus supplement or post-effective amendment such information as the underwriters and the Holders of a majority of the Registrable Securities being sold agree should be included therein relating to the sale of the Registrable
Securities, including, without limitation, information with respect to the number of Registrable Securities being sold to such underwriters, the purchase price being paid therefor by such underwriters and any other terms of the underwritten (or best
efforts underwritten) offering of the Registrable Securities to be sold in such offering, and make all required filings of such prospectus supplement or post-effective amendment promptly after being notified of the matters to be incorporated in such
prospectus supplement or post-effective amendment; 
 (m) prior to the filing of any document which is to be incorporated by reference into
the Registration Statement or the prospectus (after the initial filing of the Registration Statement with the SEC), (i) promptly provide copies of such document to counsel for the selling Holders of the Registrable Securities and counsel for
the underwriters, if any, (ii) make representatives of the Company available for discussion of such document and (iii) make such changes to the disclosure in such document as it relates to the Holders prior to the filing thereof as counsel
for such Holders or underwriters may reasonably request; 
 (n) provide a CUSIP number for all Registrable Securities not later than the
effective date of the Registration Statement; 
 (o) prior to the effectiveness of the Registration Statement and any post-effective
amendment thereto and at each closing of an underwritten offering, (i) make such representations and warranties to the selling Holders of such Registrable Securities and the underwriters, if any, with respect to the Registrable Securities and
the Registration Statement as are customarily made by issuers to underwriters in primary underwritten offerings; and (ii) deliver such documents and certificates as may be reasonably requested by the Holders of a majority of the Registrable
Securities being sold and by the underwriters, if any, to evidence compliance with clause (i) above and with any customary conditions contained in the underwriting agreement or other agreement entered into by the Company; 
  

 10 

 (p) on the date that such Registrable Securities are delivered to the underwriters for sale, if such
securities are being sold through underwriters, use its best efforts (i) to obtain opinions of counsel to the Company and updates thereof (which counsel and which opinions shall be reasonably satisfactory to the underwriters, if any) addressed
to the underwriters, if any, covering the matters customarily covered in opinions requested in underwritten offerings and such other matters as may be reasonably requested by the underwriters or their counsel; and (ii) obtain
“comfort” letters and updates thereof from the Company’s independent certified public accountants addressed to the underwriters, if any, such letters to be in customary form and covering matters of the type customarily covered in
“comfort” letters by underwriters in connection with primary underwritten offerings; 
 (q) otherwise use its best efforts to
comply with all applicable rules and regulations of the SEC, and make generally available to its security holders earnings statements satisfying the provisions of Section 11(a) of the 1933 Act, no later than 45 calendar days after the end of
any 12-month period (or for 90 calendar days, if such period is a fiscal year) (i) commencing at the end of any fiscal quarter in which Registrable Securities are sold to underwriters in a firm or best efforts underwritten offering, or
(ii) if not sold to underwriters in such an offering, beginning with the first month of the first fiscal quarter of the Company commencing after the effective date of the Registration Statement, which statements shall cover such 12-month
periods; 
 (r) cooperate with Holders including Registrable Securities in such registration and the managing underwriters, if any, to
facilitate the timely preparation and delivery of certificates representing Registrable Securities to be sold, such certificates to be in such denominations and registered in such names as such Holders or the managing underwriters may request at
least two business days prior to any sale of Registrable Securities; and 
 (s) permit any Holder which Holder, in the sole and exclusive
judgment, exercised in good faith, of such Holder, might be deemed to be a controlling person of the Company, to participate in good faith in the preparation of such Registration Statement and to require the insertion therein of material, furnished
to the Company in writing, that in the reasonable judgment of such Holder and its counsel should be included. 
 2.6 Indemnification.

 (a) The Company will, and does hereby undertake to, indemnify and hold harmless each Holder of Registrable Securities, each of such
Holder’s officers, directors, managers, partners, members and agents, and each person controlling such Holder, with respect to any registration, qualification or compliance effected pursuant to this Section 2, and each underwriter, if any,
and each person who controls any underwriter, of the Registrable Securities held by or issuable to such Holder, against all claims, losses, damages and liabilities (or actions in respect thereto) to which they may become subject under the 1933 Act,
the Securities Exchange Act of 1934, as amended (the “1934 Act”), or other federal or state law arising out of or based on (i) any untrue statement (or alleged untrue statement) of a material fact contained in any prospectus,
offering circular or other similar document (including any related Registration Statement, notification, or the like) incident to any such registration, qualification or compliance, or based on any 

  

 11 

 
omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading in
light of the circumstances in which they were made, (ii) any violation or alleged violation by the Company of any federal, state or common law rule or regulation applicable to the Company in connection with any such registration, qualification
or compliance, or (iii) any failure to register or qualify Registrable Securities in any state where the Company or its agents have affirmatively undertaken or agreed in writing that the Company (the undertaking of any underwriter chosen by the
Company being attributed to the Company) will undertake such registration or qualification on behalf of the Holders of such Registrable Securities (provided that in such instance the Company shall not be so liable if it has undertaken its best
efforts to so register or qualify such Registrable Securities) and will reimburse, as incurred, each such Holder, each such underwriter and each such director, manager, officer, partner, member agent and controlling person, for any legal and any
other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability or action; provided that the Company will not be liable in any such case to the extent that any such claim, loss, damage,
liability or expense arises out of or is based on any untrue statement or omission made in conformity with written information furnished to the Company by an instrument duly executed by such Holder or underwriter and stated to be specifically for
use therein. 
 (b) Each Holder will, and if Registrable Securities held by or issuable to such Holder are included in such registration,
qualification or compliance pursuant to this Section 2, does hereby undertake to indemnify and hold harmless the Company, each of its directors and officers, and each person controlling the Company, each underwriter, if any, and each person who
controls any underwriter, of the Company’s securities covered by such a Registration Statement, and each other Holder, each of such other Holder’s officers, directors, managers, partners, members and agents and each person controlling such
other Holder, against all claims, losses, damages and liabilities (or actions in respect thereof) arising out of or based on (i) any failure of such Holder or its agents or representatives to comply with the prospectus delivery requirements of
the 1933 Act or any other applicable securities or Blue Sky law, or (ii) any untrue statement (or alleged untrue statement) of a material fact contained in any such Registration Statement, prospectus, offering circular or other document, or any
omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances in which they were made, and will reimburse, as incurred, the
Company, each such underwriter, each such other Holder, and each such director, officer, manager, partner, member and controlling person of the foregoing, for any legal or any other expenses reasonably incurred in connection with investigating or
defending any such claim, loss, damage, liability or action, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) was made in such Registration Statement,
prospectus, offering circular or other document, in reliance upon and in conformity with written information furnished to the Company by an instrument duly executed by such Holder and stated to be specifically for use therein; provided, however,
that the liability of each Holder hereunder (unless such Holder’s liability hereunder is based upon such Holder’s willful misconduct as determined by the nonappealable final decision of a court) shall be limited to the proportion of any
such claim, loss, damage or liability that is equal to the proportion that the public offering price of the shares sold by such Holder under such Registration Statement bears to the total public offering price of all securities sold thereunder, but
in any event not to exceed the net proceeds 

  

 12 

 
received by such Holder from the sale of securities under such Registration Statement. It is understood and agreed that the indemnification obligations of
each Holder pursuant to any underwriting agreement entered into in connection with any Registration Statement shall be limited to the obligations contained in this subsection 2.6(b). 
 (c) Each party entitled to indemnification under this Section 2.6 (the “Indemnified Party”) shall give notice to the party required
to provide such indemnification (the “Indemnifying Party”) of any claim as to which indemnification may be sought promptly after such Indemnified Party has actual knowledge thereof, and shall permit the Indemnifying Party to assume
the defense of any such claim or any litigation resulting therefrom; provided that counsel for the Indemnifying Party, who shall conduct the defense of such claim or litigation, shall be subject to approval by the Indemnified Party (whose approval
shall not be unreasonably withheld) and the Indemnified Party may participate in such defense at the Indemnifying Party’s expense if representation of such Indemnified Party would be inappropriate due to actual or potential differing interests
between such Indemnified Party and any other party represented by such counsel in such proceeding; and provided further that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its
obligations under this Section 2, except to the extent that such failure to give notice shall materially adversely affect the Indemnifying Party in the defense of any such claim or any such litigation. An Indemnifying Party, in the defense of
any such claim or litigation, may, without the consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement that includes as an unconditional term thereof the giving by the claimant or plaintiff therein, to such
Indemnified Party, of a release from all liability with respect to such claim or litigation. 
 (d) In order to provide for just and
equitable contribution to joint liability under the 1933 Act in any case in which either (i) any Holder exercising rights under this Agreement, or any controlling person of any such Holder, makes a claim for indemnification pursuant to this
Section 2.6 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be
enforced in such case notwithstanding the fact that this Section 2.6 provides for indemnification in such case, or (ii) contribution under the 1933 Act may be required on the part of any such Holder or any such controlling person in
circumstances for which indemnification is provided under this Section 2.6; then, and in each such case, the Company and such Holder will contribute to the aggregate claims, losses, damages or liabilities to which they may be subject (after
contribution from others) in such proportion so that such Holder is responsible for the portion represented by the percentage that the public offering price of the securities offered by such Holder pursuant to the Registration Statement bears to the
public offering price of all securities offered by such Registration Statement, and the Company will be responsible for the remaining portion (without prejudice as to the Company’s right to contributions from any other responsible parties);
provided, however, that, in any case, (A) no such Holder will be required to contribute any amount in excess of the public offering price of all securities offered by it pursuant to such Registration Statement, after deduction of underwriting
discounts and commissions (unless such Holder’s liability hereunder is based upon such Holder’s willful misconduct as determined by the nonappealable final decision of a court); and (B) no person or entity guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the 1933 Act) will be entitled to contribution from any person or entity who was not guilty of such fraudulent misrepresentation. 
  

 13 

 (e) The indemnities provided in this Section 2.6 shall survive the transfer of any Registrable
Securities by such Holder. 
 2.7 Information by Holder. The Holder or Holders of Registrable Securities included in any registration
shall furnish to the Company such information regarding such Holder or Holders and the distribution proposed by such Holder or Holders as the Company may reasonably request in writing and as shall be required in connection with any registration,
qualification or compliance referred to in this Section 2. 
 2.8 Transfer of Rights. The rights contained in Sections 2 and 3
hereof may be assigned or otherwise conveyed by a Holder to transferees or assignees of Investor Stock who acquires at least 5% of the Investor Stock owned by such Holder as of the date of this Agreement, and who shall be considered a
“Holder” and “Investor” for purposes hereof, provided that such transfer is effected in compliance with Section 1.2 hereof and such transferee agrees in writing to be bound by the terms and conditions of this Agreement;
provided further that any Investor may transfer its rights contained in Sections 2 and 3 hereof to a current or former manager, member, limited partner, general partner, stockholder or officer of such Investor without regard to the number of shares
of Investor Stock transferred. Notwithstanding the foregoing, no Holder shall transfer or assign any Registrable Securities to any person or entity who is a direct competitor of the Company’s primary line of business. 
 2.9 Form S-3. The Company shall use its best efforts to qualify for registration on Form S-3, and to that end the Company shall register the
Registrable Securities under the 1934 Act within twelve (12) months following the effective date of the first registration of any securities of the Company on Form S-1 (or any other appropriate or substantially similar form) under the 1933 Act.
For purposes of this Section 2.9, the term “Form S-3” shall be deemed to include any future form that is substantially equivalent to the current Form S-3. After the Company has qualified for the use of Form S-3, the Holders of
Registrable Securities shall have the right to request registrations on Form S-3 thereafter under this Section 2.9. The Company shall give notice to all Holders of Registrable Securities of the receipt of a request for registration pursuant to
this Section 2.9 and shall provide a reasonable opportunity for other Holders to participate in the registration. Subject to the foregoing, the Company will use its best efforts to effect as soon as practicable the registration of all shares of
Registrable Securities on Form S-3 to the extent requested by the Holder or Holders thereof for purposes of disposition; provided, however, that the Company shall not be obligated to effect any such registration (A) if the
Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public of less than
$1,000,000 or (B) at any time when the Company has effected two (2) registrations pursuant to this Section 2.9 during the preceding twelve (12) month period. Notwithstanding the foregoing, nothing herein shall restrict, prohibit
or limit in any way a Holder’s ability to exercise its registration rights under Sections 2.2 or 2.3 hereof. The Company shall have no obligation to take any action to effect any registration pursuant to this Section 2.9 for any of the
reasons set forth in Section 2.2(a)(ii)(A) or (C), (which shall be deemed to apply to the obligations 

  

 14 

 
under this Section 2.9 with equal force). In addition, any registration pursuant to this Section 2.9 shall be subject to the provisions of
Section 2.2(b), which shall be deemed to apply to the obligations under this Section 2.9 with equal force, except that any reference therein to Section 2.2 or a subsection thereof shall, for these purposes only, be deemed to be a
reference to this Section 2.9. 
 2.10 Delay of Registration. No Holder shall have any right to obtain or seek an injunction
restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 
 2.11 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior written
consent of the holders of at least a majority of the Senior Stock then outstanding and not registered (such consent not to be unreasonably withheld or delayed), enter into any agreement with any holder or prospective holder of any securities of the
Company that would allow such holder or prospective holder to (i) require the Company to effect a registration or (ii) include any securities in any registration filed under Section 2.2, 2.3 or 2.9 hereof. 
 2.12 Rule 144 Reporting. With a view to making available to the Holders the benefits of certain rules and regulations of the SEC that may permit
the sale of the Registrable Securities to the public without registration, the Company agrees to use its best efforts to: 
 (a) make and keep
current public information available, within the meaning of SEC Rule 144 or any similar or analogous rule promulgated under the 1933 Act, at all times after it has become subject to the reporting requirements of the 1934 Act; 
 (b) file with the SEC, in a timely manner, all reports and other documents required of the Company under the 1933 Act and 1934 Act (after it has become
subject to such reporting requirements); and 
 (c) so long as a Holder owns any Registrable Securities, furnish to such Holder forthwith
upon request a written statement by the Company as to its compliance with the reporting requirements of said Rule 144 (at any time commencing ninety (90) days after the effective date of the first registration filed by the Company for an
offering of its securities to the general public), the 1933 Act and the 1934 Act (at any time after it has become subject to such reporting requirements); a copy of the most recent annual or quarterly report of the Company; and such other reports
and documents as a Holder may reasonably request in availing itself of any rule or regulation of the SEC allowing it to sell any such securities without registration. 
 2.13 “Market Stand-Off” Agreement. Each Holder and each Common Holder hereby agrees that during a period, not to exceed one hundred eighty (180) days (which period may be extended upon the
request of the managing underwriter for an additional period of up to fifteen (15) days if the Company issues or proposes to issue an earnings or other public release within fifteen (15) days of the expiration of the 180-day lockup
period), following the effective date of the initial, effective registration statement of the Company filed under the 1933 Act, it shall not, to the extent requested by the Company and any underwriter, sell, pledge, transfer, make any 

  

 15 

 
short sale of, loan, grant any option for the purchase of, or otherwise transfer or dispose of (other than to donees who agree to be similarly bound) any
Common Stock held by it at any time during such period except Common Stock included in such registration; provided, however, that all One Percent Stockholders (as defined below) and all officers and directors of the Company enter into similar
agreements. In the event any One Percent Stockholder, officer or director that enters into a standoff agreement substantially identical to the provisions of this Section 2.13 is released in whole or in part from such agreement during the one
hundred eighty (180) day period referred to herein (as such period may be extended for up to fifteen (15) days if the Company issues or proposes to issue an earnings or other public release within fifteen (15) days of the expiration
of the 180-day lockup period), each Holder shall be proportionally released from this Section 2.13. 
 For purposes of this
Section 2.13, the term “One Percent Stockholder” shall mean a stockholder of the Company who holds at least one percent (1%) of the outstanding Common Stock of the Company (assuming conversion of all outstanding Investor
Stock of the Company). 
 In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to the
Registrable Securities of each Holder (and the shares or securities of every other person subject to the foregoing restriction) until the end of such period. 
 2.14 Inclusion of Stock Held by Common Holders. In connection with any registration effected pursuant to Section 2.3 hereof, the Common Holders shall be entitled to include in such registration (on the
same terms and conditions as Holders selling their Registrable Securities in such registration) shares of Common Stock held by such Common Holders; provided that any limitation by the underwriter on the number of shares to be underwritten in
connection with such registration shall first be applied to the shares so included by such Common Holders, as provided in Section 2.3(b), and provided further that each such Common Holder’s right to include shares of Common Stock in a
registration pursuant to this Section 2.14 is contingent upon such Common Holder’s execution of an indemnification and hold harmless agreement substantially in accordance with Section 2.6(b) and an agreement to be bound by all other
applicable restrictions contained in this Section 2. For any Common Holder that is an agency of the State of North Carolina, it is understood and agreed that (a) nothing herein constitutes a waiver of that agency’s or the State’s
sovereign immunity and (b) the maximum potential liability under the indemnification and hold harmless agreement is limited to the amount of net proceeds received by such Common Holder from the sale of securities under such Registration
Statement regardless of whether the liability is based on the Common Holder’s willful misconduct. All expenses of the Common Holders in connection with such registrations shall be paid to the extent specified in Section 2.4 for other
Holders. 
 2.15 Termination of Rights. The rights of any particular Holder to participate in a registration under Sections 2.2, 2.3
and 2.9 hereof shall terminate at the earlier of (i) the date five (5) years following the closing of a Qualified Public Offering (as defined in Section 3.5 below), or (ii) as to any Holder, on the date such Holder is able to
dispose of all of its Registrable Securities in any 90-day period pursuant to SEC Rule 144 (or any similar or analogous rule promulgated under the 1933 Act). 
  

 16 

 Section 3. 
 RIGHTS OF FIRST REFUSAL 
 3.1 Certain Definitions. As used in this Section 3: 

(a) The term “New Securities” shall mean any capital stock of the Company, whether now authorized or not, and rights, options or
warrants to purchase capital stock, and securities of any type whatsoever that are, or may become, convertible into or exercisable for capital stock; provided that the term “New Securities” does not include: (i) securities issuable
upon conversion of or with respect to Investor Stock; (ii) the issuance of warrants to lending institutions or equipment lessors, issued pursuant to equipment financing arrangements; provided that each such issuance is approved by the Board of
Directors and that the aggregate number securities exercisable for or convertible into capital stock of the Company issued pursuant to this clause (ii) shall not exceed one percent (1%) of the fully-diluted capitalization of the Company
(assuming the exercise or conversion of all securities exercisable for or convertible into Common Stock or other securities convertible into Common Stock) at the time of issuance; (iii) shares of Common Stock, or securities exercisable for or
convertible into capital stock of the Company, issued in connection with a strategic or collaborative relationship with, or the acquisition of, another company by the Company pursuant to a plan, agreement or other arrangement approved by the Board
of Directors; provided that the aggregate number of shares of Common Stock or securities exercisable for or convertible into capital stock of the Company issued pursuant to this clause (iii) shall not exceed five percent (5%) of the
fully-diluted capitalization of the Company (assuming the exercise or conversion of all securities exercisable for or convertible into Common Stock or other securities convertible into Common Stock) at the time of issuance; (iv) the issuance of
shares of Common Stock or capital stock of the Company issuable upon exercise or conversion of the warrants or other convertible securities provided for in subsections (ii) or (iii) above; (v) up to 11,571,429 shares of Common Stock,
and options, warrants or rights convertible into such Common Stock, issued to employees, consultants or directors of the Company pursuant to, and as set forth in the Company’s stock option plan(s) approved by the Board of Directors and
stockholders of the Company; or (vi) securities issued pursuant to any stock dividend, stock split, combination or other reclassification by the Company of any of its capital stock. 
 (b) The term “Pro Rata Share” means the ratio (A) the numerator of which is the number of shares of Common Stock held by such
Investor, including those shares of Common Stock issuable to such Investor upon the conversion of shares of Investor Stock held by such Investor on the date of the Company’s written notice pursuant to Section 3.3 hereof, and (B) the
denominator of which is the total number of shares of the Company’s Common Stock outstanding on the date of the Company’s written notice pursuant to Section 3.3 hereof, assuming for this purpose conversion or exercise of all
securities convertible into or exercisable for shares of Common Stock or convertible securities of the Company. 
 3.2 Right of First
Refusal. The Company hereby grants to each Investor, subject to the terms and conditions specified in this Section 3, the right of first refusal to purchase, on the terms and conditions set forth in the Company’s notice pursuant to
Section 3.3 hereof, up to its Pro Rata Share of all New Securities that the Company may, from time to time, propose to sell and issue. 
  

 17 

 3.3 Required Notices. In the event the Company proposes to undertake an issuance of New
Securities, it shall give each Investor written notice of its intention, describing the type of New Securities, the price and the general terms upon which the Company proposes to issue the same. Each Investor shall have twenty (20) days from
the date of any such notice to exercise its right of first refusal under Section 3.2 hereof to purchase such New Securities for the price and upon the general terms specified in the notice by giving written notice to the Company and stating
therein the quantity of New Securities to be purchased; provided, that the notice period described above may be waived by Investors holding a majority of the Investor Stock then outstanding. Any such Investor may, at the time it accepts the offer,
subscribe to purchase any or all New Securities offered (“Oversubscription Securities”) which may be available as a result of the rejection, or partial rejection, of the offer by other such Investors. All Oversubscription Securities shall
be allocated on a pro rata basis among those Investors subscribing to purchase their entire Pro Rata Share. 
 3.4 Company’s Right to
Sell. The Company shall have ninety (90) days after the period described in Section 3.3 hereof to sell all such New Securities respecting which the Investors’ rights of first refusal hereunder were not exercised, at a price and
upon terms no more favorable in any material respect to the purchasers thereof than specified in the Company’s notice. In the event the Company has not sold all such New Securities within such 90-day period, the Company shall not thereafter
issue or sell any New Securities without first notifying the Investors in the manner provided herein and otherwise complying with the provisions of this Section 3. 
 3.5 Expiration of Right. The rights of first refusal granted under this Section 3 shall expire upon the earlier of: (i) the effectiveness of a registration statement for the sale of the Company’s
shares of Common Stock in a firm commitment fully marketed underwritten public offering registered under the 1933 Act at a public offering price per share not less than $3.54 (subject to adjustment for stock splits, stock dividends, combinations,
consolidations, recapitalizations, reorganizations and the like) with gross cash proceeds to the Company (before underwriting discounts, commissions and fees) of at least $40,000,000 (a “Qualified Public Offering”) or (ii) the
effectiveness of a registration statement for the sale of the Company’s shares of Common Stock in the Company’s first underwritten public offering (an “IPO”) in connection with which all shares of Preferred Stock have
converted into shares of Common Stock. 
  

 18 

 Section 4. 
 COMPANY COVENANTS 
 The Company hereby covenants and agrees on behalf of itself and its Subsidiaries
(as defined in the Purchase Agreement) to the following. 
 4.1 Affirmative Covenants. 
 (a) Financial Statements and Information. The Company will keep books of account and prepare financial statements and will cause to be furnished to
each Major Investor holding at least twenty percent (20%) of the Investor Stock originally purchased by such Major Investor (or common stock issued upon conversion of such Investor Stock) (shares of Investor Stock (or common stock issued upon
conversion of such Investor Stock) held by the partners, retired partners, members, stockholders or affiliated entities of a Major Investor, or the estates and family members of any such partners, retired partners, members and any trusts for the
benefit of any of the foregoing persons shall be deemed to be held by a Major Investor for purposes of determining the number of shares of Investor Stock held by a Major Investor) (all of the foregoing and following to be kept and prepared in
accordance with United States generally accepted accounting principles applied on a consistent basis): 
 (i) As soon as practicable, but in
any event within one hundred twenty (120) days after the end of each fiscal year of the Company, (1) a copy of the financial statements of the Company for such fiscal year containing a consolidated and consolidating balance sheet,
statement of income, statement of stockholders’ equity, and statement of cash flows, each as at the end of such fiscal year and for the period then ended and in each case setting forth in comparative form the figures for the preceding fiscal
year, all in reasonable detail and audited and certified by independent certified public accountants of nationally recognized standing selected by the Company’s Board of Directors, approved by a majority of the Directors designated by the
Investors pursuant to Section 5 hereof, (2) a comparison of the actual results during such fiscal year to those originally budgeted by the Company for such fiscal year and a narrative description and explanation of any budget variances,
and (3) a copy of the auditor’s letter(s) to management in connection with such audit. The annual audit report required by this Agreement will not be qualified by or make reference to any disclosure that the Company may not continue as a
going concern or otherwise be qualified or limited because of restricted or limited examination by the accountant of any portion of any of the records of the Company; 
 (ii) As soon as practicable after the end of each of the first three (3) quarters of the fiscal year, but in any event within thirty (30) days after the end of each such quarter, the unaudited consolidated
balance sheets of the Company and its Subsidiaries, if any, as of the end of such quarter, and its unaudited consolidated statements of income and losses, stockholders’ equity and cash flows for such quarter, setting forth in each case in
comparative form the figures for the corresponding period of the preceding fiscal year, all in reasonable detail. Such quarterly report shall include a narrative, summary description of the Company’s operations for such quarter, from the
Company’s Chief Executive Officer, indicating whether the Company is materially in compliance with this Agreement and other material agreements and discussing the Company’s performance highlights and setbacks, any material variances from
the Company’s operating plan and budget, accompanied by an updated forecast of financial performance for the next four (4) quarters; and 
  

 19 

 (iii) As soon as practicable after the end of each month, but in any event within twenty (20) days
thereafter, the unaudited consolidated balance sheet of the Company and its Subsidiaries, if any, as of the end of such month and its unaudited statement of income and losses, stockholders’ equity and cash flows for such month, indicating
actual results versus the Company’s plan for such month, setting forth in each case in comparative form the figures for the corresponding period of the preceding fiscal year; 
 (b) Other Information. The Company will cause to be furnished to each Major Investor holding at least twenty percent (20%) of the Investor
Stock originally purchased by such Major Investor (or Common Stock issued upon conversion of such Investor Stock): 
 (i) As soon as
practicable after the adoption thereof, but in any event at least ten (10) days prior to the beginning of each fiscal year, an annual operating plan and budget for the following fiscal year (which budget and plan shall include capital and
operating expense budgets, cash flow projections, profit and loss projections and projected balance sheets for such year), accompanied by a report from the Company’s Chief Executive Officer detailing the assumptions underlying the budget and
any other information necessary to make such budget and plan accurate and not misleading, and, as soon as practicable after the adoption thereof, copies of any revisions to such annual operating plan; 
 (ii) As soon as available, a copy of each (1) financial statement, report, notice, or proxy statement sent by the Company to its stockholders;
(2) regular, periodic, or special report, registration statement, or prospectus filed by the Company with any securities exchange, state securities regulator, or the Commission; (3) material order issued by any court, governmental
authority, or arbitrator in any material proceeding to which the Company is a party or to which any of its assets is subject; (4) press release or other statement made available generally by the Company or its officers to the public generally
concerning material developments in the business of the Company; and (5) material item of correspondence, report, or other information (excluding routine correspondence from the Company that is not related to any default or breach, or any
potential or threatened default or breach) sent by the Company to any holder of any indebtedness, including, without limitation, the Investors; 
 (iii) Prompt notice of any default of the Company under any bond, note, indenture or other debt instrument representing indebtedness for borrowed money and of any acceleration of indebtedness which may result therefrom; and 
 (iv) With reasonable promptness, such other information respecting the business, properties or the condition or operations, financial or other, of the
Company or any Subsidiary (as defined in the Purchase Agreement) as any such Major Investor may from time to time reasonably request. 
  

 20 

 (c) Inspection. The Company shall permit each Major Investor, its attorney or its other
representative to visit and inspect the Company’s properties, to examine the Company’s books of account and other records, to make copies or extracts therefrom and to discuss the Company’s affairs, finances and accounts with its
officers, management, employees and independent auditors all at such reasonable times and as often as such Major Investor or transferee may reasonably request; provided, however, that the Company shall not be obligated pursuant to this
Section 4.1(c) to provide trade secrets or confidential information or to provide information to any person whom the Company reasonably believes is a competitor of the Company; provided, further, that such Major Investor shall
bear any costs or expenses of such investigations or inquiries. 
 (d) Observation Rights. Each of Mitsui & Co. Venture
Partners II, L.P. (“Mitsui”) and Easton Capital Partners, L.P. (“Easton”) shall have the right to receive notice of all meetings of the Board of Directors, and each of Mitsui and Easton shall have the right to
attend up to 50% of such meetings in any calendar year (or designate its representative to attend such meeting on its behalf) as a nonvoting observer and to comment for the record at any such meeting, provided that Mitsui and Easton (or their
designated representatives) shall coordinate their schedules such that they (or their designated representatives) are not in attendance at the same meeting. Johnson & Johnson Development Corporation shall have the right to designate a
representative to attend all meetings of the Board of Directors in any calendar year as a nonvoting observer and to comment for the record at such meeting. Subject to the fulfillment of the obligations contained in Section 5.1(a), effective as
of January 1, 2008, Intersouth (as defined below) shall have the right to designate a representative to attend all meetings of the Board of Directors in any calendar year as a nonvoting observer and to comment for the record at any such
meeting. Each observer so appointed as provided above shall sign a confidentiality agreement reasonably acceptable to the Board of Directors of the Company prior to his or her first attendance to his or her first meeting of the Board of Directors.
The Company shall provide each such observer attending a meeting of the Board of Directors the materials provided to the Board of Directors with respect to such meeting at the time such materials as provided to the members of the Board of Directors.
Notwithstanding anything contained herein to the contrary, no observer shall be permitted to attend any meeting of any committee of the Board of Directors without the consent of a majority of the members of such committee. The Board of Directors, or
the members of any committee thereof, as applicable, shall have the right to prevent access by any or all observers to any meeting of the Board of Directors, or committee thereof, respectively, or any portion thereof, if a majority of the directors
present at such meeting deem, in their sole discretion, such action necessary to protect the confidential information of the Company or in order to comply with the provisions of this Section 4.1(d). 
 (e) Payment of Taxes. The Company shall pay, and cause each Subsidiary to pay, and discharge all taxes, assessments and governmental charges or
levies imposed upon it or upon its income, profits or business, or upon any properties belonging to it, prior to the earliest date on which penalties or interest attach thereto, and all lawful claims that, if unpaid, might become a lien or charge
upon any properties of the Company or any Subsidiary, provided that neither the Company nor any Subsidiary shall be required to pay any such tax, assessment, charge, levy or claim that is being contested in good faith and by
appropriate proceedings if the Company or any Subsidiary shall have set aside on its books sufficient reserves, if any, with respect thereto. 
  

 21 

 (f) Payment of Trade Debt. The Company shall pay, and cause each Subsidiary to pay, when due, or
in conformity with customary trade terms but not later than ninety (90) days from the due date, all lease obligations, all trade debt, and all other indebtedness incident to the operations of the Company or its Subsidiaries, except such as are
being contested in good faith and by proper proceedings if the Company or Subsidiary concerned shall have set aside on its books sufficient reserves, if any, with respect thereto. 
 (g) Maintenance of Insurance. The Company shall maintain, and cause each Subsidiary to maintain, at all times after the date hereof, insurance
with responsible and reputable insurance companies or associations in such amounts and covering such risks as is customarily carried by companies engaged in similar businesses and owning similar properties in the same general areas in which the
Company or such Subsidiary operates. 
 (h) Intellectual Property. The Company shall secure, preserve and maintain, and cause each
Subsidiary to secure, preserve and maintain, all licenses and other rights to use patents, processes, licenses, permits, trademarks, trade names, inventions, intellectual property rights or copyrights owned by it or necessary for its primary
business activities, unless a majority of the Board of Directors, including at least two of the Senior Investor Directors (as defined below) (the “Requisite Consent”) and management deem such preservation or maintenance not required
for the conduct of the Company’s primary business activities, and will acquire and keep in full force and effect any additional rights, permits, licenses, patents, copyrights, trademarks, trade names, franchises and other intellectual property
rights as management of the Company and a majority of the Board of Directors from time to time deem necessary or appropriate in connection with the conduct of the Company’s business or the businesses of any Subsidiary. 
 (i) Compliance with Laws. The Company shall comply, and cause each Subsidiary to comply, with the requirements of all applicable laws, rules,
regulations and orders of any governmental authority, noncompliance with which could materially adversely affect its business or condition, financial or otherwise. 
 (j) Records and Books of Account. The Company shall keep, and cause each Subsidiary to keep, adequate, correct and complete records and books of account in which complete entries will be made in accordance with
generally accepted accounting principles consistently applied, reflecting all financial transactions of the Company and any Subsidiary, and in which, for each fiscal year, all proper reserves for depreciation, depletion, returns of merchandise,
obsolescence, amortization, taxes, bad debts and other purposes in connection with its business shall be made. 
 (k) Maintenance of
Properties. The Company shall maintain and preserve, and cause each Subsidiary to maintain and preserve, all of its properties and assets necessary for the proper conduct of its business, in good repair, working order and condition, ordinary
wear and tear excepted. 
  

 22 

 (l) ERISA Compliance. The Company shall comply in all material respects, and cause each Subsidiary
to comply in all material respects, with all minimum funding requirements applicable to any pension, employee benefit plans, or employee contribution plans that are subject to the Employee Retirement Income Security Act of 1974, as amended
(“ERISA”), or to the Internal Revenue Code of 1986, as amended (the “Code”), and comply, and cause each Subsidiary to comply, in all other material respects with the provisions of ERISA and the Code, and the rules
and regulations thereunder, which are applicable to any such plan; provided further that neither the Company nor any Subsidiary will permit any event or condition to exist that would permit any such plan to be terminated under circumstances that
would cause any material lien provided for in section 4068 of ERISA to attach to the assets of the Company or any Subsidiary. 
 (m)
Compliance with Environmental Laws. The Company shall comply in all material respects, and cause each Subsidiary to comply in all material respects, with the provisions of all federal, state and local environmental, health and safety laws,
codes and ordinances and all rules and regulations promulgated thereunder, and the Company shall maintain, and cause each Subsidiary to maintain, all federal, state and local permits, licenses, certificates and approvals known to the Company or any
Subsidiary to be required relating to (i) air emissions, (ii) discharges to surface water or ground water, (iii) noise emissions, (iv) solid or liquid waste disposal, (v) the use, generation, storage, transportation or
disposal of toxic or hazardous substances or wastes (intended hereby and hereafter to include any and all such materials listed in any federal, state or local law, code or ordinance and all rules and regulations promulgated thereunder, as hazardous
or potentially hazardous), or (vi) other environmental, health and safety matters. 
 (n) Financings. The Company shall promptly,
fully and in detail, inform the Board of Directors of any material discussions, offers or contracts relating to possible financings of any nature for the Company, whether initiated by the Company or any other person, except for arrangements with
trade creditors. 
 (o) Nature of Business. The Company shall continue to conduct its business without material change from the nature
of the business contemplated in the written materials delivered to the Investors prior to the date hereof. 
 (p) Key-Person Life
Insurance. The Company shall at all times maintain in full force and effect, a policy or policies of “key-person” life insurance on the lives of Jan Turek, John Irick and David Spencer, with minimum coverage of $1,500,000 per life, the
proceeds of which shall be payable to the Company. 
 (q) Noncompetition, Non-Disclosure and Inventions Agreements . The Company shall
require (i) each officer of the Company and each Key Employee (as defined in the Purchase Agreement) to enter into the Company’s standard Noncompetition Agreement (restricting such officer or employee from competing with the Company or
soliciting any employees of the Company for a period of not less than 12 months) and (ii) each employee of the Company to enter into the Company’s standard Non-Disclosure and Inventions Agreement, each in form and substance reasonably
satisfactory to the Investors, prior to the commencement of such officer’s or employee’s employment. 
  

 23 

 (r) Use of Proceeds. The Company shall expend the proceeds from the sale of the Investor Stock
primarily to advance Locteron through completion of a Phase 2b trial and for the development of various preclinical drugs and for other working capital and other corporate purposes; provided, however, that such proceeds shall not be used to pay any
indebtedness of the Company for borrowed money, cash dividends, or the repurchase or redemption of the Company’s equity securities (except for repurchases of shares from former employees, officers, directors, advisors or service providers upon
termination of employment for a price not greater than the cash price paid by such former employees, officers, directors, advisors or service providers, pursuant to the terms of stock purchase agreements with such former employees, officers,
directors, advisors or service providers providing for such repurchases at the original issuance prices for such shares and approved by the Board of Directors), unless approved by the Company’s Board of Directors. 
 (s) FDA Compliance. The Company shall maintain, and cause each Subsidiary to maintain, such permits, licenses, franchises, authorizations and
clearances (“Permits”) of governmental or regulatory authorities, including, without limitation, the Food and Drug Administration (the “FDA”) of the U.S. Department of Health and Human Services and/or any committee
thereof, as are necessary to own, lease and operate its properties and to conduct its business as now conducted and as currently proposed to be conducted; the Company shall fulfill and perform, and cause each Subsidiary to fulfill and perform, all
such material obligations with respect to the Permits, and the Company shall conduct or sponsor, and cause each Subsidiary to conduct or sponsor, feasibility, pre-clinical, clinical and other studies and tests in accordance with standard medical and
scientific research procedures. 
 (t) Directed Shares. In the event that the Company effects an initial public offering of its
capital stock, the Company shall use its reasonable best efforts to permit each Investor to designate a person or persons entitled to purchase a number of directed shares in such offering, if any, in an amount equal to the total number of directed
shares available multiplied by the total percentage of the Company’s capital stock held by such Investor on a fully-diluted basis; provided, however, that no such designation shall subject the Company or its securities to the laws of any
country other than the United States; provided further that the rights of each Investor under this Section 4.1(t) shall be subject to applicable laws, applicable rules of securities regulatory organizations, exchanges and entities through which
the Company’s securities shall be listed or quoted for trading, and the reasonable requirements of the underwriters of the initial public offering. 
 (u) Committees of the Board of Directors. A Compensation Committee of the Board of Directors (the “Compensation Committee”) and an Audit Committee (the “Audit Committee”) of
the Board of Directors shall be established and maintained at all times after the date hereof, the membership of such committees to be agreed to by the Board of Directors; provided that no member of the Compensation Committee or Audit Committee
shall be an employee of the Company. The Chief Executive Officer or interim Chief Executive Officer of the Company shall be entitled to attend meetings of the Compensation Committee in a nonvoting capacity; provided, however, that such officer may
be excluded from any meeting, or portion thereof, at the discretion of the Compensation 

  

 24 

 
Committee. The Compensation Committee will, among other things, be responsible for and have discretion concerning all compensation decisions and decisions
concerning the issuance of stock options or other equity awards, including without limitation the vesting of stock options or other equity awards. The Chief Financial Officer of the Company shall be entitled to attend meetings of the Audit Committee
in a nonvoting capacity; provided, however, that such officer may be excluded from any meeting, or portion thereof, at the discretion of the Audit Committee. The Company shall establish a Directed Share Committee and a Pricing Committee of the Board
of Directors prior to an initial public offering of the Company’s securities, each such committee to consist of three members, at least one of whom shall be a Series BB or Series CC Director (as defined below). Notwithstanding anything to the
contrary contained herein, at the option of the Series CC Director (as defined below), the Series CC Director, shall be included as a member of each committee currently existing or hereafter established by the Board of Directors, whether or not
described in this section. 
 (v) Stock Vesting. All stock and stock equivalents issued to officers, employees, directors, consultants
and other service providers will be subject to vesting as determined by the Compensation Committee, with all such stock options and other equity awards for officers or employees of the Company to vest over a period of no less than four years. If
options are exercised prior to vesting, terms of any repurchase option upon termination of employment or service of the shareholder will also be determined by the Compensation Committee. 
 (w) Market Standoff Agreements. The Company will require all future purchasers of stock prior to the initial public offering of the Company’s
securities to execute a market standoff agreement in which the holders agree, if so requested by the Company or any underwriter’s representative in connection with an initial public offering, not to sell or otherwise transfer any securities of
the Company during a period of up to 180 days following the effective date of the registration statement (which period may be extended upon the request of the managing underwriter for an additional period of up to fifteen (15) days if the
Company issues or proposes to issue an earnings or other public release within fifteen (15) days of the expiration of the 180-day lockup period). 
 (x) Directors and Officers Insurance; Indemnification. The Company shall, within ninety (90) days after the date of this Agreement, and at all times thereafter, maintain in full force and effect, directors
and officers insurance providing for coverage of not less than $3,000,000 per director per occurrence, or such other amounts as mutually agreed to by the Board of Directors. The Company’s Amended and Restated Certificate of Incorporation and
Bylaws shall at all times provide (i) for elimination of the liability of directors and officers to the maximum extent permitted by law, and (ii) for indemnification of directors and officers for acts on behalf of the Company to the
maximum extent permitted by law. 
 (y) Preservation of Corporation Existence. The Company will preserve and maintain, and, unless the
Company reasonably deems it not to be in its best interests, cause each Subsidiary to preserve and maintain, its corporate existence, rights, franchises and privileges in the jurisdictions of its incorporation, and qualify and remain qualified, and
cause each Subsidiary to qualify and remain 

  

 25 

 
qualified, as a foreign corporation in each jurisdiction in which such qualification is necessary or desirable in view of its business and operations or the
ownership or lease of its properties, except when the failure to be so qualified would not have a material adverse effect on the Company or its Subsidiaries. 
 (z) Material Change; Litigation. The officers of the Company will promptly advise the Board of Directors of any material adverse change in the business or condition, financial or otherwise, of the Company and
of each suit or proceeding commenced or known to be threatened against the Company which, if adversely determined, would result in a material adverse change. 
 (aa) Board of Directors. The Company shall call and hold meetings of the Company’s Board of Directors as determined by a majority of the Board of Directors and in accordance with the Company’s Amended
and Restated Certificate of Incorporation and Bylaws, each as amended to date, but in any event not less than on a quarterly basis. Members of the Board of Directors shall be elected in accordance with the Company’s Amended and Restated
Certificate of Incorporation, as the same may be amended from time to time, and Section 5 of this Agreement. The Company shall promptly pay all expenses reasonably incurred by each nonemployee director of the Company in attending each meeting
of the Board of Directors or any committee thereof or in attending to any other business of the Company if requested in writing by the Company. 
 4.2 Negative Covenants. The Company hereby covenants and agrees on behalf of itself and its Subsidiaries to the following. 
 (a) Limitation on Investments; Advances or Loans. Without obtaining the Requisite Consent, the Company and its Subsidiaries shall not create any Subsidiaries, or purchase or otherwise acquire, or invest in the securities of, or make
or suffer to exist any loan or advance to, or enter into any arrangement for the purpose of providing funds or credit to, or make any other investment in, any person or entity, other than loans or advances to Subsidiaries not to exceed $100,000 or
as otherwise approved by the Company’s Board of Directors. 
 (b) Dividends and Redemptions. Except as otherwise permitted in the
Amended and Restated Certificate of Incorporation of the Company, as amended, or this Agreement, the Company shall not, without obtaining the Requisite Consent (i) declare or make any dividends or distributions of its cash, stock property, or
assets or redeem, retire, purchase, or otherwise acquire, directly or indirectly, any of the capital stock or capital stock or securities of any affiliate or any Subsidiary of the Company, or any securities convertible or exchangeable into capital
stock or capital stock or securities of any affiliate or any Subsidiary of the Company or otherwise make any distribution on account of the purchase, repurchase, redemption, put, call or other retirement of any shares of capital stock of the Company
or any Subsidiary thereof or of any warrant, option or other right to acquire such shares, or (ii) pay any professional consulting or management fees or any other payments to any stockholders of the Company or any Subsidiary other than as
approved by the Company’s Board of Directors. 
  

 26 

 (c) Sale of Assets. Without obtaining the Requisite Consent, the Company shall not effect any
sale, lease, license, assignment, transfer, or other conveyance of (i) any material portion of the assets or operations or the revenue or income generating capacity of the Company (other than inventory in the ordinary course of business and
other assets reasonably and in good faith determined by the Company to be obsolete or no longer necessary to the business of the Company), or (ii) any intellectual property or proprietary rights owned by or licensed to the Company (excluding
non-exclusive licenses granted by the Company in the ordinary course of business consistent with past practice), or to take any such action that has the effect of any of the foregoing. 
 (d) Employment Matters. Without obtaining the Requisite Consent, the Company shall not (i) increase the cash compensation paid to any of its
officers or directors or any employee earning at least $150,000 per year, whether by means of salary, bonus, profit sharing, options, dividends or any other means whatsoever unless such increase has been approved by the Compensation Committee, or
(ii) make any hiring or promotion decision with respect to the Company’s Chief Executive Officer. 
 (e) Related Party
Transactions. The Company shall not enter into any transaction or transactions with any director, officer or stockholder of the Company, or any affiliate or relative of the foregoing except upon terms that, in the opinion of the Investors
holding a majority of the Investor Stock, are fair and reasonable and that are, in any event, at least as favorable as would result in a comparable arm’s-length transaction with a person or entity not a director, officer, employee, stockholder,
or affiliate of the Company or any affiliate or related party of the foregoing, or advance any monies to any such persons or entities, except for travel advances in the ordinary course of business or, as approved with the Requisite Consent, equity
financing transactions or transactions relating to the compensation of officers or directors. 
 (f) Capital Expenditures. The Company
shall not, without obtaining the Requisite Consent, make any capital expenditure (including, without limitation, expenditures under capitalized leases) totaling in excess of 110% of the amount budgeted on an annual basis for capital expenditures set
forth in the operating plan and budget approved by the Board of Directors of the Company from time to time. 
 (g) Annual Operating Plan
and Budget. The Company shall not, without obtaining the Requisite Consent, adopt or approve any annual operating plan or budget for the Company, or any material amendment, modification or revision to any annual operating plan or budget
previously approved in accordance with this section. The Company shall present an annual operating plan and budget for each fiscal year to the Board of Directors for its review and approval at least ten (10) days prior to the commencement of
such fiscal year. 
 (h) Conflicts. Neither the Company nor any of its Subsidiaries will enter into any contract, agreement,
transaction or dealing with any one or more of its directors or stockholders, or any entity with which any director or stockholder is affiliated, either as director, officer, general partner, trustee, manager or similar management level position, as
stockholder, limited partner, beneficiary, member or other equity owner, or as joint venturer, promoter, finder, agent, broker, dealer or otherwise, or any member 

  

 27 

 
of the immediate family of any such person unless the terms thereof are fully disclosed to the Board of Directors of the Company and such contract,
agreement, transaction or dealing is approved in advance by (i) a majority of the disinterested members of the Board of Directors, if any, and (ii) a majority of the disinterested directors selected by the Investors, if any. 
 (i) Limitation on Liability for Obligation of Others. Without obtaining the Requisite Consent, the Company will not assume, guarantee, endorse or
otherwise become liable for the obligations of any other person or organization, except for the endorsement of negotiable instruments for deposit or collection and similar transactions in the normal course of business. 
 (j) Loans and Investments. Without obtaining the Requisite Consent, the Company will not purchase, acquire, or hold any stock or obligations of,
or make or permit to exist any loans, advances or contributions to, or investments in, the capital of, any person or entity, or create any Subsidiary, except that the Company may: 
 (i) Invest in direct obligations of the United States of America or generally accepted short-term money market instruments for which independent credit
ratings by Standard & Poors or Moody’s Investors Service, Inc. are considered nonspeculative or in certificates of deposit at commercial banks; 
 (ii) Extend credit in the ordinary course of business in connection with the sale of its products and services; 
 (iii) Invest in, or purchase shares of open-end investment companies investing in, high-grade money market instruments; 
 (iv) Make
advances to employees and consultants for expenses incurred in the ordinary course of business, which expenses would not have been incurred in conflict with any other covenant contained herein if incurred directly by the Company; 
 (v) Prepay employees’ compensation to the extent of any such employee’s average compensation for a two-week period; 
 (vi) Make deposits in the ordinary course of business with vendors, suppliers of services, and other entities; or 
 (vii) Make investments or loans, advances or contributions to others that do not exceed, individually or in the aggregate, $15,000. 
 Notwithstanding the foregoing, the Company shall not loan or advance funds to, or accept anything other than cash as payment for any obligation to the
Company from, any employee, consultant or other service provider for any reason (other than as permitted pursuant to clauses (iv) or (v) above), including without limitation, for the purpose of paying the exercise price associated with a
stock option issued by the Company or for the purpose of paying any taxes associated with the issuance, exercise or vesting of any security of the Company awarded to any employee, consultant or service provider. 
  

 28 

 (k) Liens and Encumbrances. Without obtaining the Requisite Consent, the Company will not create,
incur or permit to exist any mortgage, pledge, encumbrance, lien, security interest or charge of any kind (including liens or charges upon properties acquired or to be acquired under conditional sales agreements or other title retention devices) on
its property or assets, except for liens securing taxes, assessments or governmental charges or levies or the claims or demands of materialmen, mechanics, carriers warehousemen, landlords and the like. 
 (l) No Public Announcements. The Company shall not make any press release, public announcement or public statement with respect to the issuance
and sale of the Series CC Stock or any of the other transactions and agreements contemplated herein or in the Purchase Agreement without the prior consent of the holders of at least sixty-eight percent (68%) of the Series CC Stock. 

4.3 Expiration of Covenants. The covenants set forth in this Section 4 shall expire and be of no further force or effect upon the earlier
of (i) the effectiveness of a Qualified Public Offering (as defined in Section 3.5 hereof) or (ii) the effectiveness of a registration statement for the sale of the Company’s shares of Common Stock in the Company’s first IPO
in connection with which all shares of Preferred Stock have converted into shares of Common Stock. After such time, the Investors shall be entitled to receive such annual and quarterly reports as the Company shall distribute to its stockholders
generally. 
 Section 5. 
 VOTING AGREEMENT 
 5.1 Election of Directors. From and after the execution of this Agreement, the Board of Directors
of the Company will consist of seven persons; provided that through December 31, 2007 the Board of Directors of the Company may consist of eight persons as set forth in subsection (a)(i) below. Each time the stockholders of the Company meet, or
act by written consent in lieu of a meeting, for the purpose of electing the directors to serve on the Company’s Board of Directors, each Common Holder and each Investor shall vote the shares of the Company’s capital stock owned by it in
order to cause the election of members to the Board of Directors as follows: 
 (a) At each election of directors in which the
holders of the Series AA1 Stock and Series AA2 Stock, voting together as a single class, are entitled to elect two directors of the Company, (i) one individual (the “Intersouth Director”) designated by Intersouth Partners V,
L.P. (“Intersouth”), provided that Intersouth may designate one additional individual for a term of office that shall expire on or before December 31, 2007 (at which time Intersouth will cause such director to resign or will
take appropriate action to remove such director) and (ii) one individual (the “Quaker Director” and together with the Intersouth Director, the “Series AA Directors”) designated by Quaker BioVentures, L.P.
(“Quaker”); 
  

 29 

 (b) At each election of directors in which the holders of the Series BB Stock, voting as
a separate class, are entitled to elect one director of the Company, one individual (the “Series BB Director”) designated by Polaris Venture Partners IV, L.P. (“Polaris”); 
 (c) At each election of directors in which the holders of the Series CC Stock, voting as a separate class, are entitled to elect one
director of the Company, one individual (the “Series CC Director” and, together with the Series AA Directors and the Series BB Director, the “Senior Investor Directors”) designated by Investor Growth Capital
Limited, Investor Group, L.P., or both (collectively, “Investor Growth Capital”); 
 (d) At each election of
directors in which the holders of the Preferred Stock and Common Stock, voting together as a single class, are entitled to elect directors of the Company, (i) the Company’s Chief Executive Officer (the “CEO Director”)
(provided that, if for any reason the CEO Director shall cease to serve as the Chief Executive Officer of the Company, each Common Holder and each Investor shall promptly vote their respective shares of the Company’s capital stock (x) to
remove the former Chief Executive Officer from the Board if such person has not resigned as a member of the Board and (y) to elect such person’s replacement as the permanent or interim Chief Executive Officer of the Company as the new CEO
Director), and (ii) two independent outside designees designated by, and mutually acceptable to, Investor Growth Capital, Intersouth, Quaker and Polaris. 
 5.2 Vacancies. In the event any vacancy occurs on the Board of Directors with respect to a director so elected pursuant to the preceding Section 5.1, such vacancy shall be filled in accordance with the
intent of Section 5.1. Any vacancy on the Board of Directors shall be filled by another person designated in a manner set forth in Section 5.1 so as to preserve the constituency of the Board of Directors as provided above. In the event the
Chief Executive Officer of the Company ceases to be a director but remains the Chief Executive Officer, such vacancy shall be filled by a designee of the holders of a majority of the then outstanding shares of Common Stock and Preferred Stock (on an
as-converted basis) held by the Investors and the Common Holders, voting together as a single class. In case of any such vacancy, the parties to this Agreement agree to use their best efforts to cause a special meeting of the stockholders of the
Company to be called or a written consent of the stockholders of the Company in lieu of a meeting to be executed as quickly as possible for the purpose of filling the vacancy thereby created so that the Board of Directors at all times is constituted
so as to have the number of directors specified herein. 
 5.3 Removal. Each Common Holder and Investor also agrees to vote, or cause
to be voted, all shares owned by such Common Holder or Investor, or over which such Common Holder or Investor has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that: 
 (a) no director designated by Intersouth pursuant to Section 5.1(a) of this Agreement may be removed from office unless (i) such removal is
directed or approved by the affirmative vote of Intersouth or (ii) Intersouth is no longer so entitled to designate or approve such director; 
  

 30 

 (b) no director designated by Quaker pursuant to Section 5.1(a) of this Agreement may be removed
from office unless (i) such removal is directed or approved by the affirmative vote of Quaker or (ii) Quaker is no longer so entitled to designate or approve such director; 
 (c) no director designated by Polaris pursuant to Section 5.1(b) of this Agreement may be removed from office unless (i) such removal is
directed or approved by the affirmative vote of Polaris or (ii) Polaris is no longer so entitled to designate or approve such director; 
 (d) no director designated by Investor Growth Capital pursuant to Section 5.1(c) of this Agreement may be removed from office unless (i) such removal is directed or approved by the affirmative vote of Investor Growth Capital or
(ii) Investor Growth Capital is no longer so entitled to designate or approve such director; 
 (e) no other director elected pursuant
to Section 5.1 of this Agreement may be removed from office unless (i) such removal is directed or approved by the affirmative vote of the person(s) or entity(ies) entitled under Section 5.1 to designate that director or (ii) the
person(s) or entity(ies) originally entitled to designate or approve such director pursuant to Section 5.1 is no longer so entitled to designate or approve such director; and 
 (f) any vacancies created by the resignation, removal or death of a director elected pursuant to Section 5.1 shall be filled pursuant to the
provisions of this Section 5. 
 All Common Holders and Investors agree to execute any written consents required to perform the
obligations of this Agreement, and the Company agrees at the request of any party entitled to designate directors to call a special meeting of stockholders for the purpose of electing directors. 
 5.4 Grant of Proxy. Upon the failure of any Common Holder or Investor to vote their shares of the Company’s capital stock in accordance with
the terms of this Section 5, such Common Holder or Investor hereby grants to a stockholder designated by the Board of Directors of the Company a proxy coupled with an interest in all shares of the Company’s capital stock owned by such
Common Holder or Investor, which proxy shall be irrevocable until this Agreement terminates pursuant to its terms or this Section 5.4 is amended to remove such grant of proxy in accordance with Section 8.4 hereof, to vote all such shares
of the Company’s capital stock in the manner provided in this Section 5. 
 5.5 Election of Members of Scientific Advisory Board
and Development Advisory Board. The Company shall not take any action to change the size or membership of its Scientific Advisory Board or Development Advisory Board (whether through appointments, termination, removal or otherwise) without
obtaining the Requisite Consent. 
  

 31 

 5.6 Binding Effect of Voting Agreement. The voting agreement set forth in this Section 5
shall be binding upon the Investors, the Common Holders and any transferee of shares of the Company’s stock held by the Investors or the Common Holders. Each such transferee shall execute documents reasonably acceptable to the Company and the
Investors assuming the obligations of the transferor under this Section 5 prior to the completion of such transfer. 
 5.7
Legends. Each certificate held by or issued to the Investors or the Common Holders, whether now outstanding or subsequently issued, shall be surrendered to the Company for endorsement or be endorsed by the Company prior to its issuance with
substantially the following legend. 
 THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A VOTING AGREEMENT AMONG THE HOLDER OF
THESE SECURITIES AND CERTAIN OTHER HOLDERS OF THE ISSUER’S SECURITIES. BY ACCEPTING ANY INTEREST IN SUCH SECURITIES, THE PERSON ACCEPTING SUCH INTEREST SHALL BE DEEMED TO AGREE TO AND SHALL BECOME BOUND BY ALL OF THE PROVISIONS OF SUCH
AGREEMENT. COPIES OF SUCH VOTING AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE CORPORATION AT THE PRINCIPAL EXECUTIVE OFFICES OF THE CORPORATION. 
 5.8 Termination of Voting Agreement. The covenants set forth in this Section 5 shall terminate (i) immediately before the consummation
of an IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the 1934 Act, or (iii) the date ten years from the date hereof, whichever occurs first. 
 Section 6. 
 SPECIAL PUT OPTION RIGHTS

 6.1 Option to Sell Shares to the Company. In the event the Company receives a bona fide written offer (an
“Offer”) regarding a Change of Control Transaction (as defined below), the Company shall promptly (and in any event within fifteen (15) days after receipt of such Offer) deliver a copy of such Offer and all supporting
documentation related thereto to the Senior Investors. In the event the Company or its stockholders reject such Offer or otherwise prevent the Company from consummating such Change of Control Transaction in any manner, then the Company shall
promptly thereafter (and in any event within fifteen (15) days) provide notice of the rejection of such Offer to the Senior Investors (the “Termination Notice”). If, within thirty (30) days of delivery of the Termination
Notice, the Company receives from the Senior Investors holding a majority of the Senior Stock a written demand (the “Investors’ Notice”) that the Company purchase all, but not less than all, of the Senior Stock held by Senior
Investors electing to have their Senior Stock so redeemed by the Company (the “Participating Investors”), the Company may within 5 days after receiving the Investors’ Notice reconsider the Offer and resubmit the Offer to the
consideration of its stockholders for their approval. If the Company fails to so reconsider the Offer within 5 days after receiving the Investors’ Notice, the Company or its stockholders 

  

 32 

 
again reject such Offer or otherwise prevent the Company from consummating such Change of Control Transaction or if for any other reason the Change in
Control Transaction is not consummated, the Company shall redeem, on the Redemption Date (as defined below) at the Redemption Price (as defined below), all of the Senior Stock then held by all the Participating Investors on the terms herein
provided. Within fifteen (15) days of receipt of the Investors’ Notice, and at least thirty (30) days prior to the Redemption Date, the Company shall mail written notice (the “Redemption Notice”), postage prepaid, to
each Senior Investor at its post office address last shown on the records of the Company, (i) specifying the Redemption Date, the Redemption Price, the place at which payment of the Redemption Price may be obtained, (ii) requiring each
such Senior Investor to provide written notice to the Company of its election to become a Participating Investor (the “Election Notice”) within fifteen (15) days of receipt of the Redemption Notice (the “Election
Period”), and (iii) providing instructions for Senior Investors electing to become Participating Investors to surrender to the Company, in the manner and at the place designated, his, her or its certificate or certificates representing
the shares of Senior Stock to be redeemed on the Redemption Date. Any Senior Investor who fails to deliver his, her or its Election Notice to the Company prior to expiration of the Election Period shall forfeit all rights to have his, her or its
Senior Stock redeemed pursuant to this Section 6.1. The demand to redeem the Senior Stock of Participating Investors pursuant to this Section 6.1 shall be referred to as the “Option.” 
 6.2 Redemption Price. The price per share to be paid by the Company upon redemption of the Senior Stock of Participating Investors under the
Option (the “Redemption Price”) shall equal the maximum amount per share that the Participating Investors would have received as a result of the consummation of the Change of Control Transaction. If the proposed Change of Control
Transaction is structured as a purchase of assets, the Redemption Price shall be calculated assuming that, if the Change of Control Transaction had been consummated, the Company would have applied the proceeds first to satisfy outstanding
obligations on the date thereof and then distributed the balance thereof to the stockholders of the Company in accordance with the Company’s Amended and Restated Certificate of Incorporation. If the proposed Change of Control Transaction is
structured as a merger or stock purchase, the Redemption Price shall be calculated based on the amount per share the offeror proposed to pay or distribute to the Participating Investors in connection with such Change of Control Transaction. If the
consideration proposed in the Offer would be payable in securities or property other than cash, the value of the securities or property to be distributed in such event shall be determined as follows: 
 (a) For securities not subject to investment letter or other similar restrictions on free marketability covered by Section 6.2(b) below: (i) if
traded on a securities exchange, the value shall be deemed to be the average of the closing prices of the securities on such exchange over the 30-calendar-day period ending three business days prior to the closing of the redemption; (ii) if
actively traded over-the-counter, the value shall be deemed to be the average of the closing bid or sale prices (whichever are applicable) over the 30-calendar-day period ending three business days prior to the closing of the redemption; and
(iii) if there is no active public market, the fair value shall be the fair market value thereof, as reasonably determined by the Board of Directors in good faith; provided, however, that if one or more Participating Investors holding at least
a majority of the shares of Senior Stock to be redeemed 

  

 33 

 
by the Company object to such determination (the “Objecting Stockholders”), then the Company and a majority in voting power of the Objecting
Stockholders shall select an independent appraiser to determine the fair market value thereof, and if no agreement can be reached on selection of such independent appraiser, each of the Company and a majority in voting interest of the Objecting
Stockholders shall select an independent appraiser who shall together select a third independent appraiser who shall determine the value of such securities. The fees and expenses of any such third independent appraiser shall be borne by the party
(the Company on one hand or the Objecting Stockholders on the other hand) whose value determination is furthest from that determined by the third independent appraiser. 
 (b) The method of valuation of securities subject to investment letter or other restrictions on free marketability (other than restrictions arising solely by virtue of a stockholder’s status as an affiliate or
former affiliate) shall be to make an appropriate discount from the fair value determined as provided in clauses (i), (ii) or (iii) of Section 6.2(a) above, to reflect the adjusted value thereof, as reasonably determined by the Board
of Directors in good faith; provided, however, that if any Senior Investors object to such discount, the amount of such discount shall be determined under the same procedure as set forth in Section 6.2(a)(iii) above. 
 (c) If the distribution would be payable in assets or property other than securities, the value thereof shall be determined under the same procedure as
set forth in Section 6.2(a)(iii) above. 
 6.3 Redemption Date. Within forty five (45) days after the later of (a) the
date of the Investor’s Notice or (b) the final determination of the Redemption Price after an objection raised by Objecting Stockholders pursuant to Section 6.2(a)(iii) (including as such section applies to the provisions of
Section 6.2(b) and 6.2(c)) (the “Redemption Date”), the Company shall pay the Redemption Price for the Senior Stock by bank or certified check or wire transfer of funds to such bank account as the Participating Investors shall
direct, and the Participating Investors shall tender their stock certificate(s) representing the Senior Stock being redeemed. If the Company is prohibited from repurchasing any shares of Senior Stock on the Redemption Date due to the fact that such
repurchase would violate applicable law, the Company shall pay for such remaining Senior Stock at the next earliest date when such repurchase is permitted; and any amounts not paid at the Redemption Date shall be paid as soon as permitted. Upon
redemption of any Senior Stock, all rights of such Senior Stock shall terminate. 
 6.4 Change of Control Transaction. For purposes of
this Section 6, a “Change of Control Transaction” shall mean (i) a sale, lease, transfer, exchange or other disposition of all or substantially all the assets of the Company or an exclusive license of all or substantially
all of the Company’s intellectual property, (ii) a merger, consolidation, sale or reorganization as a result of which stockholders of the Company immediately prior to such merger, consolidation, sale or reorganization either
(a) possess less than 50% of the voting power of the acquiring, surviving or successor entity immediately following such merger, consolidation, sale or reorganization or (b) do not possess the voting power of the acquiring, surviving or
successor entity immediately following such merger, consolidation, sale or reorganization in substantially the same proportions as such stockholders possessed immediately prior thereto, or (iii) the transfer by one or more stockholders of the
Company of securities of the Company representing 50% or more of the combined voting power of the then outstanding securities of the Company. 
  

 34 

 Section 7. 
 WAIVER OF RIGHTS OF FIRST REFUSAL; CONSENTS AND WAIVERS 
 7.1 Waiver of Rights of First
Refusal. Pursuant to Sections 3 and 8.5 of the Existing Rights Agreement, the Investors having rights of first refusal under the Existing Rights Agreement hereby waive, on behalf of all parties having such rights thereunder, all rights they may
have under Section 3 of the Existing Rights Agreement with respect to the issuance and sale of the Investor Stock, including, without limitation, their right to receive notice pursuant to Section 3.3 of the Existing Rights Agreement and
their right of first refusal pursuant to Section 3.2 of the Existing Rights Agreement. 
 7.2 Consent. Notwithstanding the
provisions of Section 8.3 hereof, the consent of the Investors holding shares of the Company’s Series AA2 Stock and Series BB Stock contained in Section 7.2 of the Existing Rights Agreement to the issuance by the Company of a warrant
to Oxford Financial Corporation to purchase up to 66,964 shares of Series BB Stock at an exercise price per share equal to $1.12 per share, shall not be superseded by this Agreement and shall survive the termination of the Existing Rights Agreement.

 7.3 Waiver and Consent to Transfer of Shares by Milepost. Milepost Ventures, L.P. (“Milepost”) as a holder of
shares of Series BB Stock and Series AA2 Stock set forth in Exhibit B and Exhibit C hereto (the “Milepost Shares”), is subject to certain transfer restrictions set forth in Section 1 of the Existing Rights Agreement and this
Agreement. Milepost is liquidating its portfolio and in connection therewith is proposing to transfer the Milepost Shares to Saints Capital. The Investors and the Company hereby consent to such transfer and hereby waive the requirements in
Section 1.2 of the Existing Agreement and this Agreement that Milepost provide an opinion of counsel to the Company that the proposed transfer of the Milepost Shares may be effected without registration under the 1933 Act. 
 Section 8. 
 MISCELLANEOUS

 8.1 Governing Law. This Agreement shall be governed by, and construed and interpreted in accordance with the laws of the State
of North Carolina as applied to agreements among North Carolina residents made and to be performed entirely within the State of North Carolina, provided, however, that the provisions of Section 5 hereof shall be governed by and construed in
accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof. 
 8.2 Successors and
Assigns. Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto. Any transfer of shares by the
Common Holders or the Investors shall be effected in accordance with the applicable provisions of this Agreement. 
  

 35 

 8.3 Entire Agreement. This Agreement constitutes the full and entire understanding and agreement
among the parties with regard to the subjects hereof. Nothing in this Agreement, express or implied, is intended to confer upon any party, other than the parties hereto and their successors and assigns, any rights, remedies, obligations or
liabilities under or by reason of this Agreement, except as expressly provided herein. Except as otherwise expressly provided herein, any previous agreement among the parties relating to the specific subject matter hereof is superseded by this
Agreement including, without limitation, the Existing Rights Agreement, which is hereby terminated in its entirety. 
 8.4
Severability. Any invalidity, illegality or limitation of the enforceability with respect to any Holder of any one or more of the provisions of this Agreement, or any part thereof, whether arising by reason of the law of any such
person’s domicile or otherwise, shall in no way affect or impair the validity, legality or enforceability of this Agreement with respect to any other Holder. In case any provision of this Agreement shall be invalid, illegal or unenforceable, it
shall to the extent practicable, be modified so as to make it valid, legal and enforceable and to retain as nearly as practicable the intent of the parties, and the validity, legality, and enforceability of the remaining provisions shall not in any
way be affected or impaired thereby. 
 8.5 Amendment and Waiver. Except as otherwise expressly provided herein, this Agreement may be
terminated in its entirety, any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, either retroactively or prospectively and either for a specified
period of time or indefinitely) with the written consent of the Company and the Investors, or their transferees, holding at least a majority of the shares of Investor Stock and voting together as a single group (treated as if converted at the
conversion rate then in effect and including, for such purposes, shares of Common Stock into which any shares of Investor Stock shall have been converted that are held by a Holder); provided, however, that (i) no such amendment or
waiver shall reduce the aforesaid percentage of Investor Stock and Common Stock issued upon conversion thereof, the holders of which are required to consent to any waiver or supplemental agreement, without the consent of the holders of all of such
Investor Stock and Common Stock; (ii) any amendment to Section 2.14 (or to Section 2.3 that would affect the rights under Section 2.14) shall also require the consent of the holders of at least a majority of the shares of Common
Stock issued to, or issuable upon exercise of options held by, the Common Holders; (iii) in the event any amendment adversely affects the rights and/or obligations of a particular Investor in a different manner than all other Investors, such
amendment must also be approved by such Investor. Notwithstanding the foregoing, (i) no amendment, waiver or termination of Section 5.1(a) relating to Intersouth shall be effective without the prior written consent of Intersouth,
(ii) no amendment, waiver or termination of Section 5.1(a) relating to Quaker shall be effective without the prior written consent of Quaker, (iii) no amendment, waiver or termination of Section 5.1(b) shall be effective without
the prior written consent of Polaris, and (iv) no amendment, waiver or termination of Section 5.1(c) shall be effective without the prior written consent of Investor Growth Capital. Any amendment or waiver effected in accordance with this
Section 8.5 shall be binding upon the Company, each Common Holder, each Investor and each transferee of the Investor Stock or 

  

 36 

 
Common Stock. Upon the effectuation of each such amendment or waiver, the Company shall promptly give written notice thereof to the Investors and Common
Holders who have not previously consented thereto in writing. Notwithstanding anything to the contrary in this Section 8.5, the Company shall be entitled to include additional purchasers of its Series CC Stock pursuant to the Purchase Agreement
as parties to this Agreement, and to treat such purchasers as “Investors” and “Holders” hereunder, by amending Exhibit D attached hereto and providing such Exhibit D, as amended, to the other parties to this
Agreement. 
 8.6 Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to the Company, the
Investors, or any transferees upon any breach, default or noncompliance of the Investors or any transferee or the Company under this Agreement, shall impair any such right, power or remedy, nor shall it be construed to be a waiver of any such
breach, default or noncompliance, or any acquiescence therein, or of any similar breach, default or noncompliance thereafter occurring. It is further agreed that any waiver, permit, consent or approval of any kind or character on the part of the
Company or the Investors of any breach, default or noncompliance under this Agreement or any waiver on the Company’s or the Investors’ part of any provisions or conditions of this Agreement must be in writing and shall be effective only to
the extent specifically set forth in such writing and that all remedies, either under this Agreement, by law, or otherwise afforded to the Company and the Investors, shall be cumulative and not alternative. 
 8.7 Notices, etc. All notices and other communications required or permitted hereunder shall be in writing and shall be deemed effectively given
upon personal delivery or upon confirmed delivery by facsimile or telecopy, or on the fifth day (or the tenth day if to a party with an address outside of the United States) following mailing by registered or certified mail, return receipt
requested, postage prepaid, addressed: (a) if to the Company, at: 
 Biolex, Inc. 
 158 Credle Street 
 Pittsboro, NC 27312

 Attn: President 
 Facsimile:
(919) 542-9910 
 With a copy to: 
 Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. 
 Post Office Box 2611 
 Raleigh, North Carolina 27602-2611 
 Attn:
Michael P. Saber 
 Facsimile: (919) 821-6800 
 or at such other address as the Company shall have furnished to the Investors in writing, 
  

 37 

 (b) if to the Investors, at the addresses of such Investors specified on Exhibit A, Exhibit
B, Exhibit C or Exhibit D hereto, or at such other addresses as the Investors shall have furnished to the Company in writing, and 
 (c) if to a Common Holder, at such Common Holder’s address specified on Exhibit E hereto, or at such other address as such Common Holder shall have furnished to the Company in writing. 
 8.8 Titles and Subtitles. The titles of the sections and subsections of this Agreement are for convenience of reference only and are not to be
considered in construing this Agreement. 
 8.9 Counterparts. This Agreement may be executed in any number of counterparts, each of
which shall be deemed an original, but all of which together shall constitute one instrument. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT
BLANK] 
  

 38 

 IN WITNESS WHEREOF, this Fourth Amended and Restated Investor Rights Agreement has been duly executed and
delivered by the parties as of the date first above written. 
  

							
	COMPANY:	 		 	BIOLEX, INC.
				
		 		 	By:	 	 /s/ Jan Turek

		 		 	Name:	 	Jan Turek
		 		 	Title:	 	President and Chief Executive Officer
			
	INVESTORS:	 		 	INVESTOR GROWTH CAPITAL LIMITED
				
		 		 	By:	 	 /s/ Nigel Govett

		 		 	Name:	 	Nigel Govett
		 		 	Title:	 	‘A’ Director
				
		 		 	By:	 	 /s/ Robert de Heus

		 		 	Name:	 	Robert de Heus
		 		 	Title:	 	B Director
			
		 		 	INVESTOR GROUP, L.P.
				
		 		 	By:	 	Investor Group G.P. Limited
		 		 	Its:	 	General Partner
				
		 		 	By:	 	 /s/ Nigel Govett

		 		 	Name:	 	Nigel Govett
		 		 	Title:	 	‘A’ Director
				
		 		 	By:	 	 /s/ Robert de Heus

		 		 	Name:	 	Robert de Heus
		 		 	Title:	 	‘B’ Director

							
		 		 	JP MORGAN SECURITIES INC.
				
		 		 	By:	 	 /s/ Dan Sommers

		 		 	Name:	 	Dan Sommers
		 		 	Title:	 	 Executive Director
 Equities
Division

 IN WITNESS WHEREOF, this Fourth Amended and Restated Investor Rights Agreement has been duly
executed and delivered by the parties as of the date first above written. 
  

							
		 		 	EASTON CAPITAL PARTNERS, L.P.
				
		 		 	By:	 	ECP GP, LLC, its General Partner
		 		 	By:	 	ECP GP, Inc., its Manager
				
		 		 	By:	 	 /s/ Charles B. Hughes

		 		 	Name:	 	Charles B. Hughes
		 		 	Title:	 	Vice President
			
		 		 	POLARIS VENTURE PARTNERS IV, L.P.
			
		 		 	By its General Partner
		 		 	POLARIS VENTURE MANAGEMENT CO. IV, L.L.C.
				
		 		 	By:	 	 /s/ William E. Bilodeau

		 		 	Name:	 	William E. Bilodeau
		 		 	Title:	 	Attorney-in-fact
			
		 		 	POLARIS VENTURE PARTNERS ENTREPRENEURS’ FUND IV, L.P.
			
		 		 	By its General Partner
		 		 	POLARIS VENTURE MANAGEMENT CO. IV, L.L.C.
				
		 		 	By:	 	 /s/ William E. Bilodeau

		 		 	Name:	 	William E. Bilodeau
		 		 	Title:	 	Attorney-in-fact

 IN WITNESS WHEREOF, this Fourth Amended and Restated Investor Rights Agreement has been duly executed and
delivered by the parties as of the date first above written. 
  

							
	INVESTORS (CONTINUED):	 		 	INTERSOUTH PARTNERS V, L.P.
			
		 		 	By its General Partner
		 		 	INTERSOUTH ASSOCIATES V, LLC
				
		 		 	By:	 	 /s/ Dennis Doughterty

		 		 	Name:	 	Dennis Dougherty
		 		 	Title:	 	Member Manager
			
		 		 	INTERSOUTH AFFILIATES V, L.P.
			
		 		 	By its General Partner
		 		 	INTERSOUTH ASSOCIATES V, LLC
				
		 		 	By:	 	 /s/ Dennis Dougherty

		 		 	Name:	 	Dennis Dougherty
		 		 	Title:	 	Member Manager
			
		 		 	INTERSOUTH PARTNERS IV, L.P.
			
		 		 	By its General Partner
		 		 	INTERSOUTH ASSOCIATES IV, LLC
				
		 		 	By:	 	 /s/ Dennis Dougherty

		 		 	Name:	 	Dennis Dougherty
		 		 	Title:	 	Member Manager

 IN WITNESS WHEREOF, this Fourth Amended and Restated Investor Rights Agreement has been duly executed and
delivered by the parties as of the date first above written. 
  

							
	INVESTORS (CONTINUED):	 		 	QUAKER BIOVENTURES, L.P.
				
		 		 	By:	 	Quaker Bioventures Capital, L.P.,
		 		 		 	its general partner
				
		 		 	By:	 	Quaker Bioventures Capital, LLC,
		 		 		 	its general partner
				
		 		 	By:	 	 /s/ Sherrill Neff

		 		 	Name:	 	Sherrill Neff
		 		 	Title:	 	Member
			
		 		 	MITSUI & CO. VENTURE PARTNERS II, L.P.
				
		 		 	By:	 	Mitsui & Co. Venture Partners, Inc.,
		 		 		 	its general partner
				
		 		 	By:	 	 /s/ Koichi Ando

		 		 	Name:	 	Koichi Ando
		 		 	Title:	 	President & CEO
			
		 		 	JOHNSON & JOHNSON DEVELOPMENT CORPORATION
				
		 		 	By:	 	 /s/ Carol A. Marino

		 		 	Name:	 	Carol A. Marino
		 		 	Title:	 	Vice President, Venture Investments
			
		 		 	THE DOW CHEMICAL COMPANY
				
		 		 	By:	 	 /s/ Vincent Lai

		 		 	Name:	 	Vincent Lai
		 		 	Title:	 	Corporate Funding Director

 IN WITNESS WHEREOF, this Fourth Amended and Restated Investor Rights Agreement has been duly executed and
delivered by the parties as of the date first above written. 
  

							
	INVESTORS (CONTINUED):	 		 	NORTH CAROLINA ECONOMIC OPPORTUNITIES FUND, LIMITED PARTNERSHIP
				
		 		 	By:	 	Carlisle, Smith and Buchanan, LLC
		 		 		 	its General Partner
				
		 		 	By:	 	 /s/ H. Dabney Smith

		 		 	Name:	 	H. Dabney Smith
		 		 	Title:	 	General Partner
			
		 		 	THE TRELYS FUNDS, L.P.
				
		 		 	By:	 	Trelys Ventures, L.L.C.,
		 		 		 	Its General Partner
				
		 		 	By:	 	  

		 		 	Name:	 	  

		 		 	Title:	 	  

			
		 		 	KITTY HAWK CAPITAL LIMITED PARTNERSHIP IV
			
		 		 	By its General Partner
		 		 	KITTY HAWK PARTNERS LIMITED LIABILITY COMPANY IV
				
		 		 	By:	 	 /s/ W. Chris Hegele

		 		 	Name:	 	W. Chris Hegele
		 		 	Title:	 	Managing Member

 IN WITNESS WHEREOF, this Fourth Amended and Restated Investor Rights Agreement has been duly executed and
delivered by the parties as of the date first above written. 
  

							
	INVESTORS (CONTINUED):	 		 	ACADEMY CENTENNIAL FUND, LLC
			
		 		 	By its Manager
		 		 	ACADEMY CENTENNIAL MANAGEMENT, LLC
				
		 		 	By:	 	  

		 		 	Name:	 	  

		 		 	Title:	 	  

			
		 		 	BIOLEX PARTNERS II LLC
				
		 		 	By:	 	  

		 		 	Name:	 	  

		 		 	Title:	 	  

			
		 		 	WAKEFIELD GROUP III LLC
				
		 		 	By:	 	 /s/ David Gilroy

		 		 	Name:	 	David Gilroy
		 		 	Title:	 	Partner, Wakefield Group III, LLC
			
		 		 	VIRGINIA BIOLEX PARTNERS, L.P.
				
		 		 	By:	 	Tall Oaks Capital Partners, LLC,
		 		 		 	its general partner
				
		 		 	By:	 	 /s/ Kathryn F. Carr

		 		 	Name:	 	Kathryn F. Carr
		 		 	Title:	 	Managing Director

 IN WITNESS WHEREOF, this Fourth Amended and Restated Investor Rights Agreement has been duly executed and
delivered by the parties as of the date first above written. 
  

							
	INVESTORS (CONTINUED):	 		 	VILLAGE VENTURES PARTNERS FUND, L.P.
				
		 		 	By:	 	Village Ventures Capital Partners I, LLC,
		 		 		 	its general partner
		 		 	By:	 	Village Ventures, Inc., its manager
				
		 		 	By:	 	 /s/ Steven H. Massicotte

		 		 	Name:	 	Steven H. Massicotte
		 		 	Title:	 	Chief Operating Officer
			
		 		 	VILLAGE VENTURES PARTNERS FUND A, L.P.
				
		 		 	By:	 	Village Ventures Capital Partners I, LLC,
		 		 		 	its general partner
		 		 	By:	 	Village Ventures, Inc., its manager
				
		 		 	By:	 	 /s/ Steven H. Massicotte

		 		 	Name:	 	Steven H. Massicotte
		 		 	Title:	 	Chief Operating Officer

 IN WITNESS WHEREOF, this Fourth Amended and Restated Investor Rights Agreement has been duly executed and
delivered by the parties as of the date first above written. 
  

							
	INVESTORS (CONTINUED):	 		 	TD JAVELIN CAPITAL FUND II, L.P.
				
		 		 	By:	 	  

		 		 	Name:	 	  

		 		 	Title:	 	  

			
		 		 	TD LIGHTHOUSE CAPITAL FUND, L.P.
				
		 		 	By:	 	  

		 		 	Name:	 	  

		 		 	Title:	 	  

			
		 		 	TD ORIGEN CAPITAL FUND, L.P.
				
		 		 	By:	 	  

		 		 	Name:	 	  

		 		 	Title:	 	  

 IN WITNESS WHEREOF, this Fourth Amended and Restated Investor Rights Agreement has been duly executed and
delivered by the parties as of the date first above written. 
  

							
	INVESTORS (CONTINUED):	 		 	CMEA LIFE SCIENCES FUND, L.P.
				
		 		 	By:	 	  

		 		 	Name:	 	  

		 		 	Title:	 	  

			
		 		 	SAINTS CAPITAL V, L.P.
				
		 		 	By:	 	Saints Capital V, LLC
		 		 	Its:	 	Manager
				
		 		 	By:	 	 /s/ Lilian Shackelford Murray

		 		 	Name:	 	Lilian Shackelford Murray
		 		 	Title:	 	Member
			
		 		 	 /s/ George M. Mackie

		 		 	GEORGE M. MACKIE, IV
			
		 		 	 /s/ David V. Gilroy

		 		 	DAVID V. GILROY
			
		 		 	 /s/ Kenneth P. West

		 		 	KENNETH P. WEST
			
		 		 	 /s/ David L. Castaldi

		 		 	DAVID L. CASTALDI

 IN WITNESS WHEREOF, this Fourth Amended and Restated Investor Rights Agreement has been duly executed and
delivered by the parties as of the date first above written. 
  

							
	COMMON HOLDERS:	 		 	INTERSOUTH PARTNERS IV, L.P.
			
		 		 	By its General Partner
		 		 	INTERSOUTH ASSOCIATES IV, LLC
				
		 		 	By:	 	 /s/ Dennis Dougherty

		 		 	Name:	 	Dennis Dougherty
		 		 	Title:	 	Member Manager
			
		 		 	KITTY HAWK CAPITAL LIMITED PARTNERSHIP IV
			
		 		 	By its General Partner
		 		 	KITTY HAWK PARTNERS LIMITED LIABILITY COMPANY IV
				
		 		 	By:	 	 /s/ W. Chris Hegele

		 		 	Name:	 	W. Chris Hegele
		 		 	Title:	 	Managing Member
			
		 		 	ACADEMY CENTENNIAL FUND, LLC
			
		 		 	By its Manager
		 		 	ACADEMY CENTENNIAL MANAGEMENT, LLC
				
		 		 	By:	 	  

		 		 	Name:	 	  

		 		 	Title:	 	  

 IN WITNESS WHEREOF, this Fourth Amended and Restated Investor Rights Agreement has been duly executed and
delivered by the parties as of the date first above written. 
  

							
	COMMON HOLDERS	 		 	
	(CONTINUED) :	 		 	NORTH CAROLINA FORESTRY FOUNDATION, INC.
				
		 		 	By:	 	  

		 		 	Name:	 	  

		 		 	Title:	 	  

			
		 		 	BIOLEX PARTNERS LLC
				
		 		 	By:	 	  

		 		 	Name:	 	  

		 		 	Title:	 	  

			
		 		 	WAKEFIELD GROUP III LLC
				
		 		 	By:	 	 /s/ David Gilroy

		 		 	Name:	 	David Gilroy
		 		 	Title:	 	Partner, Wakefield Group III, LLC
			
		 		 	VIRGINIA BIOLEX PARTNERS, L.P.
				
		 		 	By:	 	Tall Oaks Capital Partners, LLC,
		 		 		 	its general partner
				
		 		 	By:	 	  

		 		 	Name:	 	  

		 		 	Title:	 	  

 IN WITNESS WHEREOF, this Fourth Amended and Restated Investor Rights Agreement has been duly executed and
delivered by the parties as of the date first above written. 
  

							
	COMMON HOLDERS	 		 	
	(CONTINUED):	 		 	VILLAGE VENTURES PARTNERS FUND, L.P.
				
		 		 	By:	 	Village Ventures Capital Partners I, LLC,
		 		 		 	its general partner
		 		 	By:	 	Village Ventures, Inc., its manager
				
		 		 	By:	 	 /s/ Steven H. Massicotte

		 		 	Name:	 	Steven H. Massicotte
		 		 	Title:	 	Chief Operating Officer
			
		 		 	VILLAGE VENTURES PARTNERS FUND A, L.P.
				
		 		 	By:	 	Village Ventures Capital Partners I, LLC,
		 		 		 	its general partner
		 		 	By:	 	Village Ventures, Inc., its manager
				
		 		 	By:	 	 /s/ Steven H. Massicotte

		 		 	Name:	 	Steven H. Massicotte
		 		 	Title:	 	Chief Operating Officer
			
		 		 	 /s/ George M. Mackie

		 		 	GEORGE M. MACKIE, IV
			
		 		 	  

		 		 	BILLY HOUGHTELING
			
		 		 	  

		 		 	LINDA ROBLES

 IN WITNESS WHEREOF, this Fourth Amended and Restated Investor Rights Agreement has been duly executed and
delivered by the parties as of the date first above written. 
  

							
	COMMON HOLDERS	 		 	
	(CONTINUED):	 		 	
			
		 		 	  

		 		 	PATTY WINGARD
			
		 		 	  

		 		 	TAMARA TATROE-MONESMITH
			
		 		 	  

		 		 	JOHN FUNKHOUSER
			
		 		 	  

		 		 	GABRIEL R. CIPAU
			
		 		 	  

		 		 	ROBERT J. ERICKSON
			
		 		 	  

		 		 	ANNE-MARIE STOMP
			
		 		 	 /s/ Kenneth P. West

		 		 	KENNETH P. WEST

 IN WITNESS WHEREOF, this Fourth Amended and Restated Investor Rights Agreement has been duly executed and
delivered by the parties as of the date first above written. 
  

							
	COMMON HOLDERS	 		 		 	
	(CONTINUED):	 		 	H&M HOLDINGS, LLC
				
		 		 	By:	 	  

		 		 	Name:	 	  

		 		 	Title:	 	  

			
		 		 	NORTH CAROLINA STATE UNIVERSITY
				
		 		 	By:	 	  

		 		 	Name:	 	  

		 		 	Title:	 	  

			
		 		 	  

		 		 	R. EDWARD BRANSON
			
		 		 	  

		 		 	KYLE CHENET
			
		 		 	  

		 		 	CARMINE DEFILIPPIS
			
		 		 	  

		 		 	PATRICIA GALLAGHER
			
		 		 	  

		 		 	JOSEPH GERSTNER

 IN WITNESS WHEREOF, this Fourth Amended and Restated Investor Rights Agreement has been duly executed and
delivered by the parties as of the date first above written. 
  

							
	COMMON HOLDERS	 		 	
	(CONTINUED):	 		 	
			
		 		 	  

		 		 	SCOTT HALLAM
			
		 		 	  

		 		 	ROBERT HESTER
			
		 		 	  

		 		 	VLADIMIR KOSTYUKOVSKY
			
		 		 	  

		 		 	DONNA RAMSEY
			
		 		 	  

		 		 	AARON STEWART
			
		 		 	  

		 		 	RON UHING
			
		 		 	  

		 		 	XIAOWEI WANG
			
		 		 	  

		 		 	MICHAEL YABLONSKI

 EXHIBIT A 
 SCHEDULE OF SERIES AA1 INVESTORS 
  

			
	 Name and Address of Series AA1 Holder
	  	Number of Shares of
Series AA1 Stock
	 Intersouth Partners IV, L.P.
 406 Blackwell Street
 Suite 200
 Durham, NC 27701
 Facsimile: (919) 493-6649
 Attn: Dennis Dougherty
	  	1,813,174
		
	 Kitty Hawk Capital Limited Partnership IV
 2901 Coltsgate Road, Suite 100
 Charlotte, NC 28211-3571
 Facsimile: (704) 362-2774
 Attn: W. Chris Hegele
	  	1,138,710
		
	 Academy Centennial Fund, LLC
 P.O. Box 14490
 Research Triangle Park, NC 27709
 Facsimile: (919) 993-3101
 Attn: Nik Stefanovic
	  	144,995
		
	 Wakefield Group III LLC
 c/o Wakefield Group
 1110 East Morehead Street
 Charlotte, NC 28204
 Facsimile: (704) 372-8216
 Attn: Steve Nelson
	  	843,297

			
	 Name and Address of Series AA1 Holder
	  	Number of Shares of
Series AA1 Stock
	 Virginia Biolex Partners, L.P.
 c/o Tall Oaks Capital Partners, LLC
 315 Old Ivy Way, Suite 301
 Charlottesville, VA 22903
 Facsimile: (804) 951-0478
 Attn: Kathryne Carr
	  	187,593
		
	 Village Ventures Partners Fund, L.P.
 c/o Village Ventures, Inc.
 430 Main Street, Suite 1
 Williamstown, MA 01267
 Facsimile: (413) 458-0338
 Attn: Robert D. Kraus
	  	87,191
		
	 Village Ventures Partners Fund A, L.P.
 c/o Village Ventures, Inc.
 430 Main Street, Suite 1
 Williamstown, MA 01267
 Facsimile: (413) 458-0338
 Attn: Robert D. Kraus
	  	6,604
		
	 Biolex Partners II LLC
 1450 Raleigh Road, Suite 300
 Chapel Hill, NC 27512
 Facsimile: (919) 489-1666
 Attn: Stuart Frantz
	  	843,297
		
	 George M. Mackie, IV
 3750 Moorland Drive
 Charlotte, NC 28226
 Facsimile: (704) 752-3594
	  	27,840
		
	 Total:
	  	5,092,701

 EXHIBIT B 
 SCHEDULE OF SERIES AA2 INVESTORS 
  

			
	 Name and Address of Series AA2 Holder
	  	 Number of Shares of
 Series AA2 Stock

	 Intersouth Partners IV, L.P.
 406 Blackwell Street
 Suite 200
 Durham, NC 27701
 Facsimile: (919) 493-6649
 Attn: Dennis Dougherty
	  	2,125,728
		
	 Intersouth Partners V, L.P.
 406 Blackwell Street
 Suite 200
 Durham, NC 27701
 Facsimile: (919) 493-6649
 Attn: Mitch Mumma
  
 With a copy to:
  
 Wyrick Robbins Yates & Ponton LLP
 4101 Lake Boone Trail, Suite 300
 Raleigh, NC 27607
 Facsimile: (919) 781-4865
 Attn: J. Christopher Lynch, Esq.
	  	4,563,162

			
	 Name and Address of Series AA2 Holder
	  	Number of Shares of
Series AA2 Stock
	 Intersouth Affiliates V, L.P.
 406 Blackwell Street
 Suite 200
 Durham, NC 27701
 Facsimile: (919) 493-6649
 Attn: Mitch Mumma
  
 With a copy to:
  
 Wyrick Robbins Yates & Ponton LLP
 4101 Lake Boone Trail, Suite 300
 Raleigh, NC 27607
 Facsimile: (919) 781-4865
 Attn: J. Christopher Lynch, Esq.
	  	208,602
		
	 Quaker BioVentures, L.P.
 Two Greenville Crossing
 4005 Kennett Pike, Suite 220
 Greenville, DE 19807
 Facsimile: (215) 717-2270
 Attn: Sherrill Neff
  
 With a copy to:
  
 Pepper Hamilton LLP
 400 Berwyn Park
 899 Cassatt Road
 Berwyn, PA 19312-1183
 Facsimile: (610) 640-7835
 Attn: Chris Miller, Esq.
	  	4,771,763
		
	 Mitsui & Co. Venture Partners II, L.P.
 c/o Mitsui & Co. Venture Partners, Inc.
 36th Floor
 200 Park Avenue
 New York, NY 10166-0130
 Facsimile: (212) 878-4070
 Attn: Walter Olesiak
	  	2,245,535

			
	 Name and Address of Series AA2 Holder
	  	Number of Shares of
Series AA2 Stock
	 Johnson & Johnson Development Corporation
 410 George Street
 New Brunswick, NJ 08901
 Attn: Carol A. Marino
 Tel: (732) 524-2702
 Fax: (732) 247-5309
 Email: CMarino@CORUS.JNJ.com
	  	2,306,328
		
	 The Dow Chemical Company
 Corporate Venture Capital
 2030 Dow Center
 Midland, MI 48674
 Facsimile: (989) 636-8127
 Attn: Ricardo “Richard” Fuentes
	  	1,132,463
		
	 The Trelys Funds, L.P.
 1901 Assembly Street Suite 390
 Columbia SC 29201
 Facsimile: (803) 251-7995
 Attn: Adrian Wilson
	  	1,122,768
		
	 North Carolina Economic Opportunities Fund, Limited Partnership
 c/o Dogwood Equity
 316 West Edenton Street, Suite 110
 Raleigh, NC 27603
 Facsimile: (919) 256-5015
 Attn: H. Dabney Smith
	  	1,122,768
		
	 Kitty Hawk Capital Limited Partnership IV
 2901 Coltsgate Road, Suite 100
 Charlotte, NC 28211-3571
 Facsimile: (704) 362-2774
 Attn: W. Chris Hegele
	  	966,246

			
	 Name and Address of Series AA2 Holder
	  	Number of Shares of
Series AA2 Stock
	 George M. Mackie, IV
 3750 Moorland Drive
 Charlotte, NC 28226
 Facsimile: (704) 752-3594
	  	38,054
		
	 Wakefield Group III LLC
 c/o Wakefield Group
 1110 East Morehead Street
 Charlotte, NC 28204
 Facsimile: (704) 372-8216
 Attn: Steve Nelson
	  	1,016,327
		
	 Virginia Biolex Partners, L.P.
 c/o Tall Oaks Capital Partners, LLC
 315 Old Ivy Way, Suite 301
 Charlottesville, VA 22903
 Facsimile: (804) 951-0478
 Attn: Kathryne Carr
	  	290,772
		
	 Village Ventures Partners Fund, L.P.
 c/o Village Ventures, Inc.
 430 Main Street, Suite 1
 Williamstown, MA 01267
 Facsimile: (413) 458-0338
 Attn: Robert D. Kraus
	  	135,127
		
	 Village Ventures Partners Fund A, L.P.
 c/o Village Ventures, Inc.
 430 Main Street, Suite 1
 Williamstown, MA 01267
 Facsimile: (413) 458-0338
 Attn: Robert D. Kraus
	  	10,234

			
	 Name and Address of Series AA2 Holder
	  	Number of Shares of
Series AA2 Stock
	 Biolex Partners II LLC
 1450 Raleigh Road, Suite 300
 Chapel Hill, NC 27512
 Facsimile: (919) 489-1666
 Attn: Stuart Frantz
	  	387,169
		
	 TD Javelin Capital Fund II, L.P.
 c/o Tullis-Dickerson & Co., Inc.
 Two Greenwich Plaza, 4th
Floor
 Greenwich, CT 06830
 Attn: Lyle A. Hohnke
	  	35,911
		
	 TD Lighthouse Capital Fund, L.P.
 c/o Tullis-Dickerson & Co., Inc.
 Two Greenwich Plaza, 4th
Floor
 Greenwich, CT 06830
 Attn: Lyle A. Hohnke
	  	30,166
		
	 TD Origen Capital Fund, L.P.
 c/o Tullis-Dickerson & Co., Inc.
 Two Greenwich Plaza, 4th
Floor
 Greenwich, CT 06830
 Attn: Lyle A. Hohnke
	  	18,844
		
	 CMEA Life Sciences Fund, L.P.
 One Embarcadero Center, Suite 3250
 San Francisco, CA 94111
 Facsimile: (415) 352-1524
 Attn: Karl Handelsman
	  	35,837
		
	 Saints Capital V, L.P.
 475 Sansome Street, Suite 1850
 San Francisco, CA 94111
 Facsimile: (415) 835-5970
 Attn: Lilian Shackelford Murray
	  	16,072

			
	 Name and Address of Series AA2 Holder
	  	Number of Shares of
Series AA2 Stock
	 David V. Gilroy
 c/o Hyde Park Capital
 13420 Reese Blvd. West
 Huntersville, NC 28078
	  	11,645
		
	 Kenneth P. West
 105 San Sophia Drive
 Chapel Hill, NC 27514
	  	3,343
		
	 Total:
	  	22,594,864

 EXHIBIT C 
 SCHEDULE OF SERIES BB INVESTORS 
  

			
	 Name and Address of Series BB Holder
	  	Number of Shares of
Series BB Stock
	 Polaris Venture Partners IV, L.P.
 1000 Winter Street, Suite 3350
 Waltham, MA 02451
 Telephone: (781) 290-0770
 Facsimile: (781) 290-0880
 Attn: William E. Bilodeau
 Email: wbilodeeau@polarisventures.com
	  	7,116,549
		
	 Polaris Venture Partners Entrepreneurs’ Fund IV, L.P.
 1000 Winter Street, Suite 3350
 Waltham, MA 02451
 Telephone: (781) 290-0770
 Facsimile: (781) 290-0880
 Attn: William E. Bilodeau
 Email: wbilodeeau@polarisventures.com
	  	133,451
		
	 Intersouth Partners IV, L.P.
 406 Blackwell Street
 Suite 200
 Durham, NC 27701
 Facsimile: (919) 493-6649
 Attn: Dennis Dougherty
	  	2,057,143

			
	 Name and Address of Series BB Holder
	  	Number of Shares of
Series BB Stock
	 Intersouth Partners V, L.P.
 406 Blackwell Street
 Suite 200
 Durham, NC 27701
 Facsimile: (919) 493-6649
 Attn: Mitch Mumma
  
 With a copy to:
  
 Wyrick Robbins Yates & Ponton LLP
 4101 Lake Boone Trail, Suite 300
 Raleigh, NC 27607
 Facsimile: (919) 781-4865
 Attn: J. Christopher Lynch, Esq.
	  	4,672,132
		
	 Intersouth Affiliates V, L.P.
 406 Blackwell Street
 Suite 200
 Durham, NC 27701
 Facsimile: (919) 493-6649
 Attn: Mitch Mumma
  
 With a copy to:
  
 Wyrick Robbins Yates & Ponton LLP
 4101 Lake Boone Trail, Suite 300
 Raleigh, NC 27607
 Facsimile: (919) 781-4865
 Attn: J. Christopher Lynch, Esq.
	  	213,583

			
	 Name and Address of Series BB Holder
	  	Number of Shares of
Series BB Stock
	 Quaker BioVentures, L.P.
 Two Greenville Crossing
 4005 Kennett Pike, Suite 220
 Greenville, DE 19807
 Facsimile: (215) 717-2270
 Attn: Sherrill Neff
  
 With a copy to:
  
 Pepper Hamilton LLP
 400 Berwyn Park
 899 Cassatt Road
 Berwyn, PA 19312-1183
 Facsimile: (610) 640-7835
 Attn: Chris Miller, Esq.
	  	5,357,143
		
	 Mitsui & Co. Venture Partners II, L.P.
 c/o Mitsui & Co. Venture Partners, Inc.
 36th Floor
 200 Park Avenue
 New York, NY 10166-0130
 Facsimile: (212) 878-4070
 Attn: Walter Olesiak
	  	1,670,551
		
	 The Dow Chemical Company
 2030 Dow Center
 Midland, MI 48674
 Facsimile: (989) 636-8127
 Attn: Vice President, Venture Capital
	  	580,000
		
	 Johnson & Johnson Development Corporation
 410 George Street
 New Brunswick, NJ 08901
 Attn: Carol A. Marino
 Tel: (732) 524-2702
 Fax: (732) 247-5309
 Email: CMarino@CORUS.JNJ.com
	  	7,142,858

			
	 Name and Address of Series BB Holder
	  	Number of Shares of
Series BB Stock
	 The Trelys Funds, L.P.
 1901 Assembly Street Suite 390
 Columbia SC 29201
 Facsimile: (803) 251-7995
 Attn: Adrian Wilson
	  	574,286
		
	 North Carolina Economic Opportunities Fund, Limited Partnership
 c/o Dogwood Equity
 316 West Edenton Street, Suite 110
 Raleigh, NC 27603
 Facsimile: (919) 256-5015
 Attn: H. Dabney Smith
	  	574,286
		
	 Kitty Hawk Capital Limited Partnership IV
 2901 Coltsgate Road, Suite 100
 Charlotte, NC 28211-3571
 Facsimile: (704) 362-2774
 Attn: W. Chris Hegele
	  	1,328,928
		
	 George M. Mackie, IV
 3750 Moorland Drive
 Charlotte, NC 28226
 Facsimile: (704) 752-3594
	  	22,321
		
	 Wakefield Group III LLC
 c/o Wakefield Group
 1110 East Morehead Street
 Charlotte, NC 28204
 Facsimile: (704) 372-8216
 Attn: Steve Nelson
	  	223,214

			
	 Name and Address of Series BB Holder
	  	Number of Shares of
Series BB Stock
	 Virginia Biolex Partners, L.P.
 c/o Tall Oaks Capital Partners, LLC
 315 Old Ivy Way, Suite 301
 Charlottesville, VA 22903
 Facsimile: (804) 951-0478
 Attn: Kathryne Carr
	  	248,571
		
	 Village Ventures Partners Fund, L.P.
 c/o Village Ventures, Inc.
 430 Main Street, Suite 1
 Williamstown, MA 01267
 Facsimile: (413) 458-0338
 Attn: Robert D. Kraus
	  	115,535
		
	 Village Ventures Partners Fund A, L.P.
 c/o Village Ventures, Inc.
 430 Main Street, Suite 1
 Williamstown, MA 01267
 Facsimile: (413) 458-0338
 Attn: Robert D. Kraus
	  	8,750
		
	 TD Javelin Capital Fund II, L.P.
 c/o Tullis-Dickerson & Co., Inc.
 Two Greenwich Plaza, 4th
Floor
 Greenwich, CT 06830
 Attn: Lyle A. Hohnke
	  	17,143
		
	 TD Lighthouse Capital Fund, L.P.
 c/o Tullis-Dickerson & Co., Inc.
 Two Greenwich Plaza, 4th
Floor
 Greenwich, CT 06830
 Attn: Lyle A. Hohnke
	  	15,092

			
	 Name and Address of Series BB Holder
	  	Number of Shares of
Series BB Stock
	 TD Origen Capital Fund, L.P.
 c/o Tullis-Dickerson & Co., Inc.
 Two Greenwich Plaza, 4th
Floor
 Greenwich, CT 06830
 Attn: Lyle A. Hohnke
	  	9,193
		
	 Saints Capital V, L.P.
 475 Sansome Street, Suite 1850
 San Francisco, CA 94111
 Facsimile: (415) 835-5970
 Attn: Lilian Shackelford Murray
	  	8,571
		
	 Kenneth P. West
 105 San Sophia Drive
 Chapel Hill, NC 27514
	  	2,857
		
	 David V. Gilroy
 c/o Hyde Park Capital
 13420 Reese Blvd. West
 Huntersville, NC 28078
	  	5,714
		
	 David L. Castaldi
 11 Bellingham Road
 Chestnut Hill, MA 02467-3229
	  	22,321
		
	 Total:
	  	32,120,192

 EXHIBIT D 
 SCHEDULE OF SERIES CC HOLDERS 
  

			
	 Name and Address of Series CC Holder
	  	Number of Shares of
Series CC Stock
	 Investor Growth Capital Limited
 Canada Court, Upland Road
 St. Peter Port, Guernsey GY1 3BQ
 Channel Islands
 Attn: Marc Hollander
 Tel:
 Fax:
  
 With a copy to:
  
 Sunny Sharma
 630 Fifth Avenue, 19th Floor
 New York, NY 10011
	  	5,932,204
		
	 Investor Group, L.P.
 Canada Court, Upland Road
 St. Peter Port, Guernsey GY1 3BQ
 Channel Islands
 Attn: Marc Hollander
 Tel:
 Fax:
  
 With a copy to:
  
 Sunny Sharma
 630 Fifth Avenue, 19th Floor
 New York, NY 10011
	  	2,542,373
		
	 JP Morgan Securities Inc.
 Dan Sommers, Vice President Proprietary Equities
 277 Park Avenue
 New York, NY 10172
 Attn: Dan Sommers
 Tel: (212) 622-2793
 Fax:
 Email: dan.x.sommers@jpmorgan.com
	  	2,007,214

			
	 Name and Address of Series CC Holder
	  	Number of Shares of
Series CC Stock
	 Easton Capital Partners, L.P.
 John H. Friedman, Managing Partner
 767 Third Avenue, 7th Floor
 New York, NY 10017
 Attn: Anup Auroa
 Tel: (212) 702-0950
 Fax: (212) 702-0952
 Email: arora@eastoncapital.com
	  	1,822,034
		
	 Polaris Venture Partners IV, L.P.
 Attn: William E. Bilodeau
 1000 Winter Street, Suite 3350
 Waltham, MA 02451
 Tel: (781)290-0770
 Fax: (781) 290-0880
 Email:
wbilodeau@polarisventures.com
	  	2,529,060
		
	 Polaris Venture Partners Entrepreneurs’ Fund IV, L.P.
 Attn: William E. Bilodeau
 1000 Winter Street, Suite 3350
 Waltham, MA 02451
 Tel: (781)290-0770
 Fax: (781) 290-0880
 Email:
wbilodeau@polarisventures.com
	  	47,412
		
	 Intersouth Partners V, L.P.
 406 Blackwell Street
 Suite 200
 Durham, NC 27701
 Facsimile: (919) 493-6649
 Attn: Mitch Mumma
  
 With a copy to:
  
 Wyrick Robbins Yates & Ponton LLP
 4101 Lake Boone Trail, Suite 300
 Raleigh, NC 27607
 Facsimile: (919) 781-4865
 Attn: J. Christopher Lynch, Esq.
	  	1,031,856

			
	 Name and Address of Series CC Holder
	  	Number of Shares of
Series CC Stock
	 Intersouth Affiliates V, L.P.
 406 Blackwell Street
 Suite 200
 Durham, NC 27701
 Facsimile: (919) 493-6649
 Attn: Mitch Mumma
  
 With a copy to:
  
 Wyrick Robbins Yates & Ponton LLP
 4101 Lake Boone Trail, Suite 300
 Raleigh, NC 27607
 Facsimile: (919) 781-4865
 Attn: J. Christopher Lynch, Esq.
	  	47,171
		
	 Intersouth Partners IV, L.P.
 406 Blackwell Street
 Suite 200
 Durham, NC 27701
 Facsimile: (919) 493-6649
 Attn: Dennis Dougherty
	  	679,448
		
	 Quaker BioVentures, L.P.
 Two Greenville Crossing
 4005 Kennett Pike, Suite 220
 Greenville, DE 19807
 Facsimile: (215) 717-2270
 Attn: Sherrill Neff
  
 With a copy to:
  
 Pepper Hamilton LLP
 400 Berwyn Park
 899 Cassatt Road
 Berwyn, PA 19312-1183
 Facsimile: (610) 640-7835
 Attn: Chris Miller, Esq.
	  	2,648,306

			
	 Name and Address of Series CC Holder
	  	Number of Shares of
Series CC Stock
	 Mitsui & Co. Venture Partners II, L.P.
 c/o Mitsui & Co. Venture Partners, Inc.
 36th Floor
 200 Park Avenue
 New York, NY 10166-0130
 Facsimile: (212) 878-4070
 Attn: Walter Olesiak
	  	690,678
		
	 North Carolina Economic Opportunities Fund, Limited Partnership
 c/o Dogwood Equity
 316 West Edenton Street, Suite 110
 Raleigh, NC 27603
 Facsimile: (919) 256-5015
 Attn: H. Dabney Smith
	  	299,788
		
	 Virginia Biolex Partners, L.P.
 c/o Tall Oaks Capital Partners, LLC
 315 Old Ivy Way, Suite 301
 Charlottesville, VA 22903
 Facsimile: (804) 951-0478
 Attn: Kathryne Carr
	  	129,237
		
	 Village Ventures Partners Fund, L.P.
 c/o Village Ventures, Inc.
 430 Main Street, Suite 1
 Williamstown, MA 01267
 Facsimile: (413) 458-0338
 Attn: Robert D. Kraus
	  	60,069
		
	 Village Ventures Partners Fund A, L.P.
 c/o Village Ventures, Inc.
 430 Main Street, Suite 1
 Williamstown, MA 01267
 Facsimile: (413) 458-0338
 Attn: Robert D. Kraus
	  	4,549

  

			
	 Name and Address of Series CC Holder
	  	Number of Shares of
Series CC Stock
	 Johnson & Johnson Development Corporation
 410 George Street
 New Brunswick, NJ 08901
 Attn: Carol A. Marino
 Tel: (732) 524-2702
 Fax: (732) 247-5309
 Email: CMarino@CORUS.JNJ.com
	  	4,476,898
		
	 The Dow Chemical Company
 2030 Dow Center
 Midland, MI 48674
 Facsimile: (989) 636-8127
 Attn: Vice President, Venture Capital
	  	677,966
		
	 Saints Capital V, L.P.
 475 Sansome Street, Suite 1850
 San Francisco, CA 94111
 Facsimile: (415) 835-5970
 Tel: (415) 773-2080
 Attn: Lilian Shackelford Murray
	  	4,237
		
	 George M. Mackie, IV
 3750 Moorland Drive
 Charlotte, NC 28226
 Facsimile: (704) 752-3594
	  	15,890
		
	 David V. Gilroy
 c/o Hyde Park Capital
 13420 Reese Blvd. West
 Huntersville, NC 28078
	  	3,178
		
	 David L. Castaldi
 11 Bellingham Road
 Chestnut Hill, MA 02467-3229
	  	12,712

			
	 Name and Address of Series CC Holder
	  	Number of Shares of
Series CC Stock
	 Kenneth P. West
 105 San Sophia Drive
 Chapel Hill, NC 27514
	  	1,059
		
	 Total:
	  	25,663,339

 EXHIBIT E 
 SCHEDULE OF COMMON HOLDERS 
  

			
	 Name and Address of Common Holder
	  	Number of Shares of
Common Stock
	 Intersouth Partners IV, L.P.
 406 Blackwell Street
 Suite 200
 Durham, NC 27701
 Facsimile: (919) 493-6649
 Attn: Dennis Dougherty
	  	85,132
		
	 Kitty Hawk Capital Limited Partnership IV
 2901 Coltsgate Road, Suite 100
 Charlotte, NC 28211-3571
 Facsimile: (704) 362-2774
 Attn: W. Chris Hegele
	  	55,640
		
	 Academy Centennial Fund, LLC
 P.O. Box 14490
 Research Triangle Park, NC 27709
 Facsimile: (919) 993-3101
 Attn: Nik Stefanovic
	  	11,042
		
	 North Carolina Forestry Foundation, Inc.
 c/o North Carolina State University
 University Treasurer
 Holladay Hall, Room B
 Box 7010
 Raleigh, North Carolina 27698
 Attn: Kathy Hart
 Phone: (919) 515-2143
 Fax: (919) 515-5121
	  	895

			
	 Name and Address of Common Holder
	  	Number of Shares of
Common Stock
	 Biolex Partners LLC
 1450 Raleigh Road, Suite 300
 Chapel Hill, NC 27512
 Facsimile: (919) 489-1666
 Attn: Stuart Frantz
	  	33,926
		
	 Wakefield Group III LLC
 c/o Wakefield Group
 1110 East Morehead Street
 Charlotte, NC 28204
 Facsimile: (704) 372-8216
 Attn: Steve Nelson
	  	33,926
		
	 Virginia Biolex Partners, L.P.
 c/o Tall Oaks Capital Partners, LLC
 315 Old Ivy Way, Suite 301
 Charlottesville, VA 22903
 Facsimile: (804) 951-0478
 Attn: Kathryne Carr
	  	7,540
		
	 Village Ventures Partners Fund, L.P.
 c/o Village Ventures, Inc.
 430 Main Street, Suite 1
 Williamstown, MA 01267
 Facsimile: (413) 458-0338
 Attn: Robert D. Kraus
	  	3,503
		
	 Village Ventures Partners Fund A, L.P.
 c/o Village Ventures, Inc.
 430 Main Street, Suite 1
 Williamstown, MA 01267
 Facsimile: (413) 458-0338
 Attn: Robert D. Kraus
	  	265
		
	 George M. Mackie, IV
 3750 Moorland Drive
 Charlotte, NC 28226
 Facsimile: (704) 752-3594
	  	1,130

			
	 Name and Address of Common Holder
	  	Number of Shares of
Common Stock
	 Billy Houghteling
 8308 Eel Court
 Raleigh, NC 27616
	  	116
		
	 Linda Robles
 2504-F Duck Pond Circle
 Morrisville, NC 27560
	  	29
		
	 Patty Wingard
 3007 Shopton Drive
 Apex, NC 27502
	  	49
		
	 Tamara Tatroe-Monesmith
 2201 Cedar Grove Road
 Durham, NC 27703
	  	181
		
	 John Funkhouser
 2880 Slater Road
 Suite 103
 Morrisville, NC 27560
	  	620
		
	 Gabriel R. Cipau
 10504 Stonton Way
 Raleigh, NC 27615
	  	2,069
		
	 *Robert J. Erickson
 Tooreen West, Kilcolgan
 County Galway, Ireland
	  	3,491
		
	 *Anne-Marie Stomp
 565 East River Road
 Moncure, NC 27559
	  	18,625

			
	 Name and Address of Common Holder
	  	Number of Shares of
Common Stock
	 *Kenneth P. West
 105 San Sophia Drive
 Chapel Hill, NC 27514
	  	2,586
		
	 *H&M Holdings, LLC
 5410 Trinity Road
 Suite 400
 Raleigh, NC 27607
 Attn: J. Robert Tyler, III, Esq.
	  	413
		
	 *North Carolina State University
 Office of Finance and Business
 Treasurer’s Office
 Campus Box 7010/ B Holladay Hall
 Raleigh, NC 27695-7010
 Facsimile: (919) 515-5121
	  	3,821
		
	 R. Edward Branson
 1329 Salem Lane
 Chapel Hill, NC 27516
	  	137,811
		
	 Kyle Chenet
 805 Edgewater Circle
 Chapel Hill, NC 27516
	  	11,882
		
	 Carmine DeFilippis
 680 Geranium Lane, Unit B
 Simi, CA 93065
	  	4,500
		
	 Patricia Gallagher
 1908 Big Branch Road
 Chapel, Hill 27516
	  	7,500
		
	 Joseph Gerstner
 914 Emily Lane
 Chapel Hill, NC 27516
	  	10,000

			
	 Name and Address of Common Holder
	  	Number of Shares of
Common Stock
	 Scott Hallam
 207 Bell Tower Way
 Morrisville, NC 27560
	  	12,312
		
	 Robert Hester
 2314 Sterling Green Drive
 Morrisville, NC 27560
	  	7,500
		
	 Vladimir Kostyukovsky
 608 Maylands Ave
 Raleigh, NC 27615
	  	6,000
		
	 Donna Ramsey
 404 Birdsong Way
 Holly Springs, NC
	  	4,687
		
	 Aaron Stewart
 3700 Dinkens Drive
 Sanford, NC 27332
	  	375
		
	 Ron Uhing
 3003 Elk Ridge Road
 Durham, NC 27712
	  	4,576
		
	 Xiaowei Wang
 13003 Ethel Rose Way
 Boyds, Maryland 20841
	  	15,937
		
	 Michael Yablonski
 1303 Mann’s Chapel Road
 Pittsboro, NC 27312
	  	10,000
		
	 Total:
	  	498,079Master Security Agreement dated 10/28/2003

 Exhibit 10.1 
  

			
	11/98(R021103) 000038022	  	* LOAN1000 *

 MASTER SECURITY AGREEMENT 
 Dated as of October 28, 2003 (“Agreement”) 
 THIS
AGREEMENT is between General Electric Capital Corporation (together with its successors and assigns, if any, “Secured Party”) and BIOLEX, INC. (“Debtor”). Secured Party has an office
at 401 Merritt 7 Suite 23, Norwalk, CT 06851-1177. Debtor is a corporation organized and existing under the laws of the state of Delaware (“the State”). Debtor’s mailing address and chief place of business is 158 CREDLE
STREET, PITTSBORO, NC 27312. 
  

	1.	CREATION OF SECURITY INTEREST. 

 Debtor grants to
Secured Party, its successors and assigns, a security interest in and against all property listed on any collateral schedule now or in the future annexed to or made a part of this Agreement (“Collateral Schedule”), and in and
against all additions, attachments, accessories and accessions to such property, all substitutions, replacements or exchanges therefor, and all insurance and/or other proceeds thereof (all such property is individually and collectively called the
“Collateral”). This security interest is given to secure the payment and performance of all debts, obligations and liabilities of any kind whatsoever of Debtor to Secured Party, now existing or arising in the future,
including but not limited to the payment and performance of certain Promissory Notes from time to time identified on any Collateral Schedule (collectively “Notes” and each a “Note”), and any renewals,
extensions and modifications of such debts, obligations and liabilities (such Notes, debts, obligations and liabilities are called the “Indebtedness”). 
  

	2.	REPRESENTATIONS, WARRANTIES AND COVENANTS OF DEBTOR. 

 Debtor represents, warrants and covenants as of the date of this Agreement and as of the date of each Collateral Schedule that: 
 (a) Debtor’s exact legal name is as set forth in the preamble of this Agreement and Debtor is, and will remain, duly organized, existing and in good standing under the laws of the State set forth in the preamble of this Agreement, has
its chief executive offices at the location specified in the preamble, and is, and will remain, duly qualified and licensed in every jurisdiction wherever necessary to carry on its business and operations; 
 (b) Debtor has adequate power and capacity to enter into, and to perform its obligations under this Agreement, each Note and any other documents
evidencing, or given in connection with, any of the Indebtedness (all of the foregoing are called the “Debt Documents”); 
 (c) This Agreement and the other Debt Documents have been duly authorized, executed and delivered by Debtor and constitute legal, valid and binding agreements enforceable in accordance with their terms, except to the extent that the
enforcement of remedies may be limited under applicable bankruptcy and insolvency laws; 

 (d) No approval, consent or withholding of objections is required from any governmental authority or
instrumentality with respect to the entry into, or performance by Debtor of any of the Debt Documents, except any already obtained; 
 (e)
The entry into, and performance by, Debtor of the Debt Documents will not (i) violate any of the organizational documents of Debtor or any judgment, order, law or regulation applicable to Debtor, or (ii) result in any breach of or
constitute a default under any contract to which Debtor is a party, or result in the creation of any lien, claim or encumbrance on any of Debtor’s property (except for liens in favor of Secured Party) pursuant to any indenture, mortgage, deed
of trust, bank loan, credit agreement, or other agreement or instrument to which Debtor is a party; 
 (f) There are no suits or proceedings
pending in court or before any commission, board or other administrative agency against or affecting Debtor which could, in the aggregate, have a material adverse effect on Debtor, its business or operations, or its ability to perform its
obligations under the Debt Documents, nor does Debtor have reason to believe that any such suits or proceedings are threatened; 
 (g) All
financial statements delivered to Secured Party in connection with the Indebtedness have been prepared in accordance with generally accepted accounting principles, and since the date of the most recent financial statement, there has been no material
adverse change in Debtors financial condition; 
 (h) The Collateral is not, and will not be, used by Debtor for personal, family or
household purposes; 
 (i) The Collateral is, and will remain, in good condition and repair and Debtor will not be negligent in its care and
use; 
 (j) Debtor is, and will remain, the sole and lawful owner, and in possession of, the Collateral, and has the sole right and lawful
authority to grant the security interest described in this Agreement; 
 (k) The Collateral is, and will remain, free and clear of all liens,
claims and encumbrances of any kind whatsoever, except for (i) liens in favor of Secured Party, (ii) liens for taxes not yet due or for taxes being contested in good faith and which do not involve, in the judgment of Secured Party, any
risk of the sale, forfeiture or loss of any of the Collateral, and (iii) inchoate materialmen’s, mechanic’s, repairmen’s and similar liens arising by operation of law in the normal course of business for amounts which are not
delinquent (all of such liens are called “Permitted Liens”); and 
 (l) Debtor is and will remain in full compliance
with all laws and regulations applicable to it including, without limitation, (i) ensuring that no person who owns a controlling interest in or otherwise controls Debtor is or shall be (Y) listed on the Specially Designated Nationals and
Blocked Person List maintained by the Office of Foreign Assets Control (“OFAC”), Department of the Treasury, and/or any other similar lists maintained by OFAC pursuant to any authorizing statute, Executive Order or regulation
or (Z) a person designated under Section 1(b), (c) or (d) of Executive Order No. 13224 (September 23, 2001), any related enabling 

 
legislation or any other similar Executive Orders, and (ii) compliance with all applicable Bank Secrecy Act (“BSA”) laws,
regulations and government guidance on BSA compliance and on the prevention and detection of money laundering violations. 
  

	3.	COLLATERAL. 

 (a) Until the declaration of any
default, Debtor shall remain in possession of the Collateral; except that Secured Party shall have the right to possess (i) any chattel paper or instrument that constitutes a part of the Collateral, and (ii) any other Collateral in which
Secured Party’s security interest may be perfected only by possession. Secured Party may inspect any of the Collateral during normal business hours after giving Debtor reasonable prior notice. If Secured Party asks, Debtor will promptly notify
Secured Party in writing of the location of any Collateral. 
 (b) Debtor shall (i) use the Collateral only in its trade or business,
(ii) maintain all of the Collateral in good operating order and repair, normal wear and tear excepted, (iii) use and maintain the Collateral only in compliance with manufacturers recommendations and all applicable laws, and (iv) keep
all of the Collateral free and clear of all liens, claims and encumbrances (except for Permitted Liens). 
 (c) Secured Party does not
authorize and Debtor agrees it shall not (i) part with possession of any of the Collateral (except to Secured Party or for maintenance and repair), (ii) remove any of the Collateral from the continental United States, or (iii) sell,
rent, lease, mortgage, license, grant a security interest in or otherwise transfer or encumber (except for Permitted Liens) any of the Collateral. 
 (d) Debtor shall pay promptly when due all taxes, license fees, assessments and public and private charges levied or assessed on any of the Collateral, on its use, or on this Agreement or any of the other Debt Documents. At its option,
Secured Party may discharge taxes, liens, security interests or other encumbrances at any time levied or placed on the Collateral and may pay for the maintenance, insurance and preservation of the Collateral and effect compliance with the terms of
this Agreement or any of the other Debt Documents. Debtor agrees to reimburse Secured Party, on demand, all costs and expenses incurred by Secured Party in connection with such payment or performance and agrees that such reimbursement obligation
shall constitute Indebtedness. 
 (e) Debtor shall, at all times, keep accurate and complete records of the Collateral, and Secured Party
shall have the right to inspect and make copies of all of Debtor’s books and records relating to the Collateral during normal business hours, after giving Debtor reasonable prior notice. 
 (f) Debtor agrees and acknowledges that any third person who may at any time possess all or any portion of the Collateral shall be deemed to hold, and
shall hold, the Collateral as the agent of, and as pledge holder for, Secured Party. Secured Party may at any time give notice to any third person described in the preceding sentence that such third person is holding the Collateral as the agent of,
and as pledge holder for, the Secured Party. 

	4.	INSURANCE. 

 (a) Debtor shall at all times bear the
entire risk of any loss, theft, damage to, or destruction of, any of the Collateral from any cause whatsoever. 
 (b) Debtor agrees to keep
the Collateral insured against loss or damage by fire and extended coverage perils, theft, burglary, and for any or all Collateral which are vehicles, for risk of loss by collision, and if requested by Secured Party, against such other risks as
Secured Party may reasonably require. The insurance coverage shall be in an amount no less than the full replacement value of the Collateral, and deductible amounts, insurers and policies shall be acceptable to Secured Party. Debtor shall deliver to
Secured Party policies or certificates of insurance evidencing such coverage. Each policy shall name Secured Party as a loss payee, shall provide for coverage to Secured Party regardless of the breach by Debtor of any warranty or representation made
therein, shall not be subject to co-insurance, and shall provide that coverage may not be canceled or altered by the insurer except upon thirty (30) days prior written notice to Secured Party. Debtor appoints-Secured Party as its
attorney-in-fact to make proof of loss, claim for insurance and adjustments with insurers, and to receive payment of and execute or endorse all documents, checks or drafts in connection with insurance payments. Secured Party shall not act as
Debtor’s attorney-in-fact unless Debtor is in default. Proceeds of insurance shall be applied, at the option of Secured Party, to repair or replace the Collateral or to reduce any of the Indebtedness. 
  

	5.	REPORTS. 

 (a) Debtor shall promptly notify Secured
Party of (i) any change in the name of Debtor, (ii) any change in the state of its incorporation or registration, (iii) any relocation of its chief executive offices, (iv) any relocation of any of the Collateral, (v) any of
the Collateral being lost, stolen, missing, destroyed, materially damaged or worn out, or (vi) any lien, claim or encumbrance other than Permitted Liens attaching to or being made against any of the Collateral. 
 (b) Debtor will deliver to Secured Party Debtor’s complete financial statements, certified by a recognized firm of certified public accountants,
within one hundred twenty days (120) days of the close of each fiscal year of Debtor. If Secured Party requests, Debtor will deliver to Secured Party copies of Debtor’s quarterly financial reports certified by Debtor’s chief financial
officer, within ninety (90) days after the close of each of Debtor’s fiscal quarter. Debtor will deliver to Secured Party copies of all Forms 10-K and 10-Q, if any, within 30 days after the dates on which they are filed with the Securities
and Exchange Commission. 
  

	6.	FURTHER ASSURANCES. 

 (a) Debtor shall, upon request
of Secured Party, furnish to Secured Party such further information, execute and deliver to Secured Party such documents and instruments (including, without limitation, Uniform Commercial Code financing statements) and shall do such other acts and
things as Secured Party may at any time reasonably request relating to the perfection or protection of the security interest created by this Agreement or for the purpose of carrying out the intent of this Agreement. Without limiting the foregoing,
Debtor shall cooperate and do all acts deemed necessary or advisable by Secured Party to continue in Secured Party a 

 
perfected first security interest in the Collateral, and shall obtain and furnish to Secured Party any subordinations, releases, landlord waivers, lessor
waivers, mortgagee waivers, or control agreements, and similar documents as may be from time to time requested by, and in form and substance satisfactory to, Secured Party. 
 (b) Debtor authorizes Secured Party to file a financing statement and amendments thereto describing the Collateral and containing any other information
required by the applicable Uniform Commercial Code. Debtor irrevocably grants to Secured Party the power to sign Debtor’s name and generally to act on behalf of Debtor to execute and file applications for title, transfers of title, financing
statements, notices of lien and other documents pertaining to any or all of the Collateral; this power is coupled with Secured Party’s interest in the Collateral. Debtor shall, if any certificate of title be required or permitted by law for any
of the Collateral, obtain and promptly deliver to Secured Party such certificate showing the lien of this Agreement with respect to the Collateral. Debtor ratifies its prior authorization for Secured Party to file financing statements and amendments
thereto describing the Collateral and containing any other information required by the Uniform Commercial Code if filed prior to the date hereof. 
 (c) Debtor shall indemnify and defend the Secured Party, its successors and assigns, and their respective directors, officers and employees, from and against all claims, actions and suits (including, without limitation, related
attorneys’ fees) of any kind whatsoever arising, directly or indirectly, in connection with any of the Collateral. 
  

	7.	DEFAULT AND REMEDIES. 

 (a) Debtor shall be in
default under this Agreement and each of the other Debt Documents if: 
 (i) Debtor breaches its obligation to pay when due any installment or
other amount due or coming due under any of the Debt Documents; 
 (ii) Debtor, without the prior written consent of Secured Party, attempts
to or does sell, rent, lease, license, mortgage, grant a security interest in, or otherwise transfer or encumber (except for Permitted Liens) any of the Collateral; 
 (iii) Debtor breaches any of its insurance obligations under Section 4; 
 (iv) Debtor breaches any of
its other obligations under any of the Debt Documents and fails to cure that breach within thirty (30) days after written notice from Secured Party; 
 (v) Any warranty, representation or statement made by Debtor in any of the Debt Documents or otherwise in connection with any of the Indebtedness shall be false or misleading in any material respect; 
 (vi) Any of the Collateral is subjected to attachment, execution, levy, seizure or confiscation in any legal proceeding or otherwise, or if any legal or
administrative proceeding is commenced against Debtor or any of the Collateral, which in the good faith judgment of Secured Party subjects any of the Collateral to a material risk of attachment, execution, levy, seizure or confiscation and no bond
is posted or protective order obtained to negate such risk; 

 (vii) Debtor breaches or is in default under any other agreement between Debtor and Secured Party;

 (viii) Debtor or any guarantor or other obligor for any of the Indebtedness (collectively “Guarantor”) dissolves,
terminates its existence, becomes insolvent or ceases to do business as a going concern; 
 (ix) If Debtor or any Guarantor is a natural
person, Debtor or any such Guarantor dies or becomes incompetent; 
 (x) A receiver is appointed for all or of any part of the property of
Debtor or any Guarantor, or Debtor or any Guarantor makes any assignment for the benefit of creditors; 
 (xi) Debtor or any Guarantor files
a petition under any bankruptcy, insolvency or similar law, or any such petition is filed against Debtor or any Guarantor and is not dismissed within forty-five (45) days; or 
 (xii) Debtor’s improper filing of an amendment or termination statement relating to a filed financing statement describing the Collateral.

 (b) If Debtor is in default, the Secured Party, at its option, may declare any or all of the Indebtedness to be immediately due and
payable, without demand or notice to Debtor or any Guarantor. The accelerated obligations and liabilities shall bear interest (both before and after any judgment) until paid in full at the lower of eighteen percent (18%) per annum or the
maximum rate not prohibited by applicable law. 
 (c) After default, Secured Party shall have all of the rights and remedies of a Secured
Party under the Uniform Commercial Code, and under any other applicable law. Without limiting the foregoing, Secured Party shall have the right to (i) notify any account debtor of Debtor or any obligor on any instrument which constitutes part
of the Collateral to make payment to the Secured Party, (ii) with or without legal process, enter any premises where the Collateral may be and take possession of and remove the Collateral from the premises or store it on the premises,
(iii) sell the Collateral at public or private sale, in whole or in part, and have the right to bid and purchase at said sale, or (iv) lease or otherwise dispose of all or part of the Collateral, applying proceeds from such disposition to
the obligations then in default. If requested by Secured Party, Debtor shall promptly assemble the Collateral and make it available to Secured Party at a place to be designated by Secured Party which is reasonably convenient to both parties. Secured
Party may also render any or all of the Collateral unusable at the Debtor’s premises and may dispose of such Collateral on such premises without liability for rent or costs. Any notice that Secured Party is required to give to Debtor under the
Uniform Commercial Code of the time and place of any public sale or the time after which any private sale or other intended disposition of the Collateral is to be made shall be deemed to constitute reasonable notice if such notice is given to the
last known address of Debtor at least five (5) days prior to such action. 

 (d) Proceeds from any sale or lease or other disposition shall be applied: first, to all costs of
repossession, storage, and disposition including without limitation attorneys’, appraisers’, and auctioneers’ fees; second, to discharge the obligations then in default; third, to discharge any other Indebtedness of Debtor to Secured
Party, whether as obligor, endorser, guarantor, surety or indemnitor; fourth, to expenses incurred in paying or settling liens and claims against the Collateral; and lastly, to Debtor, if there exists any surplus. Debtor shall remain fully liable
for any deficiency. 
 (e) Debtor agrees to pay all reasonable attorneys’ fees and other costs incurred by Secured Party in connection
with the enforcement, assertion, defense or preservation of Secured Party’s rights and remedies under this Agreement, or if prohibited by law, such lesser sum as may be permitted. Debtor further agrees that such fees and costs shall constitute
Indebtedness. 
 (f) Secured Party’s rights and remedies under this Agreement or otherwise arising are cumulative and may be exercised
singularly or concurrently. Neither the failure nor any delay on the part of the Secured Party to exercise any right, power or privilege under this Agreement shall operate as a waiver, nor shall any single or partial exercise of any right, power or
privilege preclude any other or further exercise of that or any other right, power or privilege. SECURED PARTY SHALL NOT BE DEEMED TO HAVE WAIVED ANY OF ITS RIGHTS UNDER THIS AGREEMENT OR UNDER ANY OTHER AGREEMENT, INSTRUMENT OR PAPER SIGNED BY
DEBTOR UNLESS SUCH WAIVER IS EXPRESSED IN WRITING AND SIGNED BY SECURED PARTY. A waiver on any one occasion shall not be construed as a bar to or waiver of any right or remedy on any future occasion. 
 (g) DEBTOR AND SECURED PARTY UNCONDITIONALLY WAIVE THEIR RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS
AGREEMENT, ANY OF THE OTHER DEBT DOCUMENTS, ANY OF THE INDEBTEDNESS SECURED HEREBY, ANY DEALINGS BETWEEN DEBTOR AND SECURED PARTY RELATING TO THE SUBJECT MATTER OF THIS TRANSACTION OR ANY RELATED TRANSACTIONS, AND/OR THE RELATIONSHIP THAT IS BEING
ESTABLISHED BETWEEN DEBTOR AND SECURED PARTY. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT. THIS WAIVER IS IRREVOCABLE. THIS WAIVER MAY NOT BE MODIFIED EITHER ORALLY OR IN
WRITING. THE WAIVER ALSO SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT, ANY OTHER DEBT DOCUMENTS, OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THIS TRANSACTION OR ANY RELATED TRANSACTION.
THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT. 
  

	8.	MISCELLANEOUS. 

 (a) This Agreement, any Note and/or
any of the other Debt Documents may be assigned, in whole or in part, by Secured Party without notice to Debtor, and Debtor agrees not to assert against any such assignee, or assignee’s assigns, any defense, set-off, recoupment claim or
counterclaim which Debtor has or may at any time have against Secured Party for any reason whatsoever. 

 
Debtor agrees that if Debtor receives written notice of an assignment from Secured Party, Debtor will pay all amounts payable under any assigned Debt
Documents to such assignee or as instructed by Secured Party. Debtor also agrees to confine in writing receipt of the notice of assignment as may be reasonably requested by Secured Party or assignee. 
 (b) All notices to be given in connection with this Agreement shall be in writing, shall be addressed to the parties at their respective addresses set
forth in this Agreement (unless and until a different address may be specified in a written notice to the other party), and shall be deemed given (i) on the date of receipt if delivered in hand or by facsimile transmission, (ii) on the
next business day after being sent by express mail, and (iii) on the fourth business day after being sent by regular, registered or certified mail. As used herein, the term “business day” shall mean and include any day other than
Saturdays, Sundays, or other days on which commercial banks in New York, New York are required or authorized to be closed. 
 (c) Secured
Party may correct patent errors and fill in all blanks in this Agreement or in any Collateral Schedule consistent with the agreement of the parties. 
 (d) Time is of the essence of this Agreement. This Agreement shall be binding, jointly and severally, upon all parties described as the “Debtor” and their respective heirs, executors, representatives,
successors and assigns, and shall inure to the benefit of Secured Party, its successors and assigns. 
 (e) This Agreement and its Collateral
Schedules constitute the entire agreement between the parties with respect to the subject matter of this Agreement and supersede all prior understandings (whether written, verbal or implied) with respect to such subject matter. THIS AGREEMENT AND
ITS COLLATERAL SCHEDULES SHALL NOT BE CHANGED OR TERMINATED ORALLY OR BY COURSE OF CONDUCT, BUT ONLY BY A WRITING SIGNED BY BOTH PARTIES. Section headings contained in this Agreement have been included for convenience only, and shall not affect the
construction or interpretation of this Agreement. 
 (f) This Agreement shall continue in full force and effect until all of the Indebtedness
has been indefeasibly paid in full to Secured Party or its assignee. The surrender, upon payment or otherwise, of any Note or any of the other documents evidencing any of the Indebtedness shall not affect the right of Secured Party to retain the
Collateral for such other Indebtedness as may then exist or as it may be reasonably contemplated will exist in the future. This Agreement shall automatically be reinstated if Secured Party is ever required to return or restore the payment of all or
any portion of the Indebtedness (all as though such payment had never been made). 
 (g) THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE
PARTIES HEREUNDER SHALL IN ALL RESPECTS BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF CONNECTICUT (WITHOUT REGARD TO THE CONFLICT OF LAWS PRINCIPLES OF SUCH STATE), INCLUDING ALL MATTERS OF CONSTRUCTION, VALIDITY
AND PERFORMANCE, REGARDLESS OF THE LOCATION OF THE COLLATERAL. 

 IN WITNESS WHEREOF, Debtor and Secured Party, intending to be legally bound hereby, have duly
executed this Agreement in one or more counterparts, each of which shall be deemed to be an original, as of the day and year first aforesaid. 
  

									
	SECURED PARTY:	 		 	DEBTOR:
			
	General Electric Capital Corporation	 		 	Biolex, Inc.
					
	By:	 	  
	 		 	By:	 	  

					
	Name:	 	  
	 		 	Name:	 	  

					
	Title:	 	  
	 		 	Title:	 	  

 AMENDMENT 
 THIS AMENDMENT is made as of the 28th day of October 2003, between General Electric Capital Corporation (“Secured Party”) and Biolex, Inc. (“Debtor”) in connection with that certain Master Security
Agreement, dated as of October 28, 2003 (“Agreement”). The terms of this Amendment are hereby incorporated into the Agreement as though fully set forth therein. Section references below refer to the section numbers of the Agreement.
The Agreement is hereby amended as follows: 
  

	 	5.	REPORTS. 

 Subsection (b) is hereby
amended in its entirety and replaced with the following: 
 “(b) Debtor will deliver to Secured Party financial statements as follows. If
Debtor is a privately held company, then Debtor agrees to provide monthly financial statements, certified by Debtor’s president or chief financial officer including a balance sheet, statement of operations and cash flow statement within 30 days
of each month end and its complete audited annual financial statements, certified by a recognized firm of certified public accountants, within 120 days of fiscal year end or at such time as Debtor’s Board of Directors receives the audit. If
Debtor is a publicly held company, then Debtor agrees to provide quarterly unaudited statements and annual audited statements, certified by a recognized firm of certified public accountants, within 10 days after the statements are provided to the
Securities and Exchange Commission (“SEC”). All such statements are to be prepared using generally accepted accounting principles (“GAAP”) and, if Debtor is a publicly held company, are to be in compliance with SEC
requirements.” 
  

	 	7.	DEFAULT AND REMEDIES. 

 Subsection
(a) is hereby amended in its entirety and replaced with the following: 
 “(a) Debtor shall be in default under this Agreement and
each of the other Debt Documents if: 
 (i) Debtor breaches its obligation to pay when due any installment or other amount due or coming due
under any of the Debt Documents and fails to cure the breach within ten (10) days; 
 (ii) Debtor, without the prior written consent of
Secured Party, attempts to or does sell, rent, lease, license, mortgage, grant a security interest in, or otherwise transfer or encumber (except for Permitted Liens) any of the Collateral; 
 (iii) Debtor breaches any of its insurance obligations under Section 4; 
 (iv) Debtor breaches any of its other obligations under any of the Debt Documents and fails to cure that breach within thirty (30) days after written notice from Secured Party; 

 (v) Any warranty, representation or statement made by Debtor in any of the Debt Documents or otherwise in
connection with any of the Indebtedness shall be false or misleading in any material respect; 
 (vi) Any of the Collateral is subjected to
attachment, execution, levy, seizure or confiscation in any legal proceeding or otherwise, or if any legal or administrative proceeding is commenced against Debtor or any of the Collateral, which in the good faith judgment of Secured Party subjects
any of the Collateral to a material risk of attachment, execution, levy, seizure or confiscation and no bond is posted or protective order obtained to negate such risk; 
 (vii) Debtor breaches or is in default under any other agreement between Debtor and Secured Party; 
 (viii)
Debtor or any guarantor or other obligor for any of the Indebtedness (collectively “Guarantor”) dissolves, terminates its existence, becomes insolvent or ceases to do business as a going concern; 
 (ix) If Debtor or any Guarantor is a natural person, Debtor or any such Guarantor dies or becomes incompetent; 
 (x) A receiver is appointed for all or of any part of the property of Debtor or any Guarantor, or Debtor or any Guarantor makes any assignment for the
benefit of creditors; 
 (xi) Debtor or any Guarantor files a petition under any bankruptcy, insolvency or similar law, or any such petition
is filed against Debtor or any Guarantor and is not dismissed within forty-five (45) days; 
 (xii) Debtor’s improper filing of an
amendment or termination statement relating to a filed financing statement describing the Collateral; or 
 (xiii) Debtor defaults under any
other material obligation, not disputed for (A) borrowed money, (B) the deferred purchase price of property or (C) payments due under any lease agreement. 
 (xiv) At any time during the term of this Agreement Debtor sells more than 50% of its interest in the company to another corporation or business or all or substantially all of its assets without Secured Party’s
prior written consent. 
 (xv) There is a material adverse change in the Debtor’s financial condition as determined solely by Secured
Party.” 
 TERMS USED, BUT NOT OTHERWISE DEFINED HEREIN SHALL HAVE THE MEANINGS GIVEN TO THEM IN THE AGREEMENT. EXCEPT AS EXPRESSLY
AMENDED HEREBY, THE AGREEMENT SHALL REMAIN IN FULL FORCE AND EFFECT. IF THERE IS ANY CONFLICT BETWEEN THE PROVISIONS OF THE AGREEMENT AND THIS AMENDMENT, THEN THIS AMENDMENT SHALL CONTROL. 

 IN WITNESS WHEREOF, the parties hereto have executed this Amendment simultaneously with the
Agreement by signature of their respective authorized representative set forth below. 
  

									
	General Electric Capital Corporation	 		 	Biolex, Inc.
					
	By:	 	  
	 		 	By:	 	  

					
	Name:	 	  
	 		 	Name:	 	  

					
	Title:	 	  
	 		 	Title:	 	  

 Equipment Concentration Rider 
 Biolex, Inc. (“Customer”), on or before October 15, 2004, shall cause the composition and mix of Equipment financed after October 28, 2003 under the Master Security Agreement dated as of
October 28, 2003 between Biolex, Inc. and General Electric Capital Corporation to conform to and meet the following concentration requirements (hereinafter “Concentration Requirements”) for each class of Equipment (hereinafter
“Equipment Class”) as identified and set forth below. Customer herein represents and warrants that it shall maintain each such Equipment Class and its respective Concentration Requirement from and after such above referenced date and
continuing thereafter to the end of the term: 
  

			
	 Equipment Class
	 	 Concentration Requirement

	 Laboratory & scientific equipment:
	 	Minimum of 67%
		
	 Computers, networking equipment, & similar:
	 	Maximum of 13%
		
	 Soft costs (leaseholds, software, & similar):
	 	Maximum of 20%

 Accepted and Agreed: Biolex, Inc. 
  

			
	Biolex, Inc.,
		
	By:	 	  

		
	Title:	 	  

		
	Date:	 	  

			
	(3/91)4148254254	 	*LOAN3009*

 COLLATERAL SCHEDULE NO. 001 
 THIS COLLATERAL SCHEDULE NO. 001 is annexed to and made a part of that certain Master Security Agreement dated as of October 28, 2003 between General Electric Capital Corporation, together with its
successors and assigns, if any, as Secured Party and BIOLEX, INC. as Debtor and describes collateral in which Debtor has granted Secured Party a security interest in connection with the Indebtedness (as defined in the Security Agreement) including
without limitation that certain Promissory Note dated                              in the original
principal amount of $214,704.69. 
  

									
	 Quantity
	 	 Manufacturer
	 	 Serial Number
	 	 Year/Model and Type of Equipment

		 		 		 	
		 		 		 	
		 		 		 	

 SEE EXHIBIT A ATTACHED HERETO AND MADE A PART HEREOF. 
 and including all additions, attachments, accessories and accessions thereto, and any and all substitutions, replacements or exchanges therefor, and all insurance and/or
other proceeds thereof 
  

									
	SECURED PARTY:	 		 	DEBTOR:
			
	General Electric Capital Corporation	 		 	BIOLEX, INC.
					
	By:	 	  
	 		 	By:	 	  

					
	Name:	 	  
	 		 	Name:	 	  

					
	Title:	 	  
	 		 	Title:	 	  

					
	Date:	 	  
	 		 	Date:	 	  

			
	(3/91)4148254254	 	*LOAN3006*

 ANNEX A 
 TO 
 COLLATERAL SCHEDULE NO. 001 
 TO MASTER SECURITY AGREEMENT 
 DATED AS OF October 28, 2003 
 CERTIFICATE OF DELIVERY/INSTALLATION 
  

	To:	General Electric Capital Corporation (together with its successors and assigns, if any, “Secured Party”) 

 Pursuant to the provisions of the above Collateral Schedule to the above Master Security Agreement and the related Promissory Note (collectively, the
“Loan”), the undersigned (“Debtor”) hereby certifies and warrants that (a) all Equipment listed below has been delivered and installed (if applicable); (b) the Debtor has inspected the Equipment, and all such testing as
it deems necessary has been performed by Debtor, Supplier or the manufacturer, (c) Debtor has found all such Equipment to be satisfactory and meets all applicable specifications and is fully operational for its intended use; and (d) the
Equipment was first delivered to Debtor on                              and copies of the Bill(s) of
Lading or other documentation acceptable to Secured Party which show the date of delivery are attached hereto. 
  

									
	 Number of Units
	 	 Manufacturer
	 	 Serial Numbers
	 	 Model and Type of Equipment

		 		 		 	
		 		 		 	
		 		 		 	

 SEE EXHIBIT A ATTACHED HERETO AND MADE A PART HEREOF. 
  

			
	BIOLEX, INC.
		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

		
	Date:	 	  

			
	3007 (3/91) 4148254254	 	*LOAN3007*

 Date
                             
 General Electric Capital Corporation 
 401 Merritt 7 Suite 23 
 Norwalk, CT 06851-1177 
 Gentlemen: 
 You are hereby irrevocably authorized and directed to deliver and apply the proceeds of your loan to the undersigned evidenced by that Note dated
                             and secured by that Security Agreement or Chattel Mortgage dated
October 28, 2003, as follows: 
  

						
	 Biolex, Inc.
	  	$	219,633.48	  	
	 General Electric
	  	$	71.21 (Interim Interest)	  	

 Applied $366.25 to Interim Interest from Good Faith Deposit. 
 This authorization and direction is given pursuant to the same authority authorizing the above-mentioned borrowing. 
  

			
	Very truly yours,
	
	BIOLEX, INC.
		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

					
	Company Name:	  	Biolex, Inc.	  	 FUNDING DATE 30/11/03

	Equipment Location(s):	  	158 Credle Street	  	
		  	Pittsboro, NC 27513	  	

  

																																
	 Inv
 Item
	  	Supplier	  	Invoice #	  	Inv Date	  	Description	 	QTY	  	Serial #	  	 Customer #
 Internal Tag #
 (if
applicable)
	  	Amt.
Financed	  	Vendor Total	  	Ck #	  	Proof of
Payment	  	Ck Amt	  	Equip Code	  	90 Days	  	Comments
	1.	  	Cole Palmer	  	5188361	  	09/11/03	  	Drive, Mflex, IP 115V	 	1	  	H03000361	  	303	  	1,025.00	  			  	8127	  	Yes	  	4,704.45	  	LAB	  	NO	  	
		  		  		  		  		 		  		  		  		  	$	1,025.00	  		  		  		  		  		  	
	2.	  	Agilient	  	Y3W4467	  	10/10/2003	  	1100 Series Fraction
Collec	 	1	  	DE14900225	  	317	  	4,600.00	  			  	8272	  	Yes	  	4,600.00	  	LAB	  	NO	  	
		  		  		  		  		 		  		  		  		  	$	4,600.00	  		  		  		  		  		  	
	3.	  	Bio Rad	  	2935754	  	9/26/2003	  	Trans-Blot SD Cell	 	1	  	221BR 27144	  	310	  	1,375.00	  			  	8186	  	Yes	  	1,500.84	  	LAB	  	NO	  	
		  		  		  		  		 		  		  		  		  	$	1,375.00	  		  		  		  		  		  	
	4.	  	Dennis Delgais	  	2003-62	  	9/19/2003	  	Construction GMP
Labour and
Material to
construct 250’ of
16’- 0” wall	 	1	  	N/A	  	N/A	  	11,662.25	  			  	8039	  	Yes	  	11,662.25	  	SOFT	  	NO	  	
		  		  	2003-65	  	10/6/2003	  	Construction GMP
Labour and
Material to paint
250 sqft wall, l
paint doors and
frames remove and
install new
sheetrock	 	1	  	N/A	  	N/A	  	5,890.48	  			  	8130	  	Yes	  	5,890.48	  	SOFT	  		  	
		  		  		  		  		 		  		  		  		  	$	17,552.73	  		  		  		  		  		  	
	5.	  	Fisher	  	331591	  	9/11/2003	  	Accu AR 50 Cond
Meter	 	1	  	AR93312413	  	304	  	1,705.54	  			  	8158	  	Yes	  	5,51.24	  	LAB	  	NO	  	
		  		  	844953	  	9/30/2003	  	Basic Balance
310g	 	1	  	1122382938	  	311	  	1,246.98	  			  	8235	  	Yes	  	1,950.33	  	LAB	  	NO	  	
		  		  	954022	  	10/3/2003	  	Eppendorf
Centrifuge	 	1	  	542542770/0042770	  	313	  	1,948.00	  	$	4,900.52	  	8289	  	Yes	  	6,066.40	  	LAB	  	NO	  	
	6.	  	Pall Treinity Micro	  	3637	  	10/9/2003	  	Centrasette 5 W/2	 	1	  	370015-098	  	306	  	9,655.00	  			  	8311	  	Yes	  	24,689.13	  	LAB	  	NO	  	
		  		  	3638	  	10/9/2003	  	Centrasette Hdwe	 	2	  	370303-153 &	  	307	  	11,140.00	  			  	8311	  	Yes	  	24,689.13	  	LAB	  	NO	  	
		  		  		  		  		 		  	370303-178	  	308	  	0.00	  	$	20,795.00	  		  		  		  	LAB	  	NO	  	
	7.	  	Amersham Biosciences	  	1774035	  	9/11/2003	  	Index Column
70/500	 	1	  	0301/0604	  	305	  	2,228.00	  			  	8149	  	Yes	  	4,374.58	  	LAB	  	NO	  	
		  		  	1787489	  	9/26/2003	  	Akta Pilot with
attachments 50%
deposit	 	1	  	1097453	  	314	  	104,755.00	  	$	106,983.00	  	8053	  	Yes	  	57,327.13	  	LAB	  	NO	  	
		  		  		  		  		 		  		  		  		  			  	8184	  	Yes	  	56,332.12	  		  		  	
	8.	  	Omega Eng	  	477168	  	10/8/2003	  	Mass Flow Meter	 	1	  	6792	  	321	  	1,149.00	  			  	8309	  	Yes	  	2,298.00	  	LAB	  	NO	  	
		  		  	478047	  	10/9/2003	  	Mass Flow Meter	 	1	  	6791	  	322	  	1,149.00	  	$	2,298.00	  	8309	  	Yes	  	2,298.00	  	LAB	  	NO	  	
	9.	  	Price’s Scientific	  	11236	  	10/20/2003	  	Revco Elite 21
Frezer	 	1	  	OB112117	  	323	  	4,100.00	  			  	8316	  	Yes	  	35,631.00	  	LAB	  	NO	  	
		  		  		  	10/20/2003	  	Revco 21 Ultima
Freezer	 	1	  	Z13J-4667761-ZJ	  	324	  	5,500.00	  			  		  	Yes	  		  	LAB	  	NO	  	
		  		  		  	10/20/2003	  	21 CuFT - 80 Upright
Fz	 	1	  	X07M-S02920-XM	  	325	  	6,100.00	  			  		  	Yes	  		  	LAB	  	NO	  	
		  		  		  	10/20/2003	  	17 CuFt-80 Upright
Fz	 	1	  	X03M-601827-XM	  	326	  	6,100.00	  			  		  	Yes	  		  	LAB	  	NO	  	
		  		  		  	10/20/2003	  	-86 Upright Fz	 	1	  	X03M-601828-XM	  	327	  	5,200.00	  			  		  	Yes	  		  	LAB	  	NO	  	
		  		  		  	10/20/2003	  	PSS1 Double Door
Refrig	 	1	  		  	328	  	1,200.00	  	$	28,200.00	  		  	Yes	  		  	LAB	  	NO	  	

																																
	 Inv
 Item
	  	Supplier	  	Invoice #	  	Inv Date	  	Description	  	QTY	  	Serial #	  	 Customer #
 Internal Tag #
 (if
applicable)
	  	Amt.
Financed	  	Vendor Total	  	Ck #	  	Proof of
Payment	  	Ck Amt	  	Equip Code	  	90 Days	  	Comments
	10.	  	Q-Biogene	  	10223194	  	10/3/2003	  	Fast Prep FP 120A	  	1	  	H340117-1A	  	316	  	3,972.00	  			  	8317	  	Yes	  	4,609.00	  	LAB	  	NO	  	
		  		  		  		  		  		  		  		  		  	 	3,972.00	  		  		  		  		  		  	
	11.	  	Spike International	  	3820	  	9/24/2003	  	12 Well Shepard
Plate	  	1	  	N/A	  	315	  	739.29	  			  	8214	  	Yes	  	3,857.79	  	LAB	  	NO	  	
		  		  	3825	  	9/26/2003	  	24 Well Shepard
Plates	  	25	  	N/A	  	315	  	2,842.75	  	$	3,582.04	  	8214	  	Yes	  	3,857.79	  	LAB	  	NO	  	
	12.	  	Watson Marlow	  	85074	  	9/15/2003	  	Pump and
Pumphead	  	1	  	056-4562-000/	  	309	  	6,795.00	  			  	8143	  	Yes	  	6,815.21	  	LAB	  	NO	  	
		  		  		  		  		  		  	053-4001-000	  		  		  			  		  		  		  		  		  	
		  		  	85995	  	10/10/2003	  	Model 624Di/L
Peristaltic	  	1	  	D090587	  	320	  	8,085.00	  	$	14,880.00	  	8332	  	Yes	  	8,125.18	  	LAB	  	NO	  	
	13.	  	VWR	  	16234381	  	9/30/2003	  	CO2 Analyzer	  	1	  	HU 10022	  	312	  	1,316.59	  			  	8245	  	Yes	  	1,936.49	  	LAB	  	NO	  	
		  		  	16353933	  	10/10/2003	  	Refrig
Microcentrifuge
22R	  	1	  	MHB03F023	  	319	  	4,235.29	  			  	8331	  	Yes	  	5,443.32	  	LAB	  	NO	  	
		  		  	16380166	  	10/14/2003	  	Shaker 4000	  	1	  	0703 7335	  	318	  	3,989.52	  	$	9,541.40	  	8351	  	yes	  	4,965.49	  	LAB	  	NO	  	
		  		  		  		  		  		  		  	FUNDING
TOTAL	  	219,704.69	  	$	219,704.69	  		  		  		  		  		  	
		  		  		  		  		  		  		  		  	 	  	 	 	  		  		  		  		  		  	

  

	
	EQUIPMENT LIST
	
	LAB = Lab Equipment
	
	COMP = Computer Hardware
	
	OFC = Furniture, Telephone, Fax, Etc.
	
	SOFT = Computer Software, Tooling/Molds, Tax, Freight, Extended Warranties, Service Contracts, Et.

  

							
	 Equip. Code
	  	Total (Cat.)	  	% of Total	 
	 LAB
	  	$	202,151.96	  	92.01	%
	 COMP
	  	$	0.00	  	0.00	%
	 OFC
	  	$	0.00	  	0.00	%
	 SOFT
	  	$	17,552.73	  	7.99	%
	 Total
	  	$	219,704.69	  	100.00	%

  

					
	Biolex, Inc.	 	
			
	By:	 	  
	 	
	Title:	 	  
	 	

			
	(3/91) 4148254002	  	*LOAN3009*

 COLLATERAL SCHEDULE NO. 002 
 THIS COLLATERAL SCHEDULE NO. 002 is annexed to and made a part of that certain Master Security Agreement dated as of October 28, 2003 between General Electric Capital Corporation, together with its
successors and assigns, if any, as Secured Party and BIOLEX, INC. as Debtor and describes collateral in which Debtor has granted Secured Party a security interest in connection with the Indebtedness (as defined in the Security Agreement) including
without limitation that certain Promissory Note dated
                                        ,
in the original principal amount of $279,243.42. 
  

									
	 Quantity
	 	 Manufacturer
	 	 Serial Number
	 	 Year/Model and Type of Equipment

		 		 		 	
		 		 		 	
		 		 		 	

 SEE EXHIBIT A ATTACHED HERETO AND MADE A PART HEREOF. 
 and. including all additions, attachments, accessories and accessions thereto, and any and all substitutions, replacements or exchanges therefor, and all insurance
and/or other proceeds thereof. 
  

									
	SECURED PARTY:	 		 	DEBTOR:
			
	General Electric Capital Corporation	 		 	BIOLEX, INC.
					
	By:	 	  
	 		 	By:	 	  

					
	Name:	 	  
	 		 	Name:	 	  

					
	Title:	 	  
	 		 	Title:	 	  

					
	Date:	 	  
	 		 	Date:	 	  

					
	Company Name:	  	Biolex, Inc.	  	
			
	Equipment Location(s):	  		  	 158 Credle Street

		  		  	 Pittsboro, NC 27513

			
	Date of Last Funding	  		  	 8/8/2003

  

																																
	Inv.
Item	  	Supplier	  	Invoice #	  	Inv Date	  	Description	  	QTY	  	Serial #	  	Customer’s
Internal Tag #
(if applicable)	  	Amt. Financed	  	Vendor Total	  	Ck #	  	 Proof of
Payment
	  	 Ck Amt
	  	Equip
Code	  	> 90
Days?	  	Do we need
to check
previous
schedules
for
duplication?
	1	  	Best Lab
Deals	  	28	  	11/17/2003	  	Flammable Store Refrig	  	1	  	109U0019	  	329.00	  	1,734.46	  			  	8483	  	yes	  	6,351.06	  	LAB	  		  	
		  		  	28	  	11/17/2003	  	23.1 Cu Ft Freezer	  	1	  	209N0008	  	330.00	  	1,634.74	  			  	8483	  	yes	  	6,351.06	  	LAB	  		  	
		  		  	28	  	11/17/2003	  	Low-Temp Incubator	  	1	  	B4162152	  	331.00	  	2,286.00	  			  	8483	  	yes	  	6,351.06	  	LAB	  		  	
	2	  		  	152	  	2/10/2004	  	4’ Fisher Fume Hood	  	1	  	666018	  	369.00	  	2,800.00	  			  	8924	  	yes	  	3,246.00	  	LAB	  		  	
	3	  		  	50	  	12/23/2003	  	Shimadzu TOC Analyzer	  	1	  	33828585	  	344.00	  	11,844.53	  	$	20,299.73	  	8702	  	yes	  	12,773.65	  	LAB	  		  	
	4	  	Agilient	  	100916245	  	10/30/2003	  	1100 HPLC	  	1	  	DE33224368	  	332.00	  	50,350.20	  			  	8478	  	yes	  	53,618.68	  	LAB	  		  	
	5	  		  	101008124	  	1/29/2004	  	Chemsstation Software	  	1	  		  	367.00	  	1,543.80	  	$	51,894.00	  	8952	  	yes	  	1,543.80	  	SOFT	  		  	
	6	  	Scientific
Calibra	  	7540	  	11/17/2003	  	Sterlizer	  	1	  	30181	  	347.00	  	50,000.00	  			  	8692	  	yes	  	54,200.00	  	LAB	  		  	
		  		  		  		  		  		  		  		  		  	$	50,000.00	  		  		  		  		  		  	
	7	  	Cooper
Electric	  	7230	  	11/17/2003	  	Growth Room Const	  	1	  	N/A	  	N/A	  	30,896.00	  	$	30,896.00	  	8982	  	yes	  	39,079.00	  	SOFT	  		  	
	8	  	Comfort
Engineers	  	59056	  	11/28/2003	  	Growth Room Const	  	1	  	N/A	  	N/A	  	17,585.00	  	$	17,585.00	  	8927	  	yes	  	17,585.00	  	SOFT	  		  	
	9	  	Biotest
Diagnostics	  	247352	  	1/27/2004	  	Standard RCS Air
Sampler	  	1	  	27101	  	365.00	  	1,975.00	  			  	8956	  	yes	  	2,260.61	  	LAB	  		  	
		  		  		  		  		  	1	  		  		  		  			  		  		  		  		  		  	
		  		  		  		  		  	1	  		  		  		  	$	1,975.00	  		  		  		  		  		  	
	10	  	Percival
Scientific	  	40205	  	12/18/2003	  	Md I-30BLL Incubator	  	2	  	5649.01.03L	  	345 & 346	  	15,820.00	  			  	8714	  	yes	  	16,204.64	  	LAB	  		  	
		  		  		  		  		  		  	5649.02.03L	  		  		  			  		  		  		  		  		  	
		  		  		  		  		  		  		  		  		  	$	15,820.00	  		  		  		  		  		  	
	11	  	Blue
Mountain
Rs	  	36738	  	1/14/2004	  	Calibration Software	  	1	  		  	364.00	  	2,895.00	  			  	8857	  	yes	  	2,895.00	  	SOFT	  	NO	  	
		  		  		  		  		  	1	  		  		  		  	$	2,895.00	  		  		  		  		  		  	

																																
	Inv.
Item	  	Supplier	  	Invoice #	  	Inv Date	  	Description	  	QTY	  	Serial #	  	Customer’s
Internal Tag #
(if applicable)	  	Amt. Financed	  	Vendor Total	  	Ck #	  	 Proof of
Payment
	  	 Ck Amt
	  	Equip
Code	  	> 90
Days?	  	Do we need
to check
previous
schedules
for
duplication?
	12	  	Insight	  	A2340438	  	1/9/2004	  	HP Color 2500N Laser	  	1	  	CNGHB39670	  	362.00	  	1,278.67	  			  	8820	  	yes	  	1,475.17	  	OFC	  	NO	  	
		  		  		  		  		  	1	  		  		  		  	$	1,278.67	  		  		  		  		  		  	
	13	  	Apex
Biosciences	  	1035	  	10/7/2003	  	100L SS Tank	  	1	  	01GN056298	  	334.00	  	3,000.00	  			  	8559	  	yes	  	30,199.00	  	LAB	  		  	
		  		  	1035	  	10/7/2003	  	250L SS Tank	  	1	  	SCSDC9067	  	335.00	  	2,000.00	  			  	8559	  	yes	  	30,199.00	  	LAB	  		  	
		  		  	1035	  	10/7/2003	  	1000L SS Tank	  	1	  	CSDC29022	  	336.00	  	2,000.00	  			  	8559	  	yes	  	30,199.00	  	LAB	  		  	
		  		  	1035	  	10/7/2003	  	Gruenberg Oven	  	1	  	27334	  	337.00	  	4,000.00	  			  	8559	  	yes	  	30,199.00	  	LAB	  		  	
		  		  	1035	  	10/7/2003	  	Lynx Floor Scale	  	1	  	5114241-5MA	  	338.00	  	1,200.00	  			  	8559	  	yes	  	30,199.00	  	LAB	  		  	
		  		  	1035	  	10/7/2003	  	Filtration Skid
Large	  	1	  	97-11-7738A	  	339.00	  	2,000.00	  			  	8559	  	yes	  	30,199.00	  	LAB	  		  	
		  		  	1035	  	10/7/2003	  	Filtration Skid
Small	  	1	  	01GN054006	  	340.00	  	1,000.00	  			  	8559	  	yes	  	30,199.00	  	LAB	  		  	
		  		  	1035	  	10/7/2003	  	Filtra Skid Flat
1SU24003	  	1	  	1GN025992	  	341.00	  	1,500.00	  			  	8559	  	yes	  	30,199.00	  	LAB	  		  	
		  		  	1035	  	10/7/2003	  	Filtra Skid Flat
1SU24003	  	1	  	01GN051143	  	342.00	  	1,000.00	  			  	8559	  	yes	  	30,199.00	  	LAB	  		  	
		  		  	1035	  	10/7/2003	  	Filtra Skid Intergrity
Test	  	1	  	WFC2001-OC	  	343.00	  	1,000.00	  			  	8559	  	yes	  	30,199.00	  	LAB	  		  	
		  		  		  		  		  	1	  		  		  		  	$	18,700.00	  		  		  		  	LAB	  		  	
	14	  	eQuipSell	  	144	  	11/12/2003	  	Micro-Osmometer
3300	  	1	  	9911 1062M	  	333.00	  	3,000.00	  			  	8399	  	yes	  	3,000.00	  	LAB	  	NO	  	
		  		  		  		  		  		  		  		  		  	$	3,000.00	  		  		  		  		  		  	
	15	  	Dell	  		  	10/2/2003	  	Latitude D600	  	1	  	BWX6M31	  	357.00	  	2,661.00	  			  	Credit Card	  	yes	  	2,793.83	  	COMP	  		  	
	16	  		  		  	10/23/2003	  	Pentium M
Processor	  	1	  	CNFDP31	  	358.00	  	3,141.00	  			  	Credit Card	  	yes	  	3,381.22	  	COMP	  		  	
	17	  		  	534426177	  	11/17/2003	  	Precision M 60	  	1	  	CVQWS31	  	259.00	  	3,184.00	  	$	8,986.00	  	Credit Card	  	yes	  	3,406.87	  	COMP	  		  	
	18	  	Wintech
Computer	  	40865	  	1/30/2004	  	P4 Computer	  	1	  	ABBF34802262-40865	  	366.00	  	1,548.50	  	$	1,548.50	  	8870	  	yes	  	1,656.90	  	COMP	  	NO	  	
	19	  	Amersham	  	1893635	  	2/4/2009	  	Index 100/500
Column	  	1	  	0311/207	  	370.00	  	2,869.00	  			  	9007	  	no	  	17,435.34	  	LAB	  		  	
	20/21	  		  	190135/1902695	  	2/18/2004	  	Index 100/500
Column	  	1	  	0310/203	  	372.00	  	2,869.00	  	$	5,738.00	  	9092	  	no	  	7,785.13	  	LAB	  		  	
	22	  	VWR	  	17255790	  	1/15/2004	  	AB204 Analytical
Balan	  	1	  	1122310704	  	363.00	  	2,144.67	  			  	8869	  	yes	  	2,621.43	  	LAB	  	NO	  	
	23	  		  	17392982	  	2/4/2004	  	6’ Clean
Bench/Stand	  	1	  	40114978	  	371.00	  	6,123.85	  			  	9050	  	no	  	7,711.79	  	LAB	  	NO	  	
		  		  		  		  		  	1	  		  		  		  	$	8,268.52	  		  		  		  		  		  	
	24	  	Nuaire	  	20033602	  	2/13/2004	  	Class II Safety
Cabinets	  	6	  	88856020504,
88857020504	  	373, 374, 375,	  	37,584.00	  	$	37,584.00	  	9075	  	no	  	39,640.41	  	LAB	  		  	
		  		  		  		  		  		  	88858020504,
88861020504	  	376, 377, 378	  		  			  		  		  		  		  		  	
		  		  		  		  		  		  	88862020504,
88905020904	  		  		  			  		  		  		  		  		  	
	25	  	Ultrapure
Techn	  	25985	  	1/29/2004	  	#227B Hand Particle
Count	  	1	  	40100065	  	368.00	  	2,775.00	  	$	2,775.00	  	8950	  	yes	  	2,780.39	  	LAB	  		  	
		  		  		  		  		  		  		  		  	 	  			  		  		  		  		  		  	
		  		  		  		  		  		  		  	FUNDING
TOTAL	  	279,243.42	  	$	279,243.42	  		  		  		  		  		  	
		  		  		  		  		  		  		  		  	 	  			  		  		  		  		  		  	

	
	Equipment Code List
	
	LAB = Lab Equipment
	
	COMP = Computer Hardware
	
	OFC = Furniture, Telephone, Fax, Etc.
	
	SOFT = Computer Software, Tooling/Molds, Tax, Freight, Extended Warranties, Service Contracts, Etc.

  

					
	 Equip. Code
	 	 Total (Cat.)
	 	 % of Total

	LAB	 	214,510.45	 	77%
	COMP	 	10,534.50	 	4%
	OFC	 	1,278.67	 	0%
	SOFT	 	52919.8	 	19%
	Total	 	279,243.42	 	100%

  

					
	NAME OF CUSTOMER	 	
			
	By:	 	  
	 	
	Title:	 	  
	 	

			
	(R020403) 414825-4002	 	*LOAN3006*

 ANNEX A 
 TO 
 COLLATERAL SCHEDULE NO. 002 
 TO MASTER SECURITY AGREEMENT 
 DATED AS OF October 28, 2003 
 CERTIFICATE OF DELIVERY/INSTALLATION 
  

	To:	General Electric Capital Corporation (together with its successors and assigns, if any, “Secured Party”) 

 Pursuant to the provisions of the above Collateral Schedule to the above Master Security Agreement and the related Promissory Note (collectively, the
“Loan”), the undersigned (“Debtor”) hereby certifies and warrants that (a) all Equipment listed below has been delivered and installed (if applicable); (b) the Debtor has inspected the Equipment, and all such testing as
it deems necessary has been performed by Debtor, Supplier or the manufacturer, (c) Debtor has found all such Equipment to be satisfactory and meets all applicable specifications and is fully operational for its intended use; and (d) the
Equipment was first delivered to Debtor on                              and copies of the Bill(s) of
Lading or other documentation acceptable to Secured Party which show the date of delivery are attached hereto. 
  

									
	 Number of Units
	 	 Manufacturer
	 	 Serial Numbers
	 	 Model and Type of Equipment

		 		 		 	
		 		 		 	
		 		 		 	

 SEE EXHIBIT A ATTACHED HERETO AND MADE A PART HEREOF. 
  

			
	BIOLEX, INC.
		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

		
	Date:	 	  

			
	(3/91)4148254254	 	* LOAN3009 *

 COLLATERAL SCHEDULE NO. 003 
 THIS COLLATERAL SCHEDULE NO. 003 is annexed to and made a part of that certain Master Security Agreement dated as of October 28, 2003 between General Electric Capital Corporation, together with its
successors and assigns, if any, as Secured Party and BIOLEX, INC. as Debtor and describes collateral in which Debtor has granted Secured Party a security interest in connection with the Indebtedness (as defined in the Security Agreement) including
without limitation that certain Promissory Note dated                              in the original
principal amount of $145,951.59. 
  

									
	 Quantity
	 	 Manufacturer
	 	 Serial Number
	 	 Year/Model and Type of Equipment

		 		 		 	
		 		 		 	
		 		 		 	

 SEE EXHIBIT A ATTACHED HERETO AND MADE A PART HEREOF. 
 and including all additions, attachments, accessories and accessions thereto, and any and all substitutions, replacements or exchanges therefor, and all insurance and/or
other proceeds thereof. 
  

									
	SECURED PARTY:	 		 	DEBTOR:
			
	General Electric Capital Corporation	 		 	BIOLEX, INC.
					
	By:	 	  
	 		 	By:	 	  

					
	Name:	 	  
	 		 	Name:	 	  

					
	Title:	 	  
	 		 	Title:	 	  

					
	Date:	 	  
	 		 	Date:	 	  

											
	Company Name:	 	Biolex, Inc.	 		 		 		 	
					
	Equipment Location(s):	 	158 Credle Street	 		 		 	
		 		 	Pittsboro, NC 27513	 		 		 	
					
	Date of Last Funding	 	 8/8/2003
	 		 		 	

  

																																
	 Inv.
Item
	 	 Supplier
	 	 Invoice #
	 	 Inv Date
	 	 Description
	 	QTY	 	Serial #	 	 Customer’s
Internal Tag #
 (if applicable)
	 	Amt.
Financed	 	Vendor
Total	 	 Ck #
	 	 Proof of
Payment
	 	Ck Amt	 	 Equip
Code
	 	 > 90
 Days?
	 	 Do we need
to check
previous
schedules
for
duplication?

	 1
	 	Cooper Electric	 	7230	 	2/1/2004	 	GMP Construction	 	1	 	N/A	 		 	30,896.00	 			 	 8982
	 	yes	 	39,079.00	 	Soft	 		 	
	 1
	 		 	7230	 	2/2/2004	 	GMP Construction	 	1	 	N/A	 		 	2,208.00	 			 	 8982
	 	yes	 	39,079.00	 	Soft	 		 	
	 2
	 		 	7339	 	3/11/2004	 	GMP Construction	 	1	 	N/A	 		 	2,054.00	 			 	 9129
	 	yes	 	2,054.00	 	Soft	 		 	
		 		 		 		 		 		 		 		 		 	$	35,158.00	 		 		 		 		 		 	
	 3
	 	Dell	 	—  	 	3/3/2004	 	Dell Lattitude Laptop	 	1	 	5BZSF41	 	379.00	 	2,872.49	 			 	9131	 	yes	 	3,073.64	 	Comp	 		 	
		 		 		 		 		 		 		 		 		 	$	2,872.49	 		 		 		 		 		 	
	 4
	 	Nycom	 	Y42000101	 	2/19/2004	 	Modular Steel Casework	 	1	 	—  	 	380.00	 	8,126.28	 			 	9076	 	yes	 	10,634.51	 	Lab	 		 	
		 		 		 		 		 		 		 		 		 	$	8,126.28	 		 		 		 		 		 	
	 5
	 	Comfort Engineers	 	59056	 	2/1/2004	 	GMP Construction	 	1	 	N/A	 		 	17,585.00	 	$	17,585.00	 	8927	 	yes	 	17,858.00	 	Soft	 		 	
	 6
	 	Digital Analysis	 	80002946	 	3/25/2004	 	Payment on Biosystem	 	1	 	N/A	 		 	20,064.60	 	$	20,064.60	 	9238	 	CALL	 	20,064.60	 	Soft	 		 	
	 7
	 	Dennis Delgais	 	2004-5	 	2/9/2004	 	GMP Construction	 	1	 	N/A	 		 	1,175.00	 			 	 8878
	 	yes	 	1,175.00	 	Soft	 		 	
	 8
	 		 	2004-7	 	2/17/2004	 	GMP Construction	 	1	 	N/A	 		 	1,280.50	 			 	 8959
	 	yes	 	1,550.17	 	Soft	 		 	
	 9
	 		 	2004-35	 	4/19/2004	 	GMP Construction	 	1	 	N/A	 		 	36,155.88	 			 	 9359
	 	CALL	 	36,155.88	 	Soft	 		 	
	 10
	 		 	2004-24	 	3/29/2004	 	GMP Construction	 	1	 	N/A	 		 	2,678.00	 	$	41,289.38	 	 9209
	 	CALL	 	5,047.75	 	Soft	 		 	
	 11
	 	Phoenix Imperative	 	3404	 	2/23/2004	 	GMP Construction	 	1	 	N/A	 		 	43,176.00	 			 	 9139
	 	yes	 	49,121.06	 	Soft	 		 	

																																
	 Inv.
Item
	 	 Supplier
	 	 Invoice #
	 	 Inv Date
	 	 Description
	 	QTY	 	Serial #	 	 Customer’s
Internal Tag #
 (if applicable)
	 	Amt.
Financed	 	Vendor
Total	 	 Ck #
	 	 Proof of
Payment
	 	Ck Amt	 	 Equip
Code
	 	 > 90
 Days?
	 	 Do we need
to check
previous
schedules
for
duplication?

	 12
	 		 	3492	 	3/16/2004	 	GMP Construction	 	1	 	N/A	 		 	6,586.00	 			 	 9260
	 	CALL	 	40,920.05	 	Soft	 		 	
	 13
	 		 	3469	 	3/16/2004	 	GMP Construction	 	1	 	N/A	 		 	29,171.55	 	$	78,933.55	 	 9260
	 	CALL	 	40,920.05	 	Soft	 		 	
	 14
	 	Aaron Rents	 	13691005799	 	4/13/2004	 	Conference Table	 	1	 	N/A	 		 	330.00	 			 	 9373
	 	yes	 	2,000.90	 	Ofc	 	NO	 	
		 		 	13691005799	 	4/13/2004	 	Conference Table	 	4	 	N/A	 		 	1,540.00	 	$	1,870.00	 	 9373
	 	yes	 	2,000.90	 	Ofc	 		 	
	 15
	 	Percival	 	40536	 	3/19/2004	 	Incubator	 	1	 	5754.01.04C	 	385.00	 	8,960.00	 			 	 9391
	 	yes	 	9,275.78	 	Lab	 	NO	 	
		 		 		 		 		 		 		 		 		 	$	8,960.00	 		 		 		 		 		 	
		 		 		 		 		 		 		 		 		 	$	0.00	 		 		 		 		 		 	
		 		 		 		 		 		 		 		 		 			 		 		 		 		 	NO	 	
		 		 		 		 		 		 		 		 		 	$	0.00	 		 		 		 		 		 	
		 		 		 		 		 		 		 		 		 	$	0.00	 		 		 		 		 		 	
		 		 		 		 		 		 		 		 		 	$	0.00	 		 		 		 		 	NO	 	
		 		 		 		 		 		 		 		 		 	$	0.00	 		 		 		 		 		 	
		 		 		 		 		 		 		 		 		 			 		 		 		 		 	NO	 	
		 		 		 		 		 		 		 		 		 			 		 		 		 		 	NO	 	
		 		 		 		 		 		 		 		 		 	$	0.00	 		 		 		 		 		 	
		 		 		 		 		 		 		 		 		 	$	0.00	 		 		 		 		 		 	
		 		 		 		 		 		 		 		 		 	$	0.00	 		 		 		 		 		 	
		 		 		 		 		 		 		 		 	 	 			 		 		 		 		 		 	
		 		 		 		 		 		 		 	FUNDING
TOTAL	 	214,859.30	 	 	$214,859.30	 		 		 		 		 		 	
		 		 		 		 		 		 		 		 	 	 			 		 		 		 		 		 	

	
	Equipment Code List
	
	LAB = Lab Equipment
	
	COMP = Computer Hardware
	
	OFC = Furniture, Telephone, Fax, Etc.
	
	SOFT = Computer Software, Tooling/Molds, Tax, Freight, Extended Warranties, Service Contracts, Etc.

  

					
	 Equip. Code
	 	 Total (Cat.)
	 	 % of Total

	 LAB
	 	17,086.28	 	8%
	 COMP
	 	2,872.49	 	1%
	 OFC
	 	1,870.00	 	1%
	 SOFT
	 	193030.53	 	90%
	 Total
	 	214,859.30	 	100%

  

			
	NAME OF CUSTOMER
		
	By:	 	 
		
	Title:	 	  

 ANNEX A. 
 TO 
 COLLATERAL SCHEDULE NO. 003 
 TO MASTER SECURITY AGREEMENT 
 DATED AS OF October 28, 2003 
 CERTIFICATE OF DELIVERY/INSTALLATION 
  

	To:	General Electric Capital Corporation (together with its successors and assigns, any, “Secured Party”) 

 Pursuant to the provisions of the above Collateral Schedule to the above Master Security Agreement and the related Promissory Note (collectively, the
“Loan”), the undersigned (“Debtor”) hereby certifies and warrants that (a) all Equipment listed below has been delivered and installed (if applicable); (b) the Debtor has inspected the Equipment, and all such testing as
it deems necessary has been performed by Debtor, Supplier or the manufacturer, (c) Debtor has found all such Equipment to be satisfactory and meets all applicable specifications and is fully operational for its intended use; and (d) the
Equipment was first delivered to Debtor on                              and copies of the Bill(s) of
Lading or other documentation acceptable to Secured Party which show the date of delivery are attached hereto. 
  

									
	 Number of Units
	 	 Manufacturer
	 	 Serial Numbers
	 	 Model and Type of Equipment

		 		 		 	
		 		 		 	
		 		 		 	

 SEE EXHIBIT A ATTACHED HERETO AND MADE A PART HEREOF. 
  

			
	 BIOLEX, INC.

		
	 By:
	 	  

		
	 Name:
	 	  

		
	 Title:
	 	  

		
	 Date:
	 	  

			
	3007 (3/91) 4148254254	 	*LOAN3007*

 Date
                             
 General Electric Capital Corporation 
 401 Merritt 7 Suite 23 
 Norwalk, CT 06851-1177 
 Gentlemen: 
 You are hereby irrevocably authorized and directed to deliver and apply the proceeds of your loan to the undersigned evidenced by that Note dated
                             and secured by that Security Agreement or Chattel Mortgage dated
October 28, 2003, as follows: 
  

						
	 Biolex, Inc.
	  	$	145.951.59	  	

 Applied $35.96 to Interim Interest and $207.29 to First Payment from Good Faith Deposit.

 This authorization and direction is given pursuant to the same authority authorizing the above-mentioned borrowing. 
  

			
	Very truly yours,
	
	BIOLEX, INC.
		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

			
	(3/91)4148254004	 	*LOAN3009*

 COLLATERAL SCHEDULE NO. 004 
 THIS COLLATERAL SCHEDULE NO. 004 is annexed to and made a part of that certain Master Security Agreement dated as of October 28, 2003 between General Electric Capital Corporation, together with its
successors and assigns, if any, as Secured Party and BIOLEX, INC. as Debtor and describes collateral in which Debtor has granted Secured Party a security interest in connection with the Indebtedness (as defined in the Security Agreement) including
without limitation that certain Promissory Note dated                              in the original
principal amount of $296,957.11. 
  

									
	 Quantity
	 	 Manufacturer
	 	 Serial Number
	 	 Year/Model and Type of Equipment

		 		 		 	
		 		 		 	
		 		 		 	

 SEE EXHIBIT A ATTACHED HERETO AND MADE A PART HEREOF 
 and including all additions, attachments, accessories and accessions thereto, and any and all substitutions, replacements or exchanges therefor, and all insurance and/or
other proceeds thereof. 
  

									
	SECURED PARTY:	 		 	DEBTOR:
			
	General Electric Capital Corporation	 		 	BIOLEX, INC.
					
	By:	 	  
	 		 	By:	 	  

					
	Name:	 	  
	 		 	Name:	 	  

					
	Title:	 	  
	 		 	Title:	 	  

					
	Date:	 	  
	 		 	Date:	 	  

									
	 Company Name:
	 	Biolex, Inc.	 		 	DEPRECIATION DATE	 	05/31/04
	 Equipment Location(s):
	 	158 Credle Street	 		 	LAST FUNDING DATE	 	04/30/04
		 	 Pittsboro, NC 27312
	 		 		 	

  

																																				
	Inv.
Item	 	 Supplier
	 	 Invoice #
	 	 Inv Date
	 	 Description
	 	 QTY
	 	 Serial #
	 	 Customer’s
Internal Tag #
 (if applicable)
	 	Amt.
Financed	 	Vendor Total	 	 Ck #
	 	Proof of
Payment?	 	Ck Amt	 	 Equip
Code
	 	 > 90
Days?
	 	 Do we need to
check previous
schedules for
duplication?
	 	 Comments

	1	 	Cooper Electric	 	7368	 	04/26/04	 	GMP Construction	 	1	 		 		 	$	76,000.00	 	$	76,000.00	 	9441	 	Y	 	$	76,000.00	 	SOFT	 	N	 	YES	 	Please verify for progress billing and also verify location for sevice execution, as on invoice Sold to address is “480 Hillsboro Street, suite 100, Pittsboro NC
27312”.
																	
	2	 	Percival Scientific	 	40661	 	04/16/04	 	Incubator md l-36LL	 	2	 	6108.02.04D & 6108.01.04D	 	388 & 387	 	$	21,160.00	 	$	21,160.00	 	9499	 	Y	 	$	21,545.00	 	LAB	 	N	 	YES	 	Please provide copy of invoice to match details.
																	
	3	 	Comtrex Corp.	 	AD10000446	 	05/10/04	 	AutoCad 2005 CD Full system	 	2	 	341-93951536 & 341-93951635	 		 	$	6,390.00	 	$	6,390.00	 	9537	 	Y	 	$	6,847.30	 	COMP	 	N	 	NO	 	
																	
	4	 	Best Lab Deals	 	361	 	05/25/04	 	Uvikon 930 Spectrophotometer	 	1	 		 		 	$	3,500.00	 	$	3,500.00	 	9654	 	Y	 	$	4,213.40	 	LAB	 	N	 	NO	 	
																	
	5	 	Digital Analysis	 	80002946	 	03/25/04	 	Payment on Biosystem	 	1	 		 		 	$	0.00	 			 	9238	 	N	 	$	20,064.60	 	LAB	 	N	 	YES	 	Please provide copy of invoice and proof of payment for entire vendor and also claimed amount for this vendor is $0.00 , Please verify the same.
																	
		 		 	80002976	 	05/07/04	 	Payment on Biosystem	 	1	 		 		 	$	0.00	 	$	0.00	 	9515	 	N	 	$	40,129.20	 	LAB	 	N	 	NO	 	
																	
	6	 	Dennis Delgais	 	2004-41	 	05/07/04	 	GMP Construction	 	1	 		 		 	$	19,167.48	 			 	9491	 	Y	 	$	19,167.48	 	SOFT	 	N	 	NO	 	Please verify location for sevice execution for entire vendor as we don’t have bill to / ship to address on the invoices.
																	
		 		 	2004-54	 	06/01/04	 	GMP Construction	 	1	 		 		 	$	27,431.35	 	$	46,598.83	 	9658	 	Y	 	$	27,431.35	 	SOFT	 	N	 	NO	 	

																																				
	Inv.
Item	 	 Supplier
	 	 Invoice #
	 	 Inv Date
	 	 Description
	 	 QTY
	 	 Serial #
	 	 Customer’s
Internal Tag #
 (if applicable)
	 	Amt.
Financed	 	Vendor Total	 	 Ck #
	 	Proof of
Payment?	 	Ck Amt	 	 Equip
Code
	 	 > 90
Days?
	 	 Do we need to
check previous
schedules for
duplication?
	 	 Comments

	7	 	Fisher Scientific	 	6225512	 	05/17/04	 	Accument AR50 115V	 	2	 	AR93314713 & AR93314712	 	391 & 392	 	$	2,723.28	 	$	2,723.28	 	9717	 	Y	 	$	3,130.24	 	LAB	 	N	 	NO	 	
																	
	8	 	Lancer USA Inc.	 	27759	 	03/23/04	 	Washer Super drying PCM	 	1	 	3V060073	 	382	 	$	140,585.00	 	$	140,585.00	 	9721	 	Y	 	$	140,585.00	 	LAB	 	N	 	YES	 	
		 		 		 		 		 		 		 	 FUNDING
 TOTAL
	 	 	296,957.11	 	$	296,957.11	 		 		 			 		 		 		 	
		 		 		 		 		 		 		 		 	 	 	 	 	 	 		 		 			 		 		 		 	

  

	
	Equipment Code List
	
	LAB = Lab Equipment
	
	COMP = Computer Hardware
	
	OFC = Furniture, Telephone, Fax, Etc.
	
	SOFT = Computer Software, Tooling/Molds, Tax, Freight, Extended Warranties, Service Contracts, Etc.

  

							
	 Equip. Code
	  	Total (Cat.)	  	% of Total	 
	 LAB
	  	$	167,968.28	  	57	%
	 COMP
	  	$	6,390.00	  	2	%
	 OFC
	  	$	0.00	  	0	%
	 SOFT
	  	$	122,598.83	  	41	%
	 Total
	  	$	296,957.11	  	100	%

  

			
	Biolex, Inc.
		
	By:	 	 
		
	Title:	 	  

			
	(R020403)4148254004	 	*LOAN3006*

 ANNEX A 
 TO 
 COLLATERAL SCHEDULE NO. 004 
 TO MASTER. SECURITY AGREEMENT 
 DATED AS OF October 28, 2003 
 CERTIFICATE OF DELIVERY/INSTALLATION 
  

	To:	General Electric Capital Corporation (together with its successors and assigns, if any, “Secured Party”) 

 Pursuant to the provisions of the above Collateral Schedule to the above Master Security Agreement and the related Promissory Note (collectively, the
“Loan”), the undersigned (“Debtor”) hereby certifies and warrants that (a) all Equipment listed below has been delivered and installed (if applicable); (b) the Debtor has inspected the Equipment, and all such testing as
it deems necessary has been performed by Debtor, Supplier or the manufacturer; (c) Debtor has found all such Equipment to be satisfactory and meets all applicable specifications and is fully operational for its intended use; and (d) the
Equipment was first delivered to Debtor on                              and copies of the Bill(s) of
Lading or other documentation acceptable to Secured Party which show the date of delivery are attached hereto. 
  

									
	 Number of Units
	 	 Manufacturer
	 	 Serial Numbers
	 	 Model and Type of Equipment

		 		 		 	
		 		 		 	
		 		 		 	

 SEE EXHIBIT A ATTACHED HERETO AND MADE A PART HEREOF 
  

			
	BIOLEX, INC.
		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

		
	Date:	 	  

			
	 3007 (3/91) 4148254004
	 	* LOAN3007 *

 Date June 17, 2004 
 General Electric Capital Corporation 
 83 Wooster Heights Road 
 Danbury, CT 06810 
 Gentlemen: 
 You are hereby irrevocably authorized and directed to deliver and apply the proceeds of your loan to the undersigned evidenced by that Note dated
                             and secured by that Security Agreement or Chattel Mortgage dated
October 28, 2003, as follows: 
  

						
	 Biolex, Inc.
	  	$	296,957.11	  	

 Applied $1,041.66 to Interim Interest and $383.78 to First Payment from Good Faith Deposit

 This authorization and direction is given pursuant to the same authority authorizing the above-mentioned borrowing. 
  

			
	 Very truly yours,

	
	BIOLEX, INC.
		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

			
	1(3/91)4148254005	  	*LOAN3009*

 COLLATERAL SCHEDULE NO. 005 
 THIS COLLATERAL SCHEDULE NO. 005 is annexed to and made a part of that certain Master Security Agreement dated as of October 28, 2003 between General Electric Capital Corporation, together with its
successors and assigns, if any, as Secured Party and BIOLEX, INC. as Debtor and describes collateral in which Debtor has granted Secured Party a secured interest in connection with the Indebtedness (as defined in the Security Agreement) including
without limitation that certain Promissory Note dated
                                        
in the original principal amount of $125,046.92. 
  

									
	 Quantity
	 	 Manufacturer
	 	 Serial Number
	 	 Year/Model and Type of Equipment

		 		 		 		 	
		 		 		 		 	
		 		 		 		 	

 SEE EXHIBIT A ATTACHED HERETO AND MADE A PART HEREOF. 
 and including all additions, attachments, accessories and accessions thereto, and any and all substitutions, replacements or exchanges therefor, and all insurance and/or
other proceeds thereof. 
  

									
	SECURED PARTY:	 		 	DEBTOR:
			
	General Electric Capital Corporation	 		 	BIOLEX, INC.
					
	By:	 	  
	 		 	By:	 	  

					
	Name:	 	  
	 		 	Name:	 	  

					
	Title:	 	  
	 		 	Title:	 	  

					
	Date:	 	  
	 		 	Date:	 	  

					
	Company Name:	  	Biolex, Inc.	  	
			
	Equipment Location(s):	  		  	 158 Credle Street

		  		  	 Pittsboro, NC 27513

			
	Date of Last Funding	  		  	 8/8/2003

  

																																
	Inv.
Item	  	Supplier	  	Invoice #	  	Inv Date	  	Description	  	QTY	  	Serial #	  	Customer’s
Internal Tag #
(if applicable)	  	Amt.
Financed	  	Vendor
Total	  	Ck #	  	 Proof
 of
Payment
	  	 Ck
 Amt
	  	Equip
Code	  	> 90
Days?	  	Do we need
to check
previous
schedules
for
duplication?
	1	  	Wintech Computer
Systems Inc.	  	41812	  	5/4/2004	  	IBM PC 300PL	  	2	  	1S656395U23RPMFK	  		  	788.00	  			  	9505	  	yes	  	1,038.97	  	Comp	  		  	
		  		  	42346	  	7/7/2004	  	IBM
Thinkpad	  	1	  	99-CDLVG	  	404	  	3,340.00	  			  	9999	  	yes	  	3,652.98	  	Comp	  		  	
		  		  	41960	  	6/1/2004	  	HP ProCurve
4000M Switch	  	1	  	3862H165	  	398	  	1,594.00	  			  	9698	  	yes	  	5,135.26	  	Comp	  		  	
		  		  	41960	  	6/1/2004	  	Procurve Switch
100base	  	1	  		  		  	694.00	  	$	6,416.00	  	9698	  	yes	  	5,135.26	  	Comp	  		  	
	2	  	Atacom INC.	  	BOA
Credit
Card	  	6/12/2004	  	Video/Graphics
Card	  	1	  	NA	  	399	  	1,279.95	  			  	Credit Card	  	yes	  	1,309.93	  	Comp	  		  	
		  		  		  		  		  		  		  		  		  	$	1,279.95	  		  		  		  		  		  	
	3	  	PC Connection	  	BOA
Credit
Card	  	6/12/2004	  	Sony VAIO
Notebook	  	1	  	J0002BHC	  	400	  	2,106.94	  			  	Credit Card	  	yes	  	2,598.06	  	Comp	  		  	
		  		  		  		  		  		  		  		  		  	$	2,106.94	  		  		  		  		  		  	
	4	  	Fluid Flow	  	F-01566-0	  	6/8/2004	  	PTRIN Filter
Housing	  	1	  	15123X	  	397	  	2,457.00	  	$	2,457.00	  	9854	  	yes	  	2,694.80	  	Lab	  		  	
	5	  	Amersham	  	2010676	  	6/23/2004	  	UV-Monitor
UV-1	  	1	  	1134956	  	401	  	2,657.00	  			  	9941	  	yes	  	2,843.00	  	Lab	  		  	
		  		  		  		  		  		  		  		  		  	$	2,657.00	  	0	  		  	0.00	  		  		  	
	6	  	AC Controls	  	1-84852-0	  	6/26/2004	  	Honeywell
Recorder	  	1	  	0424Y463366500001	  	402	  	5,870.00	  			  	9936	  	yes	  	6,315.38	  	Lab	  		  	
		  		  		  		  		  		  		  		  	0.00	  			  		  		  	0.00	  		  		  	
		  		  		  		  		  		  		  		  	0.00	  	$	5,870.00	  		  		  	0.00	  		  		  	

																																
	Inv.
Item	  	Supplier	  	Invoice #	  	Inv Date	  	Description	  	QTY	  	Serial #	  	Customer’s
Internal Tag #
(if applicable)	  	Amt.
Financed	  	Vendor
Total	  	Ck #	  	 Proof
 of
Payment
	  	 Ck
 Amt
	  	Equip
Code	  	> 90
Days?	  	Do we need
to check
previous
schedules
for
duplication?
	7	  	Dell	  	Credit Card	  	6/28/2004	  	Computer tower/
monitor	  	1	  	BJPZ451	  	403	  	759.00	  			  	Credit Card	  	yes	  	843.20	  	Comp	  		  	
		  		  		  		  		  		  		  		  	0.00	  	$	759.00	  		  		  	0.00	  		  		  	
	8	  	National Instrum	  	1335171	  	06/0/2004	  	Labview Pro
Software	  	1	  	na	  	405	  	4,095.00	  			  	9810	  	yes	  	6,834.51	  	Comp	  		  	
		  		  		  		  		  		  		  		  		  	$	4,095.00	  		  		  		  		  		  	
	9	  	Aloi Materials
Holding Inc	  	6276	  	7/8/2004	  	SS Clean Table	  	1	  	na	  	406	  	1,692.00	  			  	10047	  	yes	  	1,885.34	  	Lab	  		  	
		  		  		  		  		  		  		  		  		  	$	1,692.00	  		  		  		  		  		  	
	10	  	Ultrapure Tech.	  	27372	  	7/29/2004	  	Lab Sink
Station	  	1	  	YS-FPT-001-00	  	408	  	5,464.80	  			  	10076	  	yes	  	5,464.80	  	Lab	  	NO	  	
		  		  		  		  		  		  		  		  		  	$	5,464.80	  		  		  		  		  		  	
	11	  	Comfort Engineers	  	6510429	  	6/28/2004	  	Air Handling
Unit & Plat	  	1	  		  	na	  	61,817.00	  			  	9955	  	yes	  	141,708.00	  	Lab	  		  	
		  		  	6510429	  	6/28/2004	  	Steam Generator	  	1	  		  	na	  	27,757.00	  			  	9955	  	yes	  	141,708.00	  	Lab	  		  	
		  		  		  		  		  		  		  		  		  	$	89,574.00	  		  		  		  		  		  	
	12	  	Nycom Inc.	  	Y420033901	  	4/30/2004	  	Acid Base Cabinet	  	1	  	na	  	409	  	755.23	  	$	755.23	  	9575	  	yes	  	1,159.10	  	Lab	  	NO	  	
	13	  	Prices Scientific
Services Inc.	  	12220	  	6/30/2004	  	Chart Recorders	  	2	  		  	na	  	1,920.00	  			  	9982	  	yes	  	2,350.45	  	Lab	  		  	
		  		  		  		  		  		  		  		  		  	$	1,920.00	  		  		  		  		  		  	
	14	  	Security
Solution	  	98169	  	6/30/2004	  	Acess Control
Sys	  	1	  		  	na	  	0.00	  			  	9927	  	yes	  	16,616.95	  	Lab	  	NO	  	
		  		  		  		  		  		  		  		  		  			  		  		  		  		  	NO	  	
		  		  		  		  		  		  		  		  		  	$	0.00	  		  		  		  		  		  	
		  		  		  		  		  		  		  		  		  	$	0.00	  		  		  		  		  		  	
		  		  		  		  		  		  		  		  		  	$	0.00	  		  		  		  		  		  	
		  		  		  		  		  		  		  		  	 	  			  		  		  		  		  		  	
	 	  	 	  	 	  	 	  	 	  	 	  	 	  	FUNDING
TOTAL	  	125,046.92	  	$125,046.92	  	 	  	 	  	 	  	 	  	 	  	 
		  		  		  		  		  		  		  		  	 	  			  		  		  		  		  		  	

	
	Equipment Code List
	
	LAB = Lab Equipment
	
	COMP = Computer Hardware
	
	OFC = Furniture, Telephone, Fax, Etc.
	
	SOFT = Computer Software, Tooling/Molds, Tax, Freight, Extended Warranties, Service Contracts, Etc.

  

					
	 Equip. Code
	 	 Total (Cat.)
	 	 % of Total

	LAB	 	110,390.03	 	88%
	COMP	 	14,656.89	 	12%
	OFC	 	0.00	 	0%
	SOFT	 	0	 	0%
	Total	 	125,046.92	 	100%

  

					
	NAME OF CUSTOMER	 	
			
	By:	 	  
	 	
	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}]]